atos20180930

0001437749-18-020638.txt : 20181114 0001437749-18-020638.hdr.sgml : 20181114 20181113181608 ACCESSION NUMBER: 0001437749-18-020638 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 61 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181114 DATE AS OF CHANGE: 20181113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ATOSSA GENETICS INC CENTRAL INDEX KEY: 0001488039 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 264753208 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35610 FILM NUMBER: 181179636 BUSINESS ADDRESS: STREET 1: 107 SPRING STREET CITY: SEATTLE STATE: WA ZIP: 98104 BUSINESS PHONE: 206.588.0256 MAIL ADDRESS: STREET 1: 107 SPRING STREET CITY: SEATTLE STATE: WA ZIP: 98104 10-Q 1 atos20180930_10q.htm FORM 10-Q atos20180930_10q.htm

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2018

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

Commission file number: 001-35610

ATOSSA GENETICS INC.

(Exact name of registrant as specified in its charter)

Delaware	26-4753208
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

107 Spring Street	98104
Seattle, WA	(Zip Code)
(Address of principal executive offices)

Registrant’s telephone number, including area code: (206) 325-6086

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer ☐

Smaller reporting company ☒

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares of the registrant’s common stock, $0.18 par value per share, outstanding at November 9, 2018 was 5,646,552.

Table of Contents

ATOSSA GENETICS INC.

FORM 10-Q

QUARTERLY REPORT

INDEX

PART I. FINANCIAL INFORMATION		3

ITEM 1.	Condensed Consolidated Financial Statements – Unaudited	3

	Condensed Consolidated Balance Sheets as of September 30, 2018 and December 31, 2017	3

	Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2018 and 2017	4

	Condensed Consolidated Statement of Stockholders’ Equity for the nine months ended September 30, 2018	5

	Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2018 and 2017	6

	Notes to Condensed Consolidated Financial Statements	7

ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	23

ITEM 3	Quantitative and Qualitative Disclosures about Market Risk	30

ITEM 4.	Controls and Procedures	30

PART II. OTHER INFORMATION		31

ITEM 1.	Legal Proceedings	31

ITEM 1A.	Risk Factors	33

ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	33

ITEM 3.	Defaults upon Senior Securities	34

ITEM 4.	Mine Safety Disclosures	34

ITEM 5.	Other Information	34

ITEM 6.	Exhibits	34

SIGNATURES		35

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ATOSSA GENETICS INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

	September 30,			December 31,
Assets	2018			2017
Current assets
Cash and cash equivalents	$	12,935,587		$	7,217,469
Restricted cash		55,000			55,000
Prepaid expenses		290,331			250,944
Research and development tax rebate receivable		480,495			358,277
Other current assets		161,530			16,344
Total current assets		13,922,943			7,898,034

Furniture and equipment, net		57,804			11,467
Intangible assets, net		55,107			75,686
Other assets		88,518			178,907
Total Assets	$	14,124,372		$	8,164,094

Liabilities and Stockholders' Equity

Current liabilities
Accounts payable	$	550,704		$	334,901
Accrued expenses		51,673			90,105
Payroll liabilities		706,150			784,867
Stock-based compensation liability		2,180,659
Other current liabilities		66,077			15,534
Total Current Liabilities		3,555,263			1,225,407

Commitments and contingencies (note 11)
Stockholders' equity
Preferred stock - $0.001 par value; 10,000,000 shares authorized, consisting of Series A convertible preferred stock- $0.001 par value; 4,000 shares authorized, and 0 shares outstanding as of September 30, 2018 and December 31, 2017; Series B convertible preferred stock- $0.001 par value; 25,000 and 0 shares authorized, and 3,517 and 0 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively		4
Additional paid-in capital- Series B convertible preferred stock		3,516,996
Common stock - $0.18 par value; 175,000,000 shares authorized, and 5,523,255 and 2,651,952 shares issued and outstanding, as of September 30, 2018 and December 31, 2017, respectively		994,175			477,342
Additional paid-in capital		80,811,088			71,887,674
Accumulated deficit		(74,753,154	)		(65,426,329	)
Total Stockholders' Equity		10,569,109			6,938,687

Total Liabilities and Stockholders' Equity	$	14,124,372		$	8,164,094

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

ATOSSA GENETICS INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
	2018			2017			2018			2017

Operating Expenses
Research and development	$	1,421,851		$	742,450		$	3,360,563		$	2,110,846
General and administrative		1,888,119			1,313,477			5,966,504			3,544,935
Total operating expenses		3,309,970			2,055,927			9,327,067			5,655,781
Operating loss		(3,309,970	)		(2,055,927	)		(9,327,067	)		(5,655,781	)
Change in fair value of common stock warrants					(128,300	)					(280,747	)
Warrant financing expense											(192,817	)
Other income (expense)		104			(283	)		242			(208	)
Loss before income taxes		(3,309,866	)		(2,184,510	)		(9,326,825	)		(6,129,553	)
Income taxes
Net loss	$	(3,309,866	)	$	(2,184,510	)	$	(9,326,825	)	$	(6,129,553	)
Deemed Dividend attributable to preferred stock								(11,479,308	)		(2,568,132	)
Net loss applicable to common shareholders	$	(3,309,866	)	$	(2,184,510	)	$	(20,806,133	)	$	(8,697,685	)
Loss per common share - basic and diluted	$	(0.64	)	$	(2.11	)	$	(5.71	)	$	(13.23	)
Weighted average shares outstanding - basic and diluted		5,183,492			1,034,262			3,645,682			657,184

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

ATOSSA GENETICS INC.

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY

(UNAUDITED)

	Series B Convertible Preferred Stock									Common Stock
	Shares			Amount			Additional Paid-in Capital			Shares		Amount		Additional Paid-in Capital			Accumulated Deficit			Total Stockholders' Equity
Balance at December 31, 2017				$			$				2,651,952	$	477,342	$	71,887,674		$	(65,426,329	)	$	6,938,687

Issuance of Series B convertible preferred stock and warrants, net of issuance costs of $1,333,449		13,624			14			6,926,778							5,363,759						12,290,551

Allocation of Series B convertible preferred stock proceeds to beneficial conversion feature								(4,782,100	)						4,782,100

Deemed Dividend on Series B convertible preferred stock								11,479,308							(11,479,308	)

Conversion of Series B convertible preferred stock to common stock		(10,107	)		(10	)		(10,106,990	)		2,871,303		516,833		9,590,167

Amortization of commitment shares															(59,556	)					(59,556	)

Compensation cost for stock options granted to executives and employees															726,252						726,252

Net loss																		(9,326,825	)		(9,326,825	)
Balance at September 30, 2018		3,517		$	4		$	3,516,996			5,523,255	$	994,175	$	80,811,088		$	(74,753,154	)	$	10,569,109

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

ATOSSA GENETICS INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	For the Nine Months Ended September 30,
	2018			2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(9,326,825	)	$	(6,129,553	)
Adjustments to reconcile net loss to net cash used in operating activities
Compensation cost for stock options granted		726,252			560,369
Loss on disposal of assets					17,695
Depreciation and amortization		28,690			102,074
Change in fair value of common stock warrants					280,747
Change in stock-based compensation liability		2,180,659
Warrant financing expense					192,817
Changes in operating assets and liabilities:
Prepaid expenses		(39,387	)		14,195
Research and development tax rebate receivable		(122,218	)
Other assets		(114,353	)		25,831
Accounts payable		215,803			126,079
Payroll liabilities		(78,717	)		(142,312	)
Accrued expenses		(38,432	)		33,578
Other current liabilities		50,543			7,212
Net cash used in operating activities		(6,517,985	)		(4,911,268	)

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of furniture, fixtures and equipment		(54,448	)
Net cash used in investing activities		(54,448	)

CASH FLOWS FROM FINANCING ACTIVITIES
Proceed from issuance of Series B convertible preferred stock and warrants, net of issuance costs		12,290,551
Proceeds from issuance of Class A and Class B Units, net of issuance costs					3,871,636
Proceeds from exercise of warrants					745,333
Net cash provided by financing activities		12,290,551			4,616,969

NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH		5,718,118			(294,299	)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING BALANCE		7,272,469			3,082,962
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE	$	12,990,587		$	2,788,663


NONCASH INVESTING AND FINANCING ACTIVITIES
Reclassification of warrant liability upon exercise of common stock warrants	$			$	1,893,160
Amount receivable for warrant exercise					3,900
Allocation of Class A and Class B Unit proceeds to warrant liability					1,612,413
Amortization of commitment shares issued for shares distributed for capital contribution	$	59,556		$	59,558

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

ATOSSA GENETICS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 1: NATURE OF OPERATIONS

Atossa Genetics Inc. (the “Company”) was incorporated on April 30, 2009 in the State of Delaware. The Company was formed to develop and market medical devices, laboratory tests and therapeutics to address breast health conditions. The Company’s fiscal year ends on December 31. The Company is focused on development of its pharmaceutical and drug delivery programs.

NOTE 2: GOING CONCERN

The Company’s consolidated financial statements are prepared using Generally Accepted Accounting Principles in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses and negative operating cash flows since inception. For the nine months ended September 30, 2018, the Company recorded a net loss of approximately $9.3 million and used approximately $6.5 million of cash in operating activities. As of September 30, 2018, the Company had approximately $12.9 million in cash and cash equivalents and working capital of approximately $10.4 million. The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. The Company can give no assurances that any additional capital that it is able to obtain, if any, will be sufficient to meet its needs, or that any such capital will be obtained on acceptable terms. If the Company is unable to obtain adequate capital, it could be forced to cease operations or substantially curtail its activities. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities should the Company be unable to continue as a going concern.

Management’s plan to continue as a going concern includes obtaining additional capital resources. Management’s plans to obtain such resources for the Company include obtaining capital from the sale of its equity securities, entering into strategic partnership arrangements, potential exercise of outstanding warrants, and short-term borrowings from banks, stockholders or other related parties, if needed. However, management cannot provide any assurance that the Company will be successful in accomplishing any of its plans.

As of the date of filing this report, we expect that our existing resources will be sufficient to fund our planned operations for the next 9 to 15 months; however, additional capital resources will be needed to fund operations longer-term.

The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraphs and eventually to secure other sources of financing and attain profitable operations.

Table of Contents

NOTE 3: SUMMARY OF ACCOUNTING POLICIES

Basis of Presentation:

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. They do not include all information and notes required by GAAP for complete financial statements. However, except as disclosed herein, there has been no material change in the information disclosed in the Notes to Consolidated Financial Statements included in the Annual Report on Form 10-K of the Company for the year ended December 31, 2017.

In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018.

On April 20, 2018, the Company completed a 1-for-12 reverse stock split of the shares of the Company’s common stock (the “Reverse Stock Split”). As a result of the Reverse Stock Split, every 12 shares of issued and outstanding common stock were combined into one issued and outstanding share of common stock, and the par value per share was changed to $0.18 per share. The number of authorized shares of common stock was not reduced as a result of the Reverse Stock Split. The Company’s common stock began trading on a reverse stock split-adjusted basis on April 20, 2018. All share and per share data included in this report has been retroactively restated to reflect the Reverse Stock Split.

Use of Estimates:

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Recently Issued Accounting Pronouncements:

In February 2016, Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Lease Accounting Topic 842. This ASU requires a lessee to recognize lease assets and liabilities on the balance sheet for all arrangements with terms longer than 12 months. The new standard applies a right-of-use (ROU) model that requires a lessee to record, for all leases with a lease term of more than 12 months, an asset representing its right to use the underlying asset for the lease term and a liability to make lease payments. The lease term is the non-cancellable period of the lease, and includes both periods covered by an option to extend the lease, if the lessee is reasonably certain to exercise that option, and periods covered by an option to terminate the lease, if the lessee is reasonably certain not to exercise that termination option. For leases with a lease term of 12 months or less, a practical expedient is available whereby a lessee may elect, by class of underlying asset, not to recognize an ROU asset or lease liability. A lessee making this accounting policy election would recognize lease expense over the term of the lease, generally in a straight-line pattern. The lessor accounting remains largely consistent with existing GAAP. The new standard takes effect in 2019 for public entities. The Company has not currently adopted the provisions of ASU No. 2016-02 and believes that the impact of adopting ASU 2016-02 will not be material to its consolidated financial statements, though will require the recognition of an operating lease liability and right-of-use asset upon adoption, based on the lease composition disclosed in Footnote 11.

Table of Contents

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows, amending the presentation of restricted cash within the statement of cash flows. The new guidance requires that restricted cash be included within cash and cash equivalents on the statement of cash flows. The Company adopted the provisions of ASU No. 2016-18 as of January 1, 2018 and has included restricted cash with cash and cash equivalents on the accompanying statement of cash flows, including reclassifying 2017 balances. For the three and nine months ended September 30, 2018 and September 30, 2017, we included $55,000 of restricted cash in cash and cash equivalents on the statement of cash flows. The restricted cash represents a required deposit for the Company credit card and is restricted until the Company no longer has the credit card or the limit changes on the credit card.

In July 2017, the FASB issued ASU 2017-11, Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part I of this ASU addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of future equity offerings. Current accounting guidance requires financial instruments with down round features to be accounted for at fair value. Part II of the Update applies only to nonpublic companies and is therefore not applicable to the Company. The amendments in Part I of the Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. This Update is effective for public entities for fiscal years beginning after December 15, 2018. Early adoption is permitted. The Company early adopted the provisions of ASU No. 2017-11 as of January 1, 2018. As the Company does not have any financial instruments with down round features, this ASU did not have a material impact on the financial statements upon adoption.

In June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation Improvements to Nonemployee Share Based Payment Accounting. This ASU simplifies several aspects of the accounting for non-employee share-based payment transactions resulting from expanding the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide financing to the issuer or was granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers. This update is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted. The Company early adopted the provisions of ASU No. 2018-17 as of April 1, 2018 and it did not have a material impact on the financial statements upon adoption.

Table of Contents

NOTE 4: PREPAID EXPENSES

Prepaid expenses consisted of the following:

	September 30,		December 31,
	2018		2017
Prepaid insurance	$	46,618	$	125,056
Retainer and security deposits		16,718		14,218
Professional services		93,557		97,788
Prepaid research and development		104,299
Financial exchange fees		13,750
Other		15,389		13,882
	$	290,331	$	250,944

Table of Contents

NOTE 5: RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE

On May 23, 2017 Atossa formed a wholly-owned subsidiary in Australia called Atossa Genetics AUS Pty Ltd. The purpose of this subsidiary is to perform research and development activities (“R&D”) including our Phase 1 and Phase 2 Endoxifen clinical trials. Australia offers an R&D cash rebate of $0.435 per dollar spent on qualified R&D activities incurred in the country. For the nine months ended September 30, 2018, the Company incurred qualified R&D expenses of approximately $764,000 and recorded a rebate receivable of approximately $333,000 and a corresponding credit to R&D expenses for the nine months ended September 30, 2018. At September 30, 2018, we had a total R&D rebate receivable of approximately $481,000 that includes approximately $148,000 receivable remaining from the year ended December 31, 2017.

Table of Contents

NOTE 6: PAYROLL LIABILITIES

Payroll liabilities consisted of the following:

	September 30, 2018		December 31, 2017
Accrued bonus payable	$	480,917	$	566,000
Accrued vacation		156,775		147,861
Accrued payroll liabilities		68,458		71,006
Total payroll liabilities	$	706,150	$	784,867

NOTE 7: STOCKHOLDERS’ EQUITY

The Company is authorized to issue a total of 185,000,000 shares of stock consisting of 175,000,000 shares of common stock, par value $0.18 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share. The Company has designated 750,000 shares of Series A junior participating preferred stock, par value $0.001 per share, 4,000 shares of Series A convertible preferred stock, par value $0.001 per share, and 25,000 shares of Series B convertible preferred stock, par value $0.001 per share, through the filings of certificates of designation with the Delaware Secretary of State. No shares of Series A junior participating preferred stock and no shares of Series A convertible preferred stock are issued and outstanding as of September 30, 2018.

Table of Contents

On May 19, 2014, the Company adopted a stockholder rights agreement which provides that all stockholders of record on May 26, 2014 received a non-taxable distribution of one preferred stock purchase right for each share of the Company’s common stock held by such stockholder. Each right is attached to and trades with the associated share of common stock. The rights will become exercisable only if one of the following occurs: (1) a person becomes an “Acquiring Person” by acquiring beneficial ownership of 15% or more of the Company’s common stock (or, in the case of a person who beneficially owned 15% or more of the Company’s common stock on the date the stockholder rights agreement was executed, by acquiring beneficial ownership of additional shares representing 2.0% of the Company’s common stock then outstanding (excluding compensatory arrangements)), or (2) a person commences a tender offer that, if consummated, would result in such person becoming an Acquiring Person. If a person becomes an Acquiring Person, each right will entitle the holder, other than the Acquiring Person and certain related parties, to purchase a number of shares of the Company’s common stock with a market value that equals twice the exercise price of the right. The initial exercise price of each right is $15.00, so each holder (other than the Acquiring Person and certain related parties) exercising a right would be entitled to receive $30.00 worth of the Company’s common stock. If the Company is acquired in a merger or similar business combination transaction at any time after a person has become an Acquiring Person, each holder of a right (other than the Acquiring Person and certain related parties) will be entitled to purchase a similar amount of stock of the acquiring entity.

2018 Subscription Rights Offering of Units Consisting of Series B Convertible Preferred Stock and Warrants

On May 9, 2018, the Company’s Registration Statement on Form S-1 with the Securities and Exchange Commission was declared effective to offer subscription rights to purchase up to 25,000 units at $1,000 per unit with each unit consisting of one share of Series B convertible preferred stock and warrants to purchase 284 shares of common stock.

On May 29, 2018, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series B convertible preferred stock with the Delaware Secretary of State creating a new series of its authorized preferred stock, par value $0.001 per share, designated as the Series B convertible preferred stock. The number of shares initially constituting the Series B preferred stock was set at 25,000 shares.

On May 30, 2018, the Company completed its previously announced rights offering pursuant to which the Company sold an aggregate of 13,624 units consisting of an aggregate of 13,624 shares of Series B convertible preferred stock and 3,869,216 warrants, with each warrant exercisable for one share of common stock at an exercise price of $4.048 per share (the “2018 Warrants”), resulting in net proceeds to the Company of approximately $12.3 million, after deducting expenses relating to the rights offering, including dealer-manager fees and expenses, and excluding any proceeds received upon exercise of any warrants.

Series B Convertible Preferred Stock.

The terms and provisions of our Series B convertible preferred stock are:

Conversion. Each share of Series B convertible preferred stock is convertible at our option at any time on or after the first anniversary of the closing of the rights offering or at the option of the holder at any time, into the number of shares of our common stock determined by dividing the $1,000 stated value per share of the Series B convertible preferred stock by a conversion price of $3.52 per share. In addition, the conversion price per share is subject to adjustment for stock dividends, distributions, subdivisions, combinations or reclassifications. Subject to limited exceptions, a holder of the Series B convertible preferred stock will not have the right to convert any portion of the Series B convertible preferred stock to the extent that, after giving effect to the conversion, the holder, together with its affiliates, would beneficially own in excess of 9.99% of the number of shares of our common stock outstanding immediately after giving effect to its conversion.

Table of Contents

Fundamental Transactions. In the event we effect certain mergers, consolidations, sales of substantially all of our assets, tender or exchange offers, reclassifications or share exchanges in which our common stock is effectively converted into or exchanged for other securities, cash or property, we consummate a business combination in which another person acquires 50% of the outstanding shares of our common stock, or any person or group becomes the beneficial owner of 50% of the aggregate ordinary voting power represented by our issued and outstanding common stock, then, upon any subsequent conversion of the Series B convertible preferred stock, the holders of the Series B convertible preferred stock will have the right to receive any shares of the acquiring corporation or other consideration it would have been entitled to receive if it had been a holder of the number of shares of common stock then issuable upon conversion in full of the Series B convertible preferred stock.

Dividends. Holders of Series B convertible preferred stock shall be entitled to receive dividends (on an as-if-converted-to-common-stock basis) in the same form as dividends actually paid on shares of the common stock when, as and if such dividends are paid on shares of common stock.

Voting Rights. Except as otherwise provided in the certificate of designation or as otherwise required by law, the Series B convertible preferred stock has no voting rights.

Liquidation Preference. Upon our liquidation, dissolution or winding-up, whether voluntary or involuntary, holders of Series B convertible preferred stock will be entitled to receive out of our assets, whether capital or surplus, the same amount that a holder of common stock would receive if the Series B convertible preferred stock were fully converted (disregarding for such purpose any conversion limitations under the certificate of designation) to common stock, which amounts shall be paid pari passu with all holders of common stock.

Redemption Rights. We are not obligated to redeem or repurchase any shares of Series B convertible preferred stock. Shares of Series B convertible preferred stock are not otherwise entitled to any redemption rights, or mandatory sinking fund or analogous provisions.

2018 Warrants

The terms and conditions of the warrants included in the 2018 rights offering are as follows:

Exercisability. Each warrant is exercisable at any time and will expire four years from the date of issuance. The warrants are exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and payment in full for the number of shares of our common stock purchased upon such exercise, except in the case of a cashless exercise as discussed below.

The number of shares of common stock issuable upon exercise of the warrants is subject to adjustment in certain circumstances, including a stock split of, stock dividend on, or a subdivision, combination or recapitalization of the common stock. Upon the merger, consolidation, sale of substantially all of our assets, or other similar transaction, the holders of warrants shall, at the option of the company, be required to exercise the warrants immediately prior to the closing of the transaction, or such warrants shall automatically expire. Upon such exercise, the holders of warrants shall participate on the same basis as the holders of common stock in connection with the transaction.

Cashless Exercise. If at any time there is no effective registration statement registering, or the prospectus contained therein is not available for issuance of, the shares issuable upon exercise of the warrant, the holder may exercise the warrant on a cashless basis. When exercised on a cashless basis, a portion of the warrant is cancelled in payment of the purchase price payable in respect of the number of shares of our common stock purchasable upon such exercise.

Table of Contents

Exercise Price. Each warrant represents the right to purchase one share of common stock at an exercise price of $4.048 per share. In addition, the exercise price per share is subject to adjustment for stock dividends, distributions, subdivisions, combinations, or reclassifications, and for certain dilutive issuances. Subject to limited exceptions, a holder of warrants will not have the right to exercise any portion of the warrant to the extent that, after giving effect to the exercise, the holder, together with its affiliates, and any other person acting as a group together with the holder or any of its affiliates, would beneficially own in excess of 4.99% of the number of shares of our common stock outstanding immediately after giving effect to its exercise. The holder, upon notice to the Company, may increase or decrease the beneficial ownership limitation provisions of the warrant, provided that in no event shall the limitation exceed 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise of the warrant.

Transferability. Subject to applicable laws and restrictions, a holder may transfer a warrant upon surrender of the warrant to us with a completed and signed assignment in the form attached to the warrant. The transferring holder will be responsible for any tax that liability that may arise as a result of the transfer.

Exchange Listing. We do not intend to apply to list the warrants on any securities exchange or recognized trading system.

Rights as Stockholder. Except as set forth in the warrant, the holder of a warrant, solely in such holder’s capacity as a holder of a warrant, will not be entitled to vote, to receive dividends, or to any of the other rights of our stockholders.

Redemption Rights. We may redeem the warrants for $0.18 per warrant if the volume-weighted-average-price of our common stock equals or exceeds $10.56 per share for ten consecutive trading days, provided that we may not do so prior to the first anniversary of closing of the rights offering.

Accounting Treatment

The Company allocated the proceeds from the sale of the Series B convertible preferred stock and the warrants to purchase common stock to the separate securities issued. The Company allocated the amount representing the fair value of the warrants at the date of issuance to common stock based on the relative warrant fair value in the amount of $5,363,759, which is net of issuance costs allocated to the warrants. Due to the allocation of a portion of the proceeds to the warrants, the convertible preferred stock contained a beneficial conversion feature upon issuance, which was recorded in the amount of $4,782,100 based on the relative fair value of the beneficial conversion feature. The discount on the convertible preferred stock was $11,479,308, which consists of the beneficial conversion feature of $4,782,100, the allocation of a portion of the proceeds to the warrants in the amount of $5,363,759, and the total issuance costs related to the financing of $1,333,449. The discount on the convertible preferred stock of $11,479,308 was recorded as a deemed dividend upon issuance of the convertible preferred stock. The deemed dividend is reflected as an addition to net loss in the condensed consolidated statements of operations to arrive at net loss applicable to common shareholders. The Company has made an accounting policy election to record the deemed dividend related to discounts on convertible instruments at the time of issuance of the convertible instruments.

Table of Contents

Outstanding Warrants

As of September 30, 2018, warrants to purchase 4,318,475 shares of common stock were outstanding including:

	Outstanding Warrants to Purchase Shares		Exercise Price			Expiration Date

2014 public offering		6,483		$540.00		January 29, 2019
Placement agent fees for Company’s offerings		1,106	381.60	–	540.00	November 4, 2018
2017 Warrant B private placement		441,670		3.78		December 22, 2018
2018 Warrants		3,869,216		4.05		May 30, 2022
		4,318,475

Conversion of Series B Convertible Preferred Stock

During the three and nine months ended September 30, 2018, certain holders of the Series B convertible preferred stock exercised their conversion option and converted an aggregate of 2,285 and 10,107 shares, respectively, into 649,156 and 2,871,303 shares, respectively, of the Company's common stock based on the conversion ratio of approximately 284 shares of common stock for each share of Series B convertible preferred stock.

NOTE 8: NET LOSS PER SHARE

The Company accounts for and discloses net income (loss) per common share in accordance with Accounting Standards Codification ("ASC") Topic 260, Earnings Per Share. Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. In addition, in computing the dilutive effect of convertible securities, the numerator is adjusted to add back any convertible preferred dividends. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of potential future exercises of outstanding stock options and common stock warrants. Because the inclusion of potential common shares would be anti-dilutive for all periods presented they have been excluded from the calculation.

The following table summarizes the Company’s calculation of net loss per common share:

	Three Months Ended September 30,						Nine months Ended September 30,
	2018			2017			2018			2017
Net Loss Per Share
Numerator
Net loss	$	(3,309,866	)	$	(2,184,510	)	$	(9,326,825	)	$	(6,129,553	)
Deemed dividend attributable to preferred stock								(11,479,308	)		(2,568,132	)
Net loss attributable to common shareholders	$	(3,309,866	)	$	(2,184,510	)	$	(20,806,133	)	$	(8,697,685	)
Denominator
Weighted average common shares outstanding		5,183,492			1,034,262			3,645,682			657,184
Basic and diluted net loss per share	$	(0.64	)	$	(2.11	)	$	(5.71	)	$	(13.23	)

Table of Contents

The following table sets forth the number of potential common shares excluded from the calculation of net loss per diluted share for the three and nine months ended September 30, 2018 and 2017 because including them would be anti-dilutive:

	Three Months Ended September 30,				Nine months Ended September 30,
	2018		2017		2018		2017
Options to purchase common stock		783,794		176,502		388,377		100,505
Series A convertible preferred stock				42,480				74,651
Series B convertible preferred stock		1,338,916				751,332
Warrants to purchase common stock		4,716,935		138,365		2,644,946		227,229
Total		6,839,645		357,347		3,784,655		402,385

For the three and nine months ended September 30, 2018 and 2017, the average price of our common stock was less than the exercise price of the vested stock options and exercisable warrants.

NOTE 9: INCOME TAXES

Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

As a result of the Company’s cumulative losses, management has concluded that a full valuation allowance against the Company’s net deferred tax assets is appropriate. No income tax liabilities existed as of September 30, 2018 and December 31, 2017 due to the Company’s continuing operating losses.

NOTE 10: CONCENTRATION OF CREDIT RISK

Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At September 30, 2018 and December 31, 2017, the Company had $12,685,587 and $6,967,469 in excess of the FDIC insured limit, respectively.

Table of Contents

NOTE 11: COMMITMENTS AND CONTINGENCIES

Lease Commitments

On November 1, 2018, the Company entered into an operating lease to pay $3,660 monthly rent for a term of 22 months. The total future minimum lease payments due under this lease are $80,500.

Litigation and Contingencies

On October 10, 2013, a putative securities class action complaint, captioned Cook v. Atossa Genetics, Inc., et al., No. 2:13-cv-01836-RSM, was filed in the United States District Court for the Western District of Washington against us, certain of our directors and officers and the underwriters of our November 2012 initial public offering. The complaint alleged that all defendants violated Sections 11 and 12(a)(2), and that we and certain of our directors and officers violated Section 15, of the Securities Act by making material false and misleading statements and omissions in the offering’s registration statement, and that we and certain of our directors and officers violated Sections 10(b) and 20A of the Exchange Act and SEC Rule 10b-5 promulgated thereunder by making false and misleading statements and omissions in the registration statement and in certain of our subsequent press releases and SEC filings with respect to our NAF specimen collection process, our ForeCYTE Breast Health Test and our MASCT device. The complaint sought, on behalf of persons who purchased our common stock between November 8, 2012 and October 4, 2013, inclusive, damages of an unspecific amount.

Table of Contents

On March 23, 2018, the parties filed a stipulation of settlement with the court to settle the matter for $3.5 million, completely funded by defendants’ insurers, and on July 20, 2018 the Court approved the settlement. This case is considered closed as of September 30, 2018.

We are subject to other legal proceedings and claims that arise in the normal course of business. We believe these matters are either without merit or of a kind that should not have a material effect, individually or in the aggregate, on our financial position, results of operations or cash flows.

NOTE 12: STOCK BASED COMPENSATION

Stock Option and Incentive Plan

On September 28, 2010, the Board of Directors approved the adoption of the 2010 Stock Option and Incentive Plan the (“2010 Plan”) to provide for the grant of equity-based awards to employees, officers, non-employee directors and other key persons providing services to the Company. Awards of incentive options may be granted under the 2010 Plan until September 2020. No other awards may be granted under the 2010 Plan after the date that is 10 years from the date of stock-holder approval. An aggregate of 5,556 shares were initially reserved for issuance in connection with awards granted under the 2010 Plan and on May 18, 2016, an additional 11,111 shares were reserved for issuance under the 2010 Plan. On May 9, 2017, the stockholders approved an additional 125,000 shares for issuance under the 2010 Plan. On April 12, 2018, the stockholders approved an additional 500,000 shares for issuance under the 2010 Plan.

The following table presents the automatic additions to the 2010 Plan since inception pursuant to the “evergreen” terms of the 2010 Plan:

January 1,	Number of shares
2012		2,502
2013		2,871
2014		4,128
2015		5,463
2016		18,368
2017		12,623
2018		106,076
Total additional shares		152,031

Table of Contents

The Company did not grant options to purchase shares of common stock during the three months ended September 30, 2018 or 2017. No options were exercised during the three or nine months ended September 30, 2018. There are 3,197 shares available for grant under the 2010 Plan as of September 30, 2018.

Compensation costs associated with the Company’s stock options are recognized, based on the grant-date fair values of these options, over the requisite service period, or vesting period. Accordingly, the Company recognized stock-based compensation expense of $332,063 and $224,254 for the three months ended September 30, 2018 and 2017, respectively and $726,252 and $560,369 for the nine months ended September 30, 2018 and 2017, respectively (excluding the liability options discussed below).

Options issued and outstanding as of September 30, 2018 under the 2010 Plan and their activities during the nine months then ended are as follows:

	Number of Underlying Shares			Weighted- Average Exercise Price Per Share		Weighted- Average Contractual Life Remaining in Years		Aggregate Intrinsic Value
Outstanding as of January 1, 2018		172,510		$	49.27			$
Granted		611,668			2.39
Forfeited		(417	)		5.64
Expired
Outstanding as of September 30, 2018		783,761			12.70		9.42	$
Exercisable as of September 30, 2018		199,949			40.62		8.95	$
Vested and expected to vest		783,761			12.70		9.42	$

At September 30, 2018, there were 583,812 unvested options outstanding and the related unrecognized total compensation cost associated with these options was approximately $1,479,610. This expense is expected to be recognized over a weighted-average period of 1.56 years.

Option Grants Classified as Liabilities (“Liability Grants”)

On June 27, 2018, the Company granted 2,300,000 options to the Chief Executive Officer and 700,000 to the Chief Financial Officer. Each option is exercisable for an equivalent number of shares of Company common stock. The options were granted pursuant to an option award agreement and were granted outside the Company’s 2010 Plan; however, they are subject to the terms and conditions of the 2010 Plan.

Table of Contents

The Liability Grants are exercisable for shares of common stock at an exercise price of $2.38 per share, which was the fair market value on the date of grant. The options have an exercise period of ten years from their date of issuance. If at the time the options are exercised the Company cannot deliver shares of common stock to the optionee including, for example, if there are insufficient shares available under the Plan at the time of exercise, then in lieu of the optionee paying the exercise price and the Company issuing shares of stock, the option may only be exercised on a cash “net basis” so that the Company will pay cash in an amount equal to the excess of the fair market value of the common stock over the option exercise price. There currently are not sufficient shares available under the Plan and the Company would be obligated to settle these options in cash if they were exercised. Because these options contain provisions that could require the Company to settle the options in cash in an event outside the Company’s control, they are accounted for as liabilities.

The Liability Grants are subject to vesting requirements. Twenty-five percent of the options have vested as of the grant date, 50% of the options will vest quarterly over two years, and the remaining 25% vest upon achievement of certain milestones related to clinical trial progress. As of September 30 2018, 80% of the options that vest upon achievement of clinical trial milestones are vested.

Compensation costs associated with the Liability Grants are initially recognized, based on the grant-date fair values of these options, over the requisite or vesting period for time-based options or when it is probable the performance criteria will be achieved for options that vest based on performance. Compensation cost is remeasured each period based on the market value of our underlying stock until award vesting or settlement.

For the three and nine months ended September 30, 2018, the Company recognized compensation expense related to these options of $623,496 and $2,180,659, respectively.

The fair value of liability options granted for the nine months ended September 30, 2018 was calculated using the Black-Scholes option-pricing model applying the following assumptions:

	Nine months ended September 30,
	2018

Risk free interest rate	2.94	%
Expected term (in years)	4.75
Stock price	$1.75
Dividend yield		%
Expected volatility	122.0	%

Table of Contents

NOTE 13: RESTATEMENT TO PREVIOUSLY ISSUED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The Company has corrected an inadvertent error in the calculation of the deemed dividend on Series B convertible preferred stock in the financial statements for the three and six months ended June 30, 2018 that were included in the Company’s Form 10-Q filed on August 13, 2018 (the “Original Form 10-Q”). Accounting principles generally accepted in the United States of America require that we allocate the proceeds from the May 2018 financing to the warrants and preferred stock issued in the financing and that we estimate and record any discount on the securities as a deemed dividend. In the financial statements included in the Original Form 10-Q, we did not properly allocate the proceeds to the warrants, and we did not properly record the deemed dividend related to the warrant discount as additional paid in capital to common stock. The Company incorrectly stated the deemed dividend for the three and six months ended June 30, 2018 as $4,782,100, rather than $11,479,308. The corrections result from application of technical accounting rules and do not impact cash or operations.

In accordance with applicable generally accepted accounting principles, the Company has calculated and recognized adjustments accordingly. The following table shows the effect of the restatement on certain line items within the Company’s Condensed Consolidated Statement of Operations for the three months and six months ended June 30, 2018:

	For the Three Months Ended June 30, 2018						For the Six Months Ended June 30, 2018
	Previously Reported			Restated			Previously Reported			Restated
Deemed dividend attributable to preferred stock	$	(4,782,100	)	$	(11,479,308	)	$	(4,782,100	)	$	(11,479,308	)
Net loss applicable to common stockholders	$	(8,924,677	)	$	(15,621,885	)	$	(10,799,059	)	$	(17,496,267	)
Loss per common share -basic and diluted	$	(2.90	)	$	(5.08	)	$	(3.77	)	$	(6.11	)

The following table shows the effect of the restatement on certain line items within the Company’s Condensed Consolidated Statement of Stockholders’ Equity for the six months ended June 30, 2018:

	Preferred Stock Additional Paid-in Capital						Common Stock Additional Paid-in Capital
	Previously Reported			Restated			Previously Reported			Restated
Issuance of Series B convertible preferred stock, net of issuance costs	$	12,290,537		$	6,926,778		$	0		$	5,363,759
Deemed Dividend on Series B convertible preferred stock	$	4,782,100		$	11,479,308		$	(4,782,100	)	$	(11,479,308	)
Conversion of Series B convertible preferred stock to common stock	$	(7,056,421	)	$	(7,821,992	)	$	6,656,442		$	7,422,013

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of the financial condition and results of operations should be read in conjunction with the financial statements and the related notes included elsewhere in this report. This discussion contains forward-looking statements, which are based on assumptions about the future of the Company’s business. The actual results could differ materially from those contained in the forward-looking statements. Please read “Forward-Looking Statements” included below for additional information regarding forward-looking statements.

Forward-Looking Statements

This report contains, in addition to historical information, certain information, assumptions and discussions that may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have made these statements in reliance on the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are subject to certain risks and uncertainties, which could cause actual results to differ materially from those projected or anticipated. Although we believe our assumptions underlying our forward-looking statements are reasonable as of the date of this report, we cannot assure you that the forward-looking statements set out in this report will prove to be accurate. We typically identify these forward-looking statements by the use of forward-looking words such as “expect,” “potential,” “continue,” “may,” “will,” “should,” “could,” “would,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or the negative version of those words or other comparable words. Forward-looking statements contained in this report include, but are not limited to, statements about:

●

whether we can obtain approval from the U.S. Food and Drug Administration (“FDA”) and foreign regulatory bodies, to sell, market and distribute our therapeutics and devices under development;

●

our ability to successfully complete clinical trials of our pharmaceutical candidates under development, including Endoxifen and our intraductal microcatheter technology to administer therapeutics, including our study using fulvestrant;

●

the success, cost and timing of our product and drug development activities and clinical trials, including whether the ongoing clinical study using our intraductal microcatheters to administer fulvestrant and other studies will enroll a sufficient number of subjects or be completed in a timely fashion or at all;

●

our ability to contract with third-party suppliers, manufacturers and service providers, including clinical research organizations, and their ability to perform adequately;

●

our ability to successfully develop and commercialize new therapeutics currently in development or that we might identify in the future and in the time frames currently expected;

●

our ability to establish and maintain intellectual property rights covering our products;

●

our expectations regarding, and our ability to satisfy, federal, state and foreign regulatory requirements;

●

the accuracy of our estimates of the size and characteristics of the markets that our products and services may address;

●

our expectations as to future financial performance, expense levels and capital sources;

●

whether the final study results will vary from preliminary study results that we may announce; and

●

our ability to attract and retain key personnel.

These and other forward-looking statements made in this report are presented as of the date on which the statements are made. We have included important factors in the cautionary statements included in this report, particularly in the section titled “ITEM 1A. RISK FACTORS,” that we believe could cause actual results or events to differ materially from the anticipated results as set forth in the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any new information, future events or circumstances that may affect our business after the date of this report. Except as required by law, we do not intend to update any forward-looking statements after the date on which the statement is made, whether as a result of new information, future events or circumstances or otherwise.

Table of Contents

Company Overview

We are a clinical-stage biopharmaceutical company focused on developing novel, proprietary therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. We are developing Endoxifen with two routes of delivery: a topical formulation, applied like a lotion, for the treatment of a condition called mammographic breast density (or, MBD) and a breast disorder in men called gynecomastia; and an oral formulation to treat stage 1 or 2 breast cancer in the “window of opportunity” between diagnosis and surgery and for breast cancer survivors who do not benefit from taking oral tamoxifen, a current FDA-approved standard of care. We are also developing our patented intraductal microcatheter technology to potentially target the delivery of therapies, including fulvestrant, immunotherapies and Chimeric Antigen Receptor T-cell therapies (CAR-T therapies), directly to the site of breast cancer.

In 2017, we completed a Phase 1 placebo-controlled clinical study of our proprietary oral and topical formulations of Endoxifen in 48 healthy women. All objectives were met: there were no clinically significant safety signals and no clinically significant adverse events, and both the oral and topical Endoxifen were well tolerated. In the topical arm of the study, low but measurable Endoxifen levels were detected in the blood in a dose-dependent fashion. In the oral arm of the study, participants exhibited dose-dependent Endoxifen levels that met or exceeded the published therapeutic level. The median time for patients in the study to reach the steady-state serum levels of Endoxifen while taking daily doses of oral Endoxifen was 7 days. Published literature indicates that it takes approximately 50-200 days for patients to reach steady-state Endoxifen levels when taking daily doses of oral tamoxifen. In September 2018, we completed a Phase 1 placebo-controlled clinical study of our proprietary topical Endoxifen in 24 healthy men. Preliminary results from that study indicate that all of our objectives of safety, tolerability and pharmakinetics were successfully met. Based on these positive preliminary results, we are advancing our topical Endoxifen into a Phase 2 study to reduce gynecomastia and/or improve quality of life in men starting prostate cancer therapy.

We are currently conducting a Phase 2 study at Montefiore Medical Center, Bronx, New York, using our intraductal microcatheter technology to deliver fulvestrant. Our program to use our intraductal microcatheters to deliver CAR-T and other immunotherapies is in the research and development phase.

We are currently conducting two Phase 2 studies of our proprietary Endoxifen: one in Stockholm, Sweden using our topical Endoxifen for MBD and another in Australia using our oral Endoxifen for patients in the window of opportunity between diagnosis of breast cancer and surgery. In October 2018, the MBD study in Sweden was fully-enrolled with all 90 participants: 60 participants on two different dose levels and 30 participants on placebo. Some participants have reported skin rashes and irritation and have withdrawn from the study. Skin reactions were also reported in the Phase 1 studies of the same product. We are evaluating approaches to reduce skin reactions and maximize participation in the study; however, additional study participants could experience these and other more serious side effects and the study may not be successfully completed for these or other reasons.

Our key objectives are to advance our programs through Phase 2 trials and then evaluate further development independently or with partners.

Research and Development Phase

We are in the research and development phase and are not currently marketing any products or services. We do not anticipate generating revenue unless and until we develop and launch our pharmaceutical programs.

Table of Contents

Critical Accounting Policies and Estimates

In our Annual Report on Form 10-K for the year ended December 31, 2017, we disclosed our critical accounting policies and estimates upon which our financial statements are derived. There have been no changes to these policies since December 31, 2017. Readers are encouraged to review these disclosures in conjunction with the review of this report.

Results of Operations

Three and Nine months Ended September 30, 2018 and 2017

Revenue and Cost of Revenue:

For the three and nine months ended September 30, 2018 and 2017, we had no revenue and no associated cost of revenue.

Operating Expenses: Total operating expenses were approximately $3.3 million and $9.3 million for the three and nine months ended September 30, 2018, respectively, consisting of research and development (R&D) expenses of approximately $1.4 million and $3.4 million, respectively, and general and administrative (G&A) expenses of approximately $1.9 million and $6.0 million, respectively. Total operating expenses were approximately $2.1 million and $5.7 million for the three and nine months ended September 30, 2017, respectively, consisting of R&D expenses of $0.7 million and $2.1 million, respectively, and G&A expense of approximately $1.3 million and $3.5 million, respectively.

Total operating expenses for the three and nine months ended September 30, 2018 as compared to the same periods of 2017 increased approximately $1.3 million, or 61%, and increased $3.7 million, or 65%, respectively.

Table of Contents

Research and Development Expenses: R&D expenses for the three months ended September 30, 2018 were approximately $1,422,000, an increase of $680,000, or 92%, from approximately $742,000, for the same period in 2017. R&D expenses for the nine months ended September 30, 2018 were approximately $3,361,000, an increase of $1,250,000 or 59%, from approximately $2,111,000 for the same period in 2017. The increase in R&D expenses is mainly attributable to an increase in stock-based compensation expense. R&D expenses primarily consist of salaries, manufacturing and clinical trial expenses associated with our Endoxifen program. Our R&D expenses have increased over the same periods in 2017 because of a 2018 increase in stock-based compensation of $0.9 million and because we commenced two Phase 2 studies of our proprietary Endoxifen in 2018 (one of which enrollment was fully completed in 2018) as compared to no Phase 2 studies of Endoxifen in the prior year.

General and Administrative Expenses: G&A expenses for the three months ended September 30, 2018 were approximately $1,888,000, an increase of $575,000 or 44%, from approximately $1,313,000, for the same period in 2017. G&A expenses for the nine months ended September 30, 2018 were approximately $5,967,000, an increase of $2,422,000 or 68%, from approximately $3,545,000 for the same period in 2017. G&A expenses consist primarily of personnel and related benefit costs, facilities, professional services, insurance, and public company related expenses. The increase in G&A expenses for the nine months ended September 30, 2018 is mainly attributed to an increase in stock-based compensation expense of $1.4 million, payroll expenses resulting from salary increases, bonus payments of $350,000 and increased legal and professional consulting expenses of $550,000 over the prior year.

Warrant Financing Costs and Change in Fair Value of Common Stock Warrants: The April 2017 financing included the issuance of common stock liability warrants. The Company incurred financing costs associated with these common stock liability warrants of $192,817 upon issuance. The Company also recorded changes in the fair value of the liability warrants during the three months and nine months ended September 30, 2017 of $128,300 and $280,747, respectively. There were no common stock liability warrants issued during the three and nine months ended September 30, 2018.

Liquidity and Capital Resources

We have a history of operating losses as we have focused our efforts on raising capital and building our products and services in our pipeline. The Company’s consolidated financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses and negative operating cash flows since inception. For the nine months ended September 30, 2018, the Company recorded a net loss of approximately $9.3 million, and used approximately $6.5 million of cash in operating activities. As of September 30, 2018, the Company had approximately $12.9 million in cash and cash equivalents and working capital of approximately $10.4 million. The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. The Company can give no assurances that any additional capital that it is able to obtain, if any, will be sufficient to meet its needs, or that any such financing will be obtainable on acceptable terms. If the Company is unable to obtain adequate capital, it could be forced to cease operations or substantially curtail its commercial activities. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities should the Company be unable to continue as a going concern.

Table of Contents

As of the date of filing this quarterly report, we expect that our existing resources will be sufficient to fund our planned operations for the next 9 to 15 months; however, additional capital resources will be needed to fund operations longer-term.

Additional funding may not be available to us on acceptable terms or at all. In addition, the terms of any financing may adversely affect the holdings or the rights of our stockholders. For example, if we raise additional funds by issuing equity securities or by selling debt securities, if convertible, further dilution to our existing stockholders would result. To the extent our capital resources are insufficient to meet our future capital requirements, we will need to finance our future cash needs through public or private equity offerings, collaboration agreements, debt financings or licensing arrangements.

If adequate funds are not available, we may be required to terminate, significantly modify or delay our development programs, reduce our planned commercialization efforts, or obtain funds through collaborators that may require us to relinquish rights to our technologies or product candidates that we might otherwise seek to develop or commercialize independently. Further, we may elect to raise additional funds even before we need them if we believe the conditions for raising capital are favorable.

Cash Flows

As of September 30, 2018, the Company had cash and cash equivalents and restricted cash of approximately $13.0 million.

Net Cash Flows from Operating Activities: Net cash used in operating activities was approximately $6.5 million for the nine months ended September 30, 2018, compared with approximately $4.9 million for the nine months ended September 30, 2017. The increase in the 2018 period as compared to 2017 results primarily from 2018 increases in clinical study costs, compensation expenses, consulting fees, and patent expenses.

Net Cash Flows from Investing Activities: Net cash used in investing activities was approximately $54,000 for the nine months ended September 30, 2018, compared with no cash used for the nine months ended September 30, 2017. The increase in 2018 was attributable to the purchases of fixed asset equipment in 2018 for R&D activities. There were no corresponding purchases during the corresponding 2017 period.

Net Cash Flows from Financing Activities: Net cash provided by financing activities generated proceeds of $12.3 million for the nine months ended September 30, 2018, as compared with $4.6 million for the nine months ended September 30, 2017. The increase is mainly attributed to our larger completed rights offering in 2018 as compared to the same period in 2017.

Table of Contents

Off-Balance Sheet Arrangements

We do not currently have, nor have we ever had, any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not engage in trading activities involving non-exchange traded contracts.

Recent Accounting Pronouncements

Table of Contents

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows, amending the presentation of restricted cash within the statement of cash flows. The new guidance requires that restricted cash be included within cash and cash equivalents on the statement of cash flows. The Company adopted the provisions of ASU No. 2016-18 as of January 1, 2018 and has included restricted cash within cash and cash equivalents in the statements of cash flows. For the three and nine months ended September 30, 2018 and September 30, 2017, we included $55,000 of restricted cash in cash and cash equivalents on the statement of cash flows. The restricted cash represents a required deposit for the Company credit card and is restricted until the Company no longer has the credit card or the limit changes on the credit card.

Table of Contents

In July 2017, the FASB issued ASU 2017-11, Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part I of this ASU addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of future equity offerings. Current accounting guidance requires financial instruments with down round features to be accounted for at fair value. Part II of the Update applies only to nonpublic companies and is therefore not applicable to the Company. The amendments in Part I of the Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. This Update is effective for public entities for fiscal years beginning after December 15, 2018. Early adoption is permitted. The Company early adopted the provisions of ASU No. 2017-11 as of January 1, 2018. As the Company does not have any financial instruments with down round features, this ASU and it did not have a material impact on the financial statements upon adoption.

In June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation Improvements to Nonemployee Share Based Payment Accounting. This ASU simplifies several aspects of the accounting for non-employee share-based payment transactions resulting from expanding the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide financing to the issuer or was granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with customers. This update is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoptions is permitted. The Company early adopted the provisions of ASU No. 2018-07 as of April 1, 2018 and it did not have a material impact on the financial statements upon adoption.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES.

Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2018. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer and principal financial officer concluded that, as of September 30, 2018, the Company’s disclosure controls and procedures were not effective at the reasonable assurance level.

No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the quarter ended September 30, 2018, that has materially affected, or is reasonably likely to materially affect our disclosure controls and procedures

For the quarter ended June 30, 2018, we identified a material weakness in the internal controls over the calculation of the deemed dividend on Series B convertible preferred stock (the “deemed dividend”) for the three and six months June 30, 2018. Because of this error, an incorrect deemed dividend was included in net loss applicable to common stockholders which caused an incorrect calculation of loss per common share, basic and diluted. Management misinterpreted the technical guidance contained in ASC 470- Debt in calculating the deemed dividend. An appropriately detailed knowledge of ASC 470 -Debt was not present to prevent or detect this error. We incorrectly stated the amount of the deemed dividend as $4,782,100, rather than $11,479,308, for the three and six months ended June 30, 2018. We also incorrectly stated the loss per common share - basic and diluted, for the three and six months ended June 30, 2018 as $(2.90) and $(3.77) respectively, rather than the correct amount of $(5.08) and $(6.11), respectively.

Management’s remediation plan is to enhance the procedures performed to independently review technical accounting memorandums for accuracy and completeness including when appropriate with an outside independent accounting firm in future periods.

Table of Contents

PART II OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Litigation and Contingencies

Table of Contents

ITEM 1A. RISK FACTORS

There have been no material changes to the risk factors described in our Annual Report on Form 10-K, as filed with the SEC on March 8, 2018.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Not applicable.

Table of Contents

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Not applicable.

ITEM 6. EXHIBITS

(a)

Exhibits

		Incorporated by Reference Herein
Exhibit No.	Description	Form	Date

31.1	Certification pursuant to Rule 13a-14(a) under the securities Exchange Act of 1934 of Steven C. Quay	Filed herewith
31.2	Certification pursuant to Rule 13a-14(a) under the securities Exchange Act of 1934 of Kyle Guse	Filed herewith
32.1	Certification pursuant to 18 U.S.C. Section 1350 of Steven C. Quay	Filed herewith
32.2	Certification pursuant to 18 U.S.C. Section 1350 of Kyle Guse	Filed herewith

101	Interactive Data Files pursuant to Rule 405 of Regulation S-T	Filed herewith

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 13, 2018

/s/ Steven C. Quay
President and Chief Executive Officer
(On behalf of the Registrant)

/s/ Kyle Guse
Kyle Guse
Chief Financial Officer, General Counsel and Secretary
(As Principal Financial and Accounting Officer)

EX-31.1 2 ex_126793.htm EXHIBIT 31.1 ex_126793.htm

Exhibit 31.1

CERTIFICATION PURSUANT TO RULE 13a-14(a)

OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Steven C. Quay, certify that:

1. I have reviewed this Quarterly Report of Atossa Genetics Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	Date: November 13, 2018

	/s/ Steven C. Quay
	Steven C. Quay
	Chief Executive Officer and President
	(Principal executive officer)

EX-31.2 3 ex_126794.htm EXHIBIT 31.2 ex_126794.htm

Exhibit 31.2

CERTIFICATION PURSUANT TO RULE 13a-14(a)

OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Kyle Guse, certify that:

1. I have reviewed this Quarterly Report of Atossa Genetics Inc.;

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	Date: November 13, 2018

	/s/Kyle Guse
	Kyle Guse
	Chief Financial Officer, General Counsel and Secretary
	(Principal financial and accounting officer)

EX-32.1 4 ex_126795.htm EXHIBIT 32.1 ex_126795.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Atossa Genetics Inc. (the “Company”) on Form 10-Q for the period ending September 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Steven C. Quay, Chief Executive Officer and President of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	Date: November 13, 2018

	/s/ Steven C. Quay
	Steven C. Quay
	Chief Executive Officer and President
	(Principal executive officer)

EX-32.2 5 ex_126799.htm EXHIBIT 32.2 ex_126799.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Atossa Genetics Inc. (the “Company”) on Form 10-Q for the period ending September 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Kyle Guse, Chief Financial Officer, General Counsel and Secretary of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	Date: November 13, 2018

	/s/ Kyle Guse
	Kyle Guse
	Chief Financial Officer, General Counsel and Secretary
	(Principal financial and accounting officer)

EX-101.INS 6 atos-20180930.xml XBRL INSTANCE DOCUMENT 4782100 1612413 -59556 -59556 128300 280747 2180659 1893160 0.5 0.5 11479308 11479308 11479308 -11479308 4782100 11479308 -4782100 -11479308 January 29, 2019 November 4, 2018 December 22, 2018 May 30, 2022 13750 333000 122218 1 185000000 25000 13624 3660 3.52 0.0999 11479308 4782100 4782100 4782100 11479308 4782100 11479308 11479308 2568132 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">NOTE <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4:</div> PREPAID EXPENSES</div></div> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Prepaid expenses consisted of the following:</div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">September 30,</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Prepaid insurance</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">46,618</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">125,056</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Retainer and security deposits</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,718</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,218</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Professional services</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">93,557</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">97,788</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Prepaid research and development</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">104,299</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Financial exchange fees</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,750</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,389</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,882</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">290,331</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">250,944</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div></div> 12300000 12290551 3871636 93557 97788 1000 0.435 104299 481000 148000 480495 358277 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">NOTE <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5:</div> RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE</div></div> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 23, 2017 </div>Atossa formed a wholly-owned subsidiary in Australia called Atossa Genetics AUS Pty Ltd. The purpose of this subsidiary is to perform research and development activities (“R&D”) including our Phase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> and Phase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> Endoxifen clinical trials. Australia offers an R&D cash rebate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.435</div> per dollar spent on qualified R&D activities incurred in the country. For the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2018, </div>the Company incurred qualified R&D expenses of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$764,000</div> and recorded a rebate receivable of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$333,000</div> and a corresponding credit to R&D expenses for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2018. </div>At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2018, </div>we had a total R&D rebate receivable of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$481,000</div> that includes approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$148,000</div> receivable remaining from the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017. </div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div></div> 2502 2871 4128 5463 18368 12623 106076 152031 0.8 P10Y 1000 0.02 0.15 15 1 30 192817 5363759 10.56 0.18 0.0499 10400000 false --12-31 Q3 2018 2018-09-30 10-Q 0001488039 5646552 Yes false Non-accelerated Filer ATOSSA GENETICS INC true atos

550704

334901

480917

566000

51673

90105

68458

71006

156775

147861

80811088

71887674

3516996

-4782100

4782100

726252

332063

224254

726252

560369

623496

2180659

59556

59558

783794

176502

388377

100505

42480

74651

1338916

751332

4716935

138365

2644946

227229

6839645

357347

3784655

402385

14124372

8164094

13922943

7898034

12935587

7217469

7272469

3082962

12990587

2788663

5718118

-294299

12685587

6967469

4.048

540

381.60

540

3.78

4.05

284

4318475

3869216

6483

1106

441670

3869216

4318475

0.18

175000000

5523255

2651952

5523255

2651952

994175

477342

2285

10107

649156

2871303

284

2180659

16718

14218

28690

102074

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">NOTE <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12:</div> STOCK BASED COMPENSATION</div></div> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Stock Option and Incentive Plan</div></div></div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 28, 2010, </div>the Board of Directors approved the adoption of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Stock Option and Incentive Plan the (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">“2010</div> Plan”) to provide for the grant of equity-based awards to employees, officers, non-employee directors and other key persons providing services to the Company. Awards of incentive options <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be granted under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan until <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 2020. </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No</div> other awards <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be granted under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan after the date that is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div> years from the date of stock-holder approval. An aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,556</div> shares were initially reserved for issuance in connection with awards granted under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan and on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 18, 2016, </div>an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,111</div> shares were reserved for issuance under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan. On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 9, 2017, </div>the stockholders approved an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">125,000</div> shares for issuance under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan. On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 12, 2018, </div>the stockholders approved an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">500,000</div> shares for issuance under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan.</div> <div style=" margin: 0pt; text-align: justify; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">The following table presents the automatic additions to the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan since inception pursuant to the “evergreen” terms of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan:</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div> <table style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-right: 2.5%; margin-left: 2.5%; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="width: 84%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">January 1,</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Number of</div><br /> <div style="display: inline; font-weight: bold;">shares</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">2012</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,502</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">2013</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,871</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">2014</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,128</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">2015</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,463</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">2016</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,368</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">2017</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,623</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">106,076</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total additional shares</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">152,031</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">The Company did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> grant options to purchase shares of common stock during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2018 </div>or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No</div> options were exercised during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2018. </div>There are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,197</div> shares available for grant under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2018.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Compensation costs associated with the Company’s stock options are recognized, based on the grant-date fair values of these options, over the requisite service period, or vesting period. Accordingly, the Company recognized stock-based compensation expense of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$332,063</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$224,254</div> for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$726,252</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$560,369</div> for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively (excluding the liability options discussed below).</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Options issued and outstanding as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2018 </div>under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan and their activities during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months then ended are as follows:</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div> <table style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Number of<br /> Underlying<br /> Shares</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted-<br /> Average<br /> Exercise Price<br /> Per Share</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted-<br /> Average<br /> Contractual<br /> Life Remaining<br /> in Years</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Aggregate<br /> Intrinsic Value</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 52%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding as of January 1, 2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">172,510</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">49.27</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">611,668</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.39</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(417</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.64</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Expired</div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding as of September 30, 2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">783,761</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12.70</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.42</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercisable as of September 30, 2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">199,949</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40.62</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.95</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Vested and expected to vest</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">783,761</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12.70</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.42</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" margin: 0pt; text-align: justify; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2018, </div>there were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">583,812</div> unvested options outstanding and the related unrecognized total compensation cost associated with these options was approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,479,610.</div> This expense is expected to be recognized over a weighted-average period of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.56</div> years.</div> <div style=" margin: 0pt; text-align: justify; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; text-decoration: underline;">Option Grants Classified as Liabilities (“Liability Grants”)</div></div> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 27, 2018, </div>the Company granted <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,300,000</div> options to the Chief Executive Officer and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">700,000</div> to the Chief Financial Officer. Each option is exercisable for an equivalent number of shares of Company common stock. The options were granted pursuant to an option award agreement and were granted outside the Company’s <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan; however, they are subject to the terms and conditions of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">The Liability Grants are exercisable for shares of common stock at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.38</div> per share, which was the fair market value on the date of grant. The options have an exercise period of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">ten</div> years from their date of issuance. If at the time the options are exercised the Company cannot deliver shares of common stock to the optionee including, for example, if there are insufficient shares available under the Plan at the time of exercise, then in lieu of the optionee paying the exercise price and the Company issuing shares of stock, the option <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>only be exercised on a cash “net basis” so that the Company will pay cash in an amount equal to the excess of the fair market value of the common stock over the option exercise price. There currently are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> sufficient shares available under the Plan and the Company would be obligated to settle these options in cash if they were exercised. Because these options contain provisions that could require the Company to settle the options in cash in an event outside the Company’s control, they are accounted for as liabilities.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">The Liability Grants are subject to vesting requirements. Twenty-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> percent of the options have vested as of the grant date, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50%</div> of the options will vest quarterly over <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> years, and the remaining <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25%</div> vest upon achievement of certain milestones related to clinical trial progress. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30 2018, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">80%</div> of the options that vest upon achievement of clinical trial milestones are vested. </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Compensation costs associated with the Liability Grants are initially recognized, based on the grant-date fair values of these options, over the requisite or vesting period for time-based options or when it is probable the performance criteria will be achieved for options that vest based on performance. Compensation cost is remeasured each period based on the market value of our underlying stock until award vesting or settlement.</div> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">For the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2018, </div>the Company recognized compensation expense related to these options of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$623,496</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,180,659,</div> respectively.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">The fair value of liability options granted for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2018 </div>was calculated using the Black-Scholes option-pricing model applying the following assumptions:</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div> <table style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="width: 76%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="1" style="width: 22%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Nine months</div><div style="display: inline; font-weight: bold;"> ended </div><div style="display: inline; font-weight: bold;">September</div><div style="display: inline; font-weight: bold;"> 30,</div></div></div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 76%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="1" style="width: 22%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 76%;"> </td> <td style="width: 1%;"> </td> <td style="width: 22%;"> </td> <td style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 76%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk free interest rate</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 22%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.94</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 76%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected term (in years)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 22%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.75</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 76%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock price</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 22%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.75</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 76%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Dividend yield</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 22%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 76%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 22%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">122.0</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">%</td> </tr> </table> </div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div></div>

17695

-2.90

-5.08

-3.77

-6.11

-0.64

-2.11

-5.71

-13.23

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">NOTE <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8:</div> NET LOSS PER SHARE</div></div> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">The Company accounts for and discloses net income (loss) per common share in accordance with Accounting Standards Codification ("ASC") Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">260,</div> <div style="display: inline; font-style: italic;">Earnings Per Share</div>. Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. In addition, in computing the dilutive effect of convertible securities, the numerator is adjusted to add back any convertible preferred dividends. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of potential future exercises of outstanding stock options and common stock warrants. Because the inclusion of potential common shares would be anti-dilutive for all periods presented they have been excluded from the calculation.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">The following table summarizes the Company’s calculation of net loss per common share: </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div> <table style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months Ended</div><br /> <div style="display: inline; font-weight: bold;">September</div><div style="display: inline; font-weight: bold;"> 30,</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Nine months</div><div style="display: inline; font-weight: bold;"> Ended</div><br /> <div style="display: inline; font-weight: bold;">September</div><div style="display: inline; font-weight: bold;"> 30,</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 52%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net Loss Per Share</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Numerator</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net loss</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3,309,866</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,184,510</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(9,326,825</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(6,129,553</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Deemed dividend attributable to preferred stock</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(11,479,308</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,568,132</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net loss attributable to common shareholders</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3,309,866</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,184,510</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(20,806,133</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(8,697,685</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Denominator</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Weighted average common shares outstanding</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,183,492</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,034,262</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,645,682</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">657,184</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Basic and diluted net loss per share</div> </td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.64</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2.11</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(5.71</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(13.23</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> </tr> </table> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">The following table sets forth the number of potential common shares excluded from the calculation of net loss per diluted share for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> because including them would be anti-dilutive: </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div> <table style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months Ended<br /> September</div><div style="display: inline; font-weight: bold;"> 30,</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Nine months</div><div style="display: inline; font-weight: bold;"> Ended</div><br /> <div style="display: inline; font-weight: bold;">September</div><div style="display: inline; font-weight: bold;"> 30,</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 52%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Options to purchase common stock</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">783,794</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">176,502</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">388,377</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100,505</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Series A convertible preferred stock</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">42,480</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">74,651</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Series B convertible preferred stock</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,338,916</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">751,332</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrants to purchase common stock</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,716,935</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">138,365</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,644,946</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">227,229</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</div> </td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,839,645</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">357,347</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,784,655</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">402,385</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" margin: 0pt; text-align: justify; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">For the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> the average price of our common stock was less than the exercise price of the vested stock options and exercisable warrants.</div></div>

706150

784867

P1Y204D

1479610

280747

55107

75686

1888119

1313477

5966504

3544935

-3309866

-2184510

-9326825

-6129553

215803

126079

-38432

33578

-78717

-142312

114353

-25831

50543

7212

39387

-14195

P1Y300D

14124372

8164094

3555263

1225407

3500000

12290551

4616969

-54448

-6517985

-4911268

-9326825

-6129553

-9326825

-3309866

-2184510

-8924677

-15621885

-10799059

-17496267

-3309866

-2184510

-20806133

-8697685

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Recently Issued Accounting Pronouncements:</div></div> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2016, </div>Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02,</div> <div style="display: inline; font-style: italic;">Lease Accounting Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842.</div></div> This ASU requires a lessee to recognize lease assets and liabilities on the balance sheet for all arrangements with terms longer than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> months. The new standard applies a right-of-use (ROU) model that requires a lessee to record, for all leases with a lease term of more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> months, an asset representing its right to use the underlying asset for the lease term and a liability to make lease payments. The lease term is the non-cancellable period of the lease, and includes both periods covered by an option to extend the lease, if the lessee is reasonably certain to exercise that option, and periods covered by an option to terminate the lease, if the lessee is reasonably certain <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> to exercise that termination option. For leases with a lease term of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> months or less, a practical expedient is available whereby a lessee <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>elect, by class of underlying asset, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> to recognize an ROU asset or lease liability. A lessee making this accounting policy election would recognize lease expense over the term of the lease, generally in a straight-line pattern. The lessor accounting remains largely consistent with existing GAAP. The new standard takes effect in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> for public entities. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> currently adopted the provisions of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> and believes that the impact of adopting ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be material to its consolidated financial statements, though will require the recognition of an operating lease liability and right-of-use asset upon adoption, based on the lease composition disclosed in Footnote <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 2016, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,</div> <div style="display: inline; font-style: italic;">Statement of Cash Flows</div>, amending the presentation of restricted cash within the statement of cash flows. The new guidance requires that restricted cash be included within cash and cash equivalents on the statement of cash flows. The Company adopted the provisions of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18</div> as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2018 </div>and has included restricted cash with cash and cash equivalents on the accompanying statement of cash flows, including reclassifying <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> balances. For the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017, </div>we included <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$55,000</div></div> of restricted cash in cash and cash equivalents on the statement of cash flows. The restricted cash represents a required deposit for the Company credit card and is restricted until the Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> longer has the credit card or the limit changes on the credit card.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2017, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,</div> <div style="display: inline; font-style: italic;">Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception</div>. Part I of this ASU addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of future equity offerings. Current accounting guidance requires financial instruments with down round features to be accounted for at fair value. Part II of the Update applies only to nonpublic companies and is therefore <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> applicable to the Company. The amendments in Part I of the Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">260</div> to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. This Update is effective for public entities for fiscal years beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2018. </div>Early adoption is permitted. The Company early adopted the provisions of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div> as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2018. </div>As the Company does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have any financial instruments with down round features, this ASU did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material impact on the financial statements upon adoption.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 2018, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">07,</div> <div style="display: inline; font-style: italic;">Compensation-Stock Compensation Improvements to Nonemployee Share Based Payment Accounting. </div>This ASU simplifies several aspects of the accounting for non-employee share-based payment transactions resulting from expanding the scope of Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div> to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div> to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost. The amendments also clarify that Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div> does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> apply to share-based payments used to effectively provide financing to the issuer or was granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606,</div> <div style="display: inline; font-style: italic;">Revenue from Contracts with Customers</div>. This update is effective for public entities for fiscal years beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2018, </div>including interim periods within that fiscal year. Early adoption is permitted. The Company early adopted the provisions of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17</div> as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 1, 2018 </div>and it did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material impact on the financial statements upon adoption.</div></div></div></div></div></div></div></div></div></div></div></div>

3900

104

-283

242

-208

3309970

2055927

9327067

5655781

-3309970

-2055927

-9327067

-5655781

80500

161530

16344

88518

178907

66077

15534

15389

13882

1333449

54448

0.001

10000000

750000

4000

25000

10000000

4000

3517

290331

250944

46618

125056

745333

57804

11467

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">NOTE <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13:</div>  RESTATEMENT TO PREVIOUSLY ISSUED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div></div> <div style=" margin: 0pt 7.5pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">The Company has corrected an inadvertent error in the calculation of the deemed dividend on Series B convertible preferred stock in the financial statements for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>that were included in the Company’s Form <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-Q filed on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 13, 2018 (</div>the “Original Form <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-Q”). Accounting principles generally accepted in the United States of America require that we allocate the proceeds from the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2018 </div>financing to the warrants and preferred stock issued in the financing and that we estimate and record any discount on the securities as a deemed dividend. In the financial statements included in the Original Form <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-Q, we did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> properly allocate the proceeds to the warrants, and we did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> properly record the deemed dividend related to the warrant discount as additional paid in capital to common stock. The Company incorrectly stated the deemed dividend for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>as <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4,782,100</div>,</div> rather than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$11,479,308</div>.</div> The corrections result from application of technical accounting rules and do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> impact cash or operations.</div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">In accordance with applicable generally accepted accounting principles, the Company has calculated and recognized adjustments accordingly. The following table shows the effect of the restatement on certain line items within the Company’s Condensed Consolidated Statement of Operations for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018: </div><div style="display: inline; font-weight: bold;"> </div></div> <div style=" margin: 0pt 7.5pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div> <table style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="width: 44%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="width: 111111%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">For the Three Months Ended<br /> June 30, 2018</div></div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td colspan="6" style="width: 111111%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">For the Six Months Ended<br /> June 30, 2018</div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 44%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="width: 1%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Previously</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Reported</div></div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="width: 1%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Restated</div></div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="width: 1%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Previously</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Reported</div></div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="width: 1%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Restated</div></div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 44%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deemed dividend attributable to preferred stock</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4,782,100</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(11,479,308</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4,782,100</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(11,479,308</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 44%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss applicable to common stockholders</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(8,924,677</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(15,621,885</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(10,799,059</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(17,496,267</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 44%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loss per common share -basic and diluted</div> </td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2.90</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(5.08</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3.77</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(6.11</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> </tr> </table> </div> <div style=" margin: 0pt 7.5pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">The following table shows the effect of the restatement on certain line items within the Company’s Condensed Consolidated Statement of Stockholders’ Equity for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018: </div><div style="display: inline; font-weight: bold;"> </div></div> <div style=" margin: 0pt 7.5pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></div> <div> <table style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Preferred Stock Additional Paid-in Capital</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Common Stock Additional Paid-in Capital</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Previously</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Reported</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Restated</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Previously</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Reported</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Restated</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 44%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Issuance of Series B convertible preferred stock, net of issuance costs</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,290,537</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,926,778</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,363,759</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deemed Dividend on Series B convertible preferred stock</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,782,100</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,479,308</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4,782,100</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(11,479,308</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Conversion of Series B convertible preferred stock to common stock</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(7,056,421</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(7,821,992</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,656,442</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,422,013</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div></div>

764000

1421851

742450

3360563

2110846

55000

-74753154

-65426329

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months Ended</div><br /> <div style="display: inline; font-weight: bold;">September</div><div style="display: inline; font-weight: bold;"> 30,</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Nine months</div><div style="display: inline; font-weight: bold;"> Ended</div><br /> <div style="display: inline; font-weight: bold;">September</div><div style="display: inline; font-weight: bold;"> 30,</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 52%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net Loss Per Share</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Numerator</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net loss</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3,309,866</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,184,510</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(9,326,825</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(6,129,553</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Deemed dividend attributable to preferred stock</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(11,479,308</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,568,132</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net loss attributable to common shareholders</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3,309,866</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,184,510</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(20,806,133</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(8,697,685</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Denominator</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Weighted average common shares outstanding</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,183,492</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,034,262</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,645,682</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">657,184</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Basic and diluted net loss per share</div> </td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.64</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2.11</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(5.71</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(13.23</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="width: 44%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="width: 111111%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">For the Three Months Ended<br /> June 30, 2018</div></div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td colspan="6" style="width: 111111%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">For the Six Months Ended<br /> June 30, 2018</div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 44%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="width: 1%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Previously</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Reported</div></div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="width: 1%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Restated</div></div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="width: 1%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Previously</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Reported</div></div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="width: 1%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Restated</div></div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 44%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deemed dividend attributable to preferred stock</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4,782,100</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(11,479,308</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4,782,100</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(11,479,308</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 44%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss applicable to common stockholders</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(8,924,677</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(15,621,885</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(10,799,059</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(17,496,267</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 44%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loss per common share -basic and diluted</div> </td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2.90</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(5.08</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3.77</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(6.11</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Preferred Stock Additional Paid-in Capital</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Common Stock Additional Paid-in Capital</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Previously</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Reported</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Restated</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Previously</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Reported</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Restated</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 44%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Issuance of Series B convertible preferred stock, net of issuance costs</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,290,537</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,926,778</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,363,759</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deemed Dividend on Series B convertible preferred stock</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,782,100</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,479,308</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4,782,100</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(11,479,308</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Conversion of Series B convertible preferred stock to common stock</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(7,056,421</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(7,821,992</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,656,442</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,422,013</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table></div>

0.0294

1.22

11111

125000

500000

5556

3197

199949

40.62

417

2300000

700000

611668

172510

783761

49.27

12.70

783761

12.70

5.64

2.38

2.39

1.75

0.25

0.5

0.25

0.5

P10Y

P4Y273D

P8Y346D

583812

P9Y153D

2651952

3517

5523255

-10107

2871303

13624

-10

-10106990

516833

9590167

-7056421

-7821992

6656442

7422013

6926778

5363759

12290551

12290537

6926778

5363759

726252

560369

10569109

6938687

477342

71887674

-65426329

3516996

994175

80811088

-74753154

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">NOTE <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7:</div> STOCKHOLDERS’ EQUITY</div></div> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">The Company is authorized to issue a total of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">185,000,000</div> shares of stock consisting of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">175,000,000</div> shares of common stock, par value <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.18</div> per share, and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,000,000</div> shares of preferred stock, par value <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.001</div> per share. The Company has designated <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">750,000</div> shares of Series A junior participating preferred stock, par value <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.001</div> per share, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,000</div> shares of Series A convertible preferred stock, par value <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.001</div> per share, and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25,000</div> shares of Series B convertible preferred stock, par value <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.001</div> per share, through the filings of certificates of designation with the Delaware Secretary of State. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No</div> </div>shares of Series A junior participating preferred stock and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> </div>shares of Series A convertible preferred stock are issued and outstanding as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2018.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 19, 2014, </div>the Company adopted a stockholder rights agreement which provides that all stockholders of record on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 26, 2014 </div>received a non-taxable distribution of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> preferred stock purchase right for each share of the Company’s common stock held by such stockholder. Each right is attached to and trades with the associated share of common stock. The rights will become exercisable only if <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> of the following occurs: (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>) a person becomes an “Acquiring Person” by acquiring beneficial ownership of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15%</div> or more of the Company’s common stock (or, in the case of a person who beneficially owned <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15%</div> or more of the Company’s common stock on the date the stockholder rights agreement was executed, by acquiring beneficial ownership of additional shares representing <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.0%</div> of the Company’s common stock then outstanding (excluding compensatory arrangements)), or (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div>) a person commences a tender offer that, if consummated, would result in such person becoming an Acquiring Person. If a person becomes an Acquiring Person, each right will entitle the holder, other than the Acquiring Person and certain related parties, to purchase a number of shares of the Company’s common stock with a market value that equals twice the exercise price of the right. The initial exercise price of each right is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$15.00,</div> so each holder (other than the Acquiring Person and certain related parties) exercising a right would be entitled to receive <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$30.00</div> worth of the Company’s common stock. If the Company is acquired in a merger or similar business combination transaction at any time after a person has become an Acquiring Person, each holder of a right (other than the Acquiring Person and certain related parties) will be entitled to purchase a similar amount of stock of the acquiring entity.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; text-decoration: underline;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> Subscription Rights Offering of Units Consisting of Series B Convertible Preferred Stock and Warrants</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 9, 2018, </div>the Company’s Registration Statement on Form S-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> with the Securities and Exchange Commission was declared effective to offer subscription rights to purchase up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25,000</div> units at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,000</div> per unit with each unit consisting of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> share of Series B convertible preferred stock and warrants to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">284</div> shares of common stock.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 29, 2018, </div>the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series B convertible preferred stock with the Delaware Secretary of State creating a new series of its authorized preferred stock, par value <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.001</div> per share, designated as the Series B convertible preferred stock. The number of shares initially constituting the Series B preferred stock was set at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25,000</div> shares.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 30, 2018, </div>the Company completed its previously announced rights offering pursuant to which the Company sold an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,624</div> units consisting of an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,624</div> shares of Series B convertible preferred stock and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,869,216</div> warrants, with each warrant exercisable for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> share of common stock at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4.048</div> per share (the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">“2018</div> Warrants”), resulting in net proceeds to the Company of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$12.3</div> million, after deducting expenses relating to the rights offering, including dealer-manager fees and expenses, and excluding any proceeds received upon exercise of any warrants.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Series B Convertible Preferred Stock</div></div>.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">The terms and provisions of our Series B convertible preferred stock are:</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Conversion.</div> Each share of Series B convertible preferred stock is convertible at our option at any time on or after the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> anniversary of the closing of the rights offering or at the option of the holder at any time, into the number of shares of our common stock determined by dividing the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,000</div> stated value per share of the Series B convertible preferred stock by a conversion price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.52</div> per share. In addition, the conversion price per share is subject to adjustment for stock dividends, distributions, subdivisions, combinations or reclassifications. Subject to limited exceptions, a holder of the Series B convertible preferred stock will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have the right to convert any portion of the Series B convertible preferred stock to the extent that, after giving effect to the conversion, the holder, together with its affiliates, would beneficially own in excess of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.99%</div> of the number of shares of our common stock outstanding immediately after giving effect to its conversion.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Fundamental Transactions.</div> In the event we effect certain mergers, consolidations, sales of substantially all of our assets, tender or exchange offers, reclassifications or share exchanges in which our common stock is effectively converted into or exchanged for other securities, cash or property, we consummate a business combination in which another person acquires <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50%</div> of the outstanding shares of our common stock, or any person or group becomes the beneficial owner of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50%</div> of the aggregate ordinary voting power represented by our issued and outstanding common stock, then, upon any subsequent conversion of the Series B convertible preferred stock, the holders of the Series B convertible preferred stock will have the right to receive any shares of the acquiring corporation or other consideration it would have been entitled to receive if it had been a holder of the number of shares of common stock then issuable upon conversion in full of the Series B convertible preferred stock.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Dividends.</div> Holders of Series B convertible preferred stock shall be entitled to receive dividends (on an as-if-converted-to-common-stock basis) in the same form as dividends actually paid on shares of the common stock when, as and if such dividends are paid on shares of common stock.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Voting Rights.</div> Except as otherwise provided in the certificate of designation or as otherwise required by law, the Series B convertible preferred stock has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> voting rights.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Liquidation Preference</div><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">. </div></div>Upon our liquidation, dissolution or winding-up, whether voluntary or involuntary, holders of Series B convertible preferred stock will be entitled to receive out of our assets, whether capital or surplus, the same amount that a holder of common stock would receive if the Series B convertible preferred stock were fully converted (disregarding for such purpose any conversion limitations under the certificate of designation) to common stock, which amounts shall be paid pari passu with all holders of common stock.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Redemption Rights. </div>We are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> obligated to redeem or repurchase any shares of Series B convertible preferred stock. Shares of Series B convertible preferred stock are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> otherwise entitled to any redemption rights, or mandatory sinking fund or analogous provisions.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> Warrants</div></div><div style="display: inline; font-style: italic;"> </div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">The terms and conditions of the warrants included in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> rights offering are as follows:</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Exercisability</div>. Each warrant is exercisable at any time and will expire <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">four</div> years from the date of issuance. The warrants are exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and payment in full for the number of shares of our common stock purchased upon such exercise, except in the case of a cashless exercise as discussed below.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">The number of shares of common stock issuable upon exercise of the warrants is subject to adjustment in certain circumstances, including a stock split of, stock dividend on, or a subdivision, combination or recapitalization of the common stock. Upon the merger, consolidation, sale of substantially all of our assets, or other similar transaction, the holders of warrants shall, at the option of the company, be required to exercise the warrants immediately prior to the closing of the transaction, or such warrants shall automatically expire. Upon such exercise, the holders of warrants shall participate on the same basis as the holders of common stock in connection with the transaction.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Cashless Exercise</div>. If at any time there is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> effective registration statement registering, or the prospectus contained therein is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> available for issuance of, the shares issuable upon exercise of the warrant, the holder <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>exercise the warrant on a cashless basis. When exercised on a cashless basis, a portion of the warrant is cancelled in payment of the purchase price payable in respect of the number of shares of our common stock purchasable upon such exercise.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Exercise Price</div>. Each warrant represents the right to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> share of common stock at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4.048</div> per share. In addition, the exercise price per share is subject to adjustment for stock dividends, distributions, subdivisions, combinations, or reclassifications, and for certain dilutive issuances. Subject to limited exceptions, a holder of warrants will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have the right to exercise any portion of the warrant to the extent that, after giving effect to the exercise, the holder, together with its affiliates, and any other person acting as a group together with the holder or any of its affiliates, would beneficially own in excess of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.99%</div> of the number of shares of our common stock outstanding immediately after giving effect to its exercise. The holder, upon notice to the Company, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>increase or decrease the beneficial ownership limitation provisions of the warrant, provided that in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> event shall the limitation exceed <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.99%</div> of the number of shares of our common stock outstanding immediately after giving effect to the exercise of the warrant.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Transferability</div>. Subject to applicable laws and restrictions, a holder <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>transfer a warrant upon surrender of the warrant to us with a completed and signed assignment in the form attached to the warrant. The transferring holder will be responsible for any tax that liability that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>arise as a result of the transfer.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Exchange Listing</div>. We do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> intend to apply to list the warrants on any securities exchange or recognized trading system.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Rights as Stockholder</div>. Except as set forth in the warrant, the holder of a warrant, solely in such holder’s capacity as a holder of a warrant, will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be entitled to vote, to receive dividends, or to any of the other rights of our stockholders.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Redemption Rights</div>. We <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>redeem the warrants for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.18</div> per warrant if the volume-weighted-average-price of our common stock equals or exceeds <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10.56</div> per share for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">ten</div> consecutive trading days, provided that we <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> do so prior to the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> anniversary of closing of the rights offering.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt 7.5pt 0pt 43.5pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Accounting Treatment</div></div></div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">The Company allocated the proceeds from the sale of the Series B convertible preferred stock and the warrants to purchase common stock to the separate securities issued. The Company allocated the amount representing the fair value of the warrants at the date of issuance to common stock based on the relative warrant fair value in the amount of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5,363,759,</div> which is net of issuance costs allocated to the warrants. Due to the allocation of a portion of the proceeds to the warrants, the convertible preferred stock contained a beneficial conversion feature upon issuance, which was recorded in the amount of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4,782,100</div> based on the relative fair value of the beneficial conversion feature. The discount on the convertible preferred stock was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$11,479,308,</div> which consists of the beneficial conversion feature of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4,782,100,</div> the allocation of a portion of the proceeds to the warrants in the amount of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5,363,759,</div> and the total issuance costs related to the financing of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,333,449.</div> The discount on the convertible preferred stock of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$11,479,308</div> was recorded as a deemed dividend upon issuance of the convertible preferred stock. The deemed dividend is reflected as an addition to net loss in the condensed consolidated statements of operations to arrive at net loss applicable to common shareholders. The Company has made an accounting policy election to record the deemed dividend related to discounts on convertible instruments at the time of issuance of the convertible instruments.</div>   <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Outstanding Warrants</div></div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2018, </div>warrants to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,318,475</div> shares of common stock were outstanding including:</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div> <table style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="width: 57%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="width: 1%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Outstanding </div><br /> <div style="display: inline; font-weight: bold;">Warrants to </div><br /> <div style="display: inline; font-weight: bold;">Purchase </div><br /> <div style="display: inline; font-weight: bold;">Shares</div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="3" rowspan="1" style="width: 35%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Exercise Price</div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Expiration Date</div></div> </td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 57%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 12%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 3%;"> </td> <td style="width: 5%;"> </td> <td style="width: 3%;"> </td> <td style="width: 1%;"> </td> <td style="width: 15%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 57%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2014 public offering</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,483</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 3%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$540.00 </div></td> <td style="width: 3%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;">January 29, 2019</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 57%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Placement agent fees for Company’s offerings</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,106</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 3%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">381.60</div></td> <td style="width: 5%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">– </div></td> <td style="width: 3%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">540.00</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;">November 4, 2018</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 57%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2017 Warrant B private placement</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">441,670</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 3%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.78 </div></td> <td style="width: 3%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;">December 22, 2018</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 57%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2018 Warrants</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,869,216</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 3%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; text-align: center; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.05 </div></td> <td style="width: 3%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;">May 30, 2022</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 57%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,318,475</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 3%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 3%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> </tr> </table> </div> <div style=" margin: 0pt 0pt 0pt 36pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt 0pt 0pt 36pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Conversion of Series B Convertible Preferred Stock</div></div></div> <div style=" margin: 0pt 0pt 0pt 36pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2018, </div>certain holders of the Series B convertible preferred stock exercised their conversion option and converted an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,285</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,107</div> shares, respectively, into <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">649,156</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,871,303</div> shares, respectively, of the Company's common stock based on the conversion ratio of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">284</div> shares of common stock for each share of Series B convertible preferred stock.</div></div>

P4Y

5183492

1034262

3645682

657184

xbrli:shares iso4217:USD thunderdome:item xbrli:pure iso4217:USD iso4217:USD xbrli:shares 0001488039 atos:The2010StockOptionAndIncentivePlanMember 2010-09-28 2010-09-28 0001488039 atos:The2010StockOptionAndIncentivePlanMember 2011-01-01 2011-12-31 0001488039 atos:The2010StockOptionAndIncentivePlanMember 2011-01-01 2017-12-31 0001488039 atos:The2010StockOptionAndIncentivePlanMember 2012-01-01 2012-12-31 0001488039 atos:The2010StockOptionAndIncentivePlanMember 2013-01-01 2013-12-31 0001488039 atos:The2010StockOptionAndIncentivePlanMember 2014-01-01 2014-12-31 0001488039 atos:The2010StockOptionAndIncentivePlanMember 2015-01-01 2015-12-31 0001488039 atos:The2010StockOptionAndIncentivePlanMember 2016-01-01 2016-12-31 0001488039 us-gaap:EmployeeStockOptionMember atos:The2010StockOptionAndIncentivePlanMember 2016-05-18 2016-05-18 0001488039 2017-01-01 2017-09-30 0001488039 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-09-30 0001488039 atos:SeriesAConvertiblePreferredStockMember 2017-01-01 2017-09-30 0001488039 atos:SeriesBConvertiblePreferredStockMember 2017-01-01 2017-09-30 0001488039 us-gaap:WarrantMember 2017-01-01 2017-09-30 0001488039 us-gaap:EmployeeStockOptionMember atos:The2010StockOptionAndIncentivePlanMember 2017-01-01 2017-09-30 0001488039 atos:OtherAssets1Member 2017-01-01 2017-09-30 0001488039 atos:ClassAAndClassBUnitsMember 2017-01-01 2017-09-30 0001488039 atos:UnitsConsistingOfSeriesBConvertiblePreferredStockAndWarrantsMember 2017-01-01 2017-09-30 0001488039 atos:The2010StockOptionAndIncentivePlanMember 2017-01-01 2017-12-31 0001488039 us-gaap:EmployeeStockOptionMember atos:The2010StockOptionAndIncentivePlanMember 2017-05-09 2017-05-09 0001488039 2017-07-01 2017-09-30 0001488039 us-gaap:EmployeeStockOptionMember 2017-07-01 2017-09-30 0001488039 atos:SeriesAConvertiblePreferredStockMember 2017-07-01 2017-09-30 0001488039 atos:SeriesBConvertiblePreferredStockMember 2017-07-01 2017-09-30 0001488039 us-gaap:WarrantMember 2017-07-01 2017-09-30 0001488039 us-gaap:EmployeeStockOptionMember atos:The2010StockOptionAndIncentivePlanMember 2017-07-01 2017-09-30 0001488039 2018-01-01 2018-06-30 0001488039 srt:ScenarioPreviouslyReportedMember 2018-01-01 2018-06-30 0001488039 srt:ScenarioPreviouslyReportedMember atos:SeriesBConvertiblePreferredStockMember 2018-01-01 2018-06-30 0001488039 srt:ScenarioPreviouslyReportedMember atos:AdditionalPaidInCapitalCommonStockMember 2018-01-01 2018-06-30 0001488039 atos:SeriesBConvertiblePreferredStockMember 2018-01-01 2018-06-30 0001488039 atos:AdditionalPaidInCapitalCommonStockMember 2018-01-01 2018-06-30 0001488039 2018-01-01 2018-09-30 0001488039 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001488039 atos:SeriesAConvertiblePreferredStockMember 2018-01-01 2018-09-30 0001488039 atos:SeriesBConvertiblePreferredStockMember 2018-01-01 2018-09-30 0001488039 us-gaap:WarrantMember 2018-01-01 2018-09-30 0001488039 us-gaap:EmployeeStockOptionMember atos:The2010StockOptionAndIncentivePlanMember 2018-01-01 2018-09-30 0001488039 atos:LiabilityOptionsMember 2018-01-01 2018-09-30 0001488039 atos:AtossaGeneticsAUSPtyLtdMember 2018-01-01 2018-09-30 0001488039 atos:OtherAssets1Member 2018-01-01 2018-09-30 0001488039 atos:PlacementAgentFeeMember 2018-01-01 2018-09-30 0001488039 atos:The2010StockOptionAndIncentivePlanMember 2018-01-01 2018-09-30 0001488039 atos:The2014PublicOfferingMember 2018-01-01 2018-09-30 0001488039 atos:The2017WarrantBPrivatePlacementMember 2018-01-01 2018-09-30 0001488039 atos:The2018WarrantsMember 2018-01-01 2018-09-30 0001488039 atos:ClassAAndClassBUnitsMember 2018-01-01 2018-09-30 0001488039 us-gaap:CommonStockMember 2018-01-01 2018-09-30 0001488039 atos:UnitsConsistingOfSeriesBConvertiblePreferredStockAndWarrantsMember 2018-01-01 2018-09-30 0001488039 atos:AdditionalPaidInCapitalCommonStockMember 2018-01-01 2018-09-30 0001488039 atos:AdditionalPaidInCapitalConvertiblePreferredStockMember 2018-01-01 2018-09-30 0001488039 us-gaap:CommonStockMember 2018-01-01 2018-09-30 0001488039 us-gaap:PreferredStockMember 2018-01-01 2018-09-30 0001488039 us-gaap:RetainedEarningsMember 2018-01-01 2018-09-30 0001488039 atos:The2018SubscriptionRightsOfferingMember 2018-01-01 2018-09-30 0001488039 2018-03-23 2018-03-23 0001488039 2018-04-01 2018-06-30 0001488039 srt:ScenarioPreviouslyReportedMember 2018-04-01 2018-06-30 0001488039 srt:ScenarioPreviouslyReportedMember atos:SeriesBConvertiblePreferredStockMember 2018-04-01 2018-06-30 0001488039 srt:ScenarioPreviouslyReportedMember atos:AdditionalPaidInCapitalConvertiblePreferredStockMember 2018-04-01 2018-06-30 0001488039 atos:SeriesBConvertiblePreferredStockMember 2018-04-01 2018-06-30 0001488039 atos:AdditionalPaidInCapitalConvertiblePreferredStockMember 2018-04-01 2018-06-30 0001488039 us-gaap:EmployeeStockOptionMember atos:The2010StockOptionAndIncentivePlanMember 2018-04-12 2018-04-12 0001488039 atos:ReverseStockSplitMember 2018-04-20 2018-04-20 0001488039 atos:SeriesBConvertiblePreferredStockMember atos:The2018SubscriptionRightsOfferingMember 2018-05-30 2018-05-30 0001488039 atos:The2018SubscriptionRightsOfferingMember 2018-05-30 2018-05-30 0001488039 atos:LiabilityOptionsMember 2018-06-27 2018-06-27 0001488039 atos:LiabilityOptionsMember atos:ChairmanOfTheBoardPresidentAndChiefExecutiveOfficerMember 2018-06-27 2018-06-27 0001488039 atos:LiabilityOptionsMember atos:ChiefFinancialOfficerGeneralCounselAndSecretaryMember 2018-06-27 2018-06-27 0001488039 atos:LiabilityOptionsMember atos:ShareBasedCompensationAwardTrancheFourMember 2018-06-27 2018-06-27 0001488039 atos:LiabilityOptionsMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2018-06-27 2018-06-27 0001488039 atos:LiabilityOptionsMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2018-06-27 2018-06-27 0001488039 atos:LiabilityOptionsMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2018-06-27 2018-06-27 0001488039 2018-07-01 2018-09-30 0001488039 us-gaap:EmployeeStockOptionMember 2018-07-01 2018-09-30 0001488039 atos:SeriesAConvertiblePreferredStockMember 2018-07-01 2018-09-30 0001488039 atos:SeriesBConvertiblePreferredStockMember 2018-07-01 2018-09-30 0001488039 us-gaap:WarrantMember 2018-07-01 2018-09-30 0001488039 us-gaap:EmployeeStockOptionMember atos:The2010StockOptionAndIncentivePlanMember 2018-07-01 2018-09-30 0001488039 atos:LiabilityOptionsMember 2018-07-01 2018-09-30 0001488039 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0001488039 us-gaap:SubsequentEventMember 2018-11-01 2018-11-01 0001488039 us-gaap:EmployeeStockOptionMember atos:The2010StockOptionAndIncentivePlanMember 2010-09-28 0001488039 2014-05-19 0001488039 2016-12-31 0001488039 atos:AtossaGeneticsAUSPtyLtdMember 2017-05-23 0001488039 2017-09-30 0001488039 2017-12-31 0001488039 atos:AtossaGeneticsAUSPtyLtdMember 2017-12-31 0001488039 atos:The2010StockOptionAndIncentivePlanMember 2017-12-31 0001488039 atos:SeriesAConvertiblePreferredStockMember 2017-12-31 0001488039 atos:SeriesBConvertiblePreferredStockMember 2017-12-31 0001488039 atos:AdditionalPaidInCapitalCommonStockMember 2017-12-31 0001488039 atos:AdditionalPaidInCapitalConvertiblePreferredStockMember 2017-12-31 0001488039 us-gaap:CommonStockMember 2017-12-31 0001488039 us-gaap:PreferredStockMember 2017-12-31 0001488039 us-gaap:RetainedEarningsMember 2017-12-31 0001488039 atos:The2018SubscriptionRightsOfferingMember 2018-05-09 0001488039 atos:SeriesBConvertiblePreferredStockMember 2018-05-29 0001488039 atos:The2018WarrantsMember 2018-05-30 0001488039 atos:The2018WarrantsMember atos:The2018SubscriptionRightsOfferingMember 2018-05-30 0001488039 2018-09-30 0001488039 us-gaap:EmployeeStockOptionMember atos:The2010StockOptionAndIncentivePlanMember 2018-09-30 0001488039 atos:LiabilityOptionsMember 2018-09-30 0001488039 atos:The2018WarrantsMember 2018-09-30 0001488039 atos:The2018WarrantsMember atos:The2018SubscriptionRightsOfferingMember 2018-09-30 0001488039 atos:AtossaGeneticsAUSPtyLtdMember 2018-09-30 0001488039 atos:PlacementAgentFeeMember 2018-09-30 0001488039 atos:PlacementAgentFeeMember srt:MaximumMember 2018-09-30 0001488039 atos:PlacementAgentFeeMember srt:MinimumMember 2018-09-30 0001488039 atos:The2010StockOptionAndIncentivePlanMember 2018-09-30 0001488039 atos:The2014PublicOfferingMember 2018-09-30 0001488039 atos:The2017WarrantBPrivatePlacementMember 2018-09-30 0001488039 atos:The2018WarrantsMember 2018-09-30 0001488039 atos:SeriesAConvertiblePreferredStockMember 2018-09-30 0001488039 atos:SeriesAJuniorParticipatingPreferredStockMember 2018-09-30 0001488039 atos:SeriesBConvertiblePreferredStockMember 2018-09-30 0001488039 atos:AdditionalPaidInCapitalCommonStockMember 2018-09-30 0001488039 atos:AdditionalPaidInCapitalConvertiblePreferredStockMember 2018-09-30 0001488039 us-gaap:CommonStockMember 2018-09-30 0001488039 us-gaap:PreferredStockMember 2018-09-30 0001488039 us-gaap:RetainedEarningsMember 2018-09-30 0001488039 us-gaap:SubsequentEventMember 2018-11-01 0001488039 2018-11-09

EX-101.SCH 7 atos-20180930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 1 - Nature of Operations link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 2 - Going Concern link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 3 - Summary of Accounting Policies link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 4 - Prepaid Expenses link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 5 - Research and Development Tax Rebate Receivable link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 6 - Payroll Liabilities link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 7 - Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 9 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 10 - Concentration of Credit Risk link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 11 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 12 - Stock Based Compensation link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 13 - Restatement to Previously Issued Condensed Consolidated Financial Statements link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 4 - Prepaid Expenses (Tables) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 6 - Payroll Liabilities (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 7 - Stockholders' Equity (Tables) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 12 - Stock Based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 13 - Restatement to Previously Issued Condensed Consolidated Financial Statements (Tables) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 2 - Going Concern (Details Textual) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 3 - Summary of Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 4 - Prepaid Expenses - Schedule of Prepaid Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 5 - Research and Development Tax Rebate Receivable (Details Textual) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 6 - Payroll Liabilities - Schedule of Payroll Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 7 - Stockholders' Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 7 - Stockholders' Equity - Schedule of Warrants (Details) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 9 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 10 - Concentration of Credit Risk (Details Textual) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 11 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 12 - Stock Based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 12 - Stock Based Compensation - Additional Shares Authorized (Details) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 12 - Stock Based Compensation - Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note 12 - Stock Based Compensation - Valuation Assumptions (Details) link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note 13 - Restatement to Previously Issued Condensed Consolidated Financial Statements (Details Textual) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note 13 - Restatement to Previously Issued Condensed Consolidated Financial Statements - Restatements (Details) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 8 atos-20180930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 atos-20180930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 atos-20180930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Dividend yield Note To Financial Statement Details Textual Significant Accounting Policies Note 4 - Prepaid Expenses Note 6 - Payroll Liabilities Risk free interest rate Note 7 - Stockholders' Equity Note 8 - Net Loss Per Share Note 12 - Stock Based Compensation Note 13 - Restatement to Previously Issued Condensed Consolidated Financial Statements Expected volatility Note 4 - Prepaid Expenses - Schedule of Prepaid Expenses (Details) Note 6 - Payroll Liabilities - Schedule of Payroll Liabilities (Details) Income Tax Disclosure [Text Block] Change in fair value of common stock warrants Note 7 - Stockholders' Equity - Schedule of Warrants (Details) Compensation cost for stock options granted Note 8 - Net Loss Per Share - Schedule of Earnings Per Share (Details) Note 8 - Net Loss Per Share - Schedule of Antidilutive Securities (Details) Note 12 - Stock Based Compensation - Additional Shares Authorized (Details) Other assets Note 12 - Stock Based Compensation - Stock Option Activity (Details) us-gaap_LiabilitiesCurrent Total Current Liabilities Note 12 - Stock Based Compensation - Valuation Assumptions (Details) Title of Individual [Axis] Note 13 - Restatement to Previously Issued Condensed Consolidated Financial Statements - Restatements (Details) Relationship to Entity [Domain] Notes To Financial Statements Other current liabilities Expected term (in years) (Year) Notes To Financial Statements [Abstract] Reclassification of warrant liability upon exercise of common stock warrants It represents common stock issued for exercise of common stock warrants. Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Other Assets 1 [Member] Related to a distinct category of other assets. Operating Expenses Class A and Class B Units [Member] Related to both class A and class B units. Share-based Compensation, Stock Options, Activity [Table Text Block] atos_OperatingLeaseLesseeMonthlyRentExpense Operating Lease, Lessee, Monthly Rent Expense The amount of monthly rent expense due from the lessee under the terms of an operating lease. us-gaap_LesseeOperatingLeaseTermOfContract Lessee, Operating Lease, Term of Contract us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio us-gaap_ConversionOfStockSharesIssued1 Conversion of Stock, Shares Issued Stock-based compensation liability Depreciation and amortization Vested and expected to vest, weighted average contractual life remaining in years (Year) us-gaap_ConversionOfStockSharesConverted1 Conversion of Stock, Shares Converted Vested and expected to vest, Aggregate intrinsic value Vested and expected to vest, shares (in shares) Vested and expected to vest, Weighted average exercise price per share (in dollars per share) Exercisable, Weighted average exercise price per share (in dollars per share) us-gaap_AssetsCurrent Total current assets Exercisable, weighted average contractual life remaining in years (Year) Exercisable, Aggregate intrinsic value Amount receivable for warrant exercise Stockholders' Equity Note Disclosure [Text Block] Exercisable, shares (in shares) Outstanding, weighted average contractual life remaining in years (Year) Outstanding, Aggregate intrinsic value Common stock - $0.18 par value; 175,000,000 shares authorized, and 5,523,255 and 2,651,952 shares issued and outstanding, as of September 30, 2018 and December 31, 2017, respectively us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance Adjustments to reconcile net loss to net cash used in operating activities us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Outstanding, Weighted average exercise price per share (in dollars per share) Outstanding, Weighted average exercise price per share (in dollars per share) Common stock, authorized (in shares) Common Stock, Shares Authorized Forfeited, Weighted average exercise price per share (in dollars per share) Common stock, issued (in shares) Expired, Weighted average exercise price per share (in dollars per share) Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Granted, Weighted average exercise price per share (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Restatement [Axis] Accrued expenses Restatement [Domain] Payroll liabilities Total payroll liabilities Previously Reported [Member] Range [Domain] Maximum [Member] Minimum [Member] Accounts payable us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Outstanding, shares (in shares) Outstanding, shares (in shares) Other current assets Range [Axis] Accrued bonus payable us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Expired, shares (in shares) Preferred stock - $0.001 par value; 10,000,000 shares authorized, consisting of Series A convertible preferred stock- $0.001 par value; 4,000 shares authorized, and 0 shares outstanding as of September 30, 2018 and December 31, 2017; Series B convertible preferred stock- $0.001 par value; 25,000 and 0 shares authorized, and 3,517 and 0 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively Preferred stock, issued (in shares) Preferred Stock, Shares Issued, Total Accrued payroll liabilities Other us-gaap_PolicyTextBlockAbstract Accounting Policies Accrued vacation Prepaid expenses Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Prepaid insurance us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion Convertible Preferred Stock, Shares Issued upon Conversion us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized NONCASH INVESTING AND FINANCING ACTIVITIES us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Additional paid-in capital- Series B convertible preferred stock us-gaap_PaymentsToAcquireFurnitureAndFixtures Purchase of furniture, fixtures and equipment Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Share-based Compensation Award, Tranche Three [Member] Current liabilities Vesting [Axis] Vesting [Domain] Share-based Compensation Award, Tranche One [Member] Share-based Compensation Award, Tranche Two [Member] us-gaap_Assets Total Assets Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Plan Name [Axis] Plan Name [Domain] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options CASH FLOWS FROM OPERATING ACTIVITIES us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Net loss applicable to common stockholders Net loss applicable to common shareholders Statement [Line Items] us-gaap_LossContingencyDamagesPaidValue Loss Contingency, Damages Paid, Value Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Additional paid-in capital Stockholders' equity Schedule of Error Corrections and Prior Period Adjustments [Table Text Block] Other income (expense) Equity Award [Domain] us-gaap_RestrictedCashAndCashEquivalents Restricted Cash and Cash Equivalents, Total Current assets Net loss Net Income (Loss) Attributable to Parent, Total Net loss Basis of Presentation and Significant Accounting Policies [Text Block] Award Type [Axis] Intangible assets, net us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING BALANCE CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE Retainer and security deposits us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH Net cash provided by financing activities Commitments and contingencies (note 11) Sale of Stock [Axis] Sale of Stock [Domain] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Operating loss Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities, Total Employee Stock Option [Member] us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities Warrant [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Commitments and Contingencies Disclosure [Text Block] atos_WarrantsAllocatedToCommonStockNetOfIssuanceCost Warrants Allocated to Common Stock , Net of Issuance Cost Represents the fair value of warrants allocated to common stock at the date of issuance. Furniture and equipment, net Units Consisting of Series B Convertible Preferred Stock and Warrants [Member] Represents information about units consisting of series B convertible preferred stock and warrants. Consolidated Entities [Axis] us-gaap_AccruedIncomeTaxes Accrued Income Taxes, Total Consolidated Entities [Domain] Payments of Class A units issuance costs Payments of Stock Issuance Costs CASH FLOWS FROM INVESTING ACTIVITIES Proceeds from exercise of warrants Retained Earnings [Member] Earnings Per Share [Text Block] Common Stock [Member] us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities Payroll liabilities Preferred Stock [Member] us-gaap_IncreaseDecreaseInAccruedLiabilities Accrued expenses Income taxes Equity Components [Axis] Equity Component [Domain] Loss on disposal of assets us-gaap_IncreaseDecreaseInAccountsPayable Accounts payable Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Class of Warrant or Right, Outstanding (in shares) Class of Warrant or Right, Outstanding us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Loss before income taxes us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights Series A Convertible Preferred Stock [Member] Represents information about series A convertible preferred stock. us-gaap_OperatingExpenses Total operating expenses Proceed for issuance of Units, net of issuance costs Proceeds from Issuance of Stock units The cash inflow from issuance of stock units. atos_ChangeInFairValueOfCommonStockWarrants Change in fair value of common stock warrants The amount of change in fair value of common stock warrants. Warrant financing expense Warrant financing expense The amount of warrant financing expense. Series B Convertible Preferred Stock [Member] Represents information about series B convertible preferred stock. General and administrative atos_PreferredStockDeemedDividend Preferred Stock, Deemed Dividend Deemed dividend attributable to preferred stock The amount of deemed dividend on preferred stock. Deemed Dividend on Series B convertible preferred stock Deemed Dividend on Series B convertible preferred stock Refers to the amount related to dividend on series A convertible preferred stock incurred during period. atos_AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOnPreferredStock Adjustments to Additional Paid in Capital, Beneficial Conversion Feature on Preferred Stock Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of convertible preferred stock with a beneficial conversion feature. Restricted cash Amortization of commitment shares It represents value of amortization of commitment shares. Change in stock-based compensation liability Represents the amount of change in stock-based compensation liability during the period. Allocation of Class A and Class B Unit proceeds to warrant liability The value represents the allocation of class A and class B unit proceeds to warrant liability. Reverse Stock Split [Member] The conversion of a reverse stock split where there is a reduction in the shares outstanding. atos_WorkingCapital Working Capital Represents the value of total net current assets after deducting net current liabilities as of the balance sheet date. EX-101.PRE 11 atos-20180930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2018	Nov. 09, 2018
Document Information [Line Items]
Entity Registrant Name	ATOSSA GENETICS INC
Entity Central Index Key	0001488039
Trading Symbol	atos
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		5,646,552
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q3
Amendment Flag	false

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 12,935,587	$ 7,217,469
Restricted cash	55,000	55,000
Prepaid expenses	290,331	250,944
Research and development tax rebate receivable	480,495	358,277
Other current assets	161,530	16,344
Total current assets	13,922,943	7,898,034
Furniture and equipment, net	57,804	11,467
Intangible assets, net	55,107	75,686
Other assets	88,518	178,907
Total Assets	14,124,372	8,164,094
Current liabilities
Accounts payable	550,704	334,901
Accrued expenses	51,673	90,105
Payroll liabilities	706,150	784,867
Stock-based compensation liability	2,180,659
Other current liabilities	66,077	15,534
Total Current Liabilities	3,555,263	1,225,407
Commitments and contingencies (note 11)
Stockholders' equity
Preferred stock - $0.001 par value; 10,000,000 shares authorized, consisting of Series A convertible preferred stock- $0.001 par value; 4,000 shares authorized, and 0 shares outstanding as of September 30, 2018 and December 31, 2017; Series B convertible preferred stock- $0.001 par value; 25,000 and 0 shares authorized, and 3,517 and 0 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively	4
Additional paid-in capital- Series B convertible preferred stock	3,516,996
Common stock - $0.18 par value; 175,000,000 shares authorized, and 5,523,255 and 2,651,952 shares issued and outstanding, as of September 30, 2018 and December 31, 2017, respectively	994,175	477,342
Additional paid-in capital	80,811,088	71,887,674
Accumulated deficit	(74,753,154)	(65,426,329)
Total Stockholders' Equity	10,569,109	6,938,687
Total Liabilities and Stockholders' Equity	$ 14,124,372	$ 8,164,094

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	10,000,000	10,000,000
Common stock, par value (in dollars per share)	$ 0.18	$ 0.18
Common stock, authorized (in shares)	175,000,000	175,000,000
Common stock, issued (in shares)	5,523,255	2,651,952
Common stock, outstanding (in shares)	5,523,255	2,651,952
Series A Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	4,000	4,000
Preferred stock, outstanding (in shares)	0	0
Preferred stock, issued (in shares)	0
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	25,000	0
Preferred stock, outstanding (in shares)	3,517	0
Preferred stock, issued (in shares)	3,517	0

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Operating Expenses
Research and development	$ 1,421,851	$ 742,450	$ 3,360,563	$ 2,110,846
General and administrative	1,888,119	1,313,477	5,966,504	3,544,935
Total operating expenses	3,309,970	2,055,927	9,327,067	5,655,781
Operating loss	(3,309,970)	(2,055,927)	(9,327,067)	(5,655,781)
Change in fair value of common stock warrants		(128,300)		(280,747)
Warrant financing expense				(192,817)
Other income (expense)	104	(283)	242	(208)
Loss before income taxes	(3,309,866)	(2,184,510)	(9,326,825)	(6,129,553)
Income taxes
Net loss	(3,309,866)	(2,184,510)	(9,326,825)	(6,129,553)
Deemed dividend attributable to preferred stock			(11,479,308)	(2,568,132)
Net loss applicable to common shareholders	$ (3,309,866)	$ (2,184,510)	$ (20,806,133)	$ (8,697,685)
Loss per common share -basic and diluted (in dollars per share)	$ (0.64)	$ (2.11)	$ (5.71)	$ (13.23)
Weighted average shares outstanding - basic and diluted (in shares)	5,183,492	1,034,262	3,645,682	657,184

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - 9 months ended Sep. 30, 2018 - USD ($)	Preferred Stock [Member]	Additional Paid in Capital, Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid in Capital, Common Stock [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2017			2,651,952
Balance at Dec. 31, 2017			$ 477,342	$ 71,887,674	$ (65,426,329)	$ 6,938,687
Issuance of Series B convertible preferred stock and warrants, net of issuance costs of $1,333,449 (in shares)	13,624
Issuance of Series B convertible preferred stock and warrants, net of issuance costs of $1,333,449	$ 14	6,926,778		5,363,759		12,290,551
Allocation of Series B convertible preferred stock proceeds to beneficial conversion feature		(4,782,100)		4,782,100
Deemed Dividend on Series B convertible preferred stock		11,479,308		(11,479,308)
Conversion of Series B convertible preferred stock to common stock (in shares)	(10,107)		2,871,303
Conversion of Series B convertible preferred stock to common stock	$ (10)	(10,106,990)	$ 516,833	9,590,167
Amortization of commitment shares				(59,556)		(59,556)
Compensation cost for stock options granted to executives and employees				726,252		726,252
Net loss					(9,326,825)	(9,326,825)
Balance (in shares) at Sep. 30, 2018	3,517		5,523,255
Balance at Sep. 30, 2018	$ 4	$ 3,516,996	$ 994,175	$ 80,811,088	$ (74,753,154)	$ 10,569,109

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (Parentheticals)	9 Months Ended
	Sep. 30, 2018 USD ($)
Payments of Class A units issuance costs	$ 1,333,449

XML 18 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (9,326,825)	$ (6,129,553)
Adjustments to reconcile net loss to net cash used in operating activities
Compensation cost for stock options granted	726,252	560,369
Loss on disposal of assets		17,695
Depreciation and amortization	28,690	102,074
Change in fair value of common stock warrants		280,747
Change in stock-based compensation liability	2,180,659
Warrant financing expense		192,817
Changes in operating assets and liabilities:
Prepaid expenses	(39,387)	14,195
Research and development tax rebate receivable	(122,218)
Accounts payable	215,803	126,079
Payroll liabilities	(78,717)	(142,312)
Accrued expenses	(38,432)	33,578
Other current liabilities	50,543	7,212
Net cash used in operating activities	(6,517,985)	(4,911,268)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of furniture, fixtures and equipment	(54,448)
Net cash used in investing activities	(54,448)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from exercise of warrants		745,333
Net cash provided by financing activities	12,290,551	4,616,969
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	5,718,118	(294,299)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING BALANCE	7,272,469	3,082,962
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE	12,990,587	2,788,663
NONCASH INVESTING AND FINANCING ACTIVITIES
Reclassification of warrant liability upon exercise of common stock warrants		1,893,160
Amount receivable for warrant exercise		3,900
Allocation of Class A and Class B Unit proceeds to warrant liability		1,612,413
Amortization of commitment shares issued for shares distributed for capital contribution	59,556	59,558
Units Consisting of Series B Convertible Preferred Stock and Warrants [Member]
CASH FLOWS FROM FINANCING ACTIVITIES
Proceed for issuance of Units, net of issuance costs	12,290,551
Class A and Class B Units [Member]
CASH FLOWS FROM FINANCING ACTIVITIES
Proceed for issuance of Units, net of issuance costs		3,871,636
Other Assets 1 [Member]
Changes in operating assets and liabilities:
Other assets	$ (114,353)	$ 25,831

XML 19 R8.htm IDEA: XBRL DOCUMENT

Note 1 - Nature of Operations	9 Months Ended
Note 1 - Nature of Operations	Sep. 30, 2018
Notes to Financial Statements
Nature of Operations [Text Block]	NOTE 1: NATURE OF OPERATIONS Atossa Genetics Inc. (the “Company”) was incorporated on April 30, 2009 in the State of Delaware. The Company was formed to develop and market medical devices, laboratory tests and therapeutics to address breast health conditions. The Company’s fiscal year ends on December 31. The Company is focused on development of its pharmaceutical and drug delivery programs.

XML 20 R9.htm IDEA: XBRL DOCUMENT

Note 2 - Going Concern	9 Months Ended
Note 2 - Going Concern	Sep. 30, 2018
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	NOTE 2: GOING CONCERN The Company’s consolidated financial statements are prepared using Generally Accepted Accounting Principles in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses and negative operating cash flows since inception. For the nine months ended September 30, 2018, the Company recorded a net loss of approximately $9.3 million and used approximately $6.5 million of cash in operating activities. As of September 30, 2018, the Company had approximately $12.9 million in cash and cash equivalents and working capital of approximately $10.4 million. The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. The Company can give no assurances that any additional capital that it is able to obtain, if any, will be sufficient to meet its needs, or that any such capital will be obtained on acceptable terms. If the Company is unable to obtain adequate capital, it could be forced to cease operations or substantially curtail its activities. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities should the Company be unable to continue as a going concern. Management’s plan to continue as a going concern includes obtaining additional capital resources. Management’s plans to obtain such resources for the Company include obtaining capital from the sale of its equity securities, entering into strategic partnership arrangements, potential exercise of outstanding warrants, and short-term borrowings from banks, stockholders or other related parties, if needed. However, management cannot provide any assurance that the Company will be successful in accomplishing any of its plans. As of the date of filing this report, we expect that our existing resources will be sufficient to fund our planned operations for the next 9 to 15 months; however, additional capital resources will be needed to fund operations longer-term. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraphs and eventually to secure other sources of financing and attain profitable operations.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Note 3 - Summary of Accounting Policies	9 Months Ended
Note 3 - Summary of Accounting Policies	Sep. 30, 2018
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	NOTE 3: SUMMARY OF ACCOUNTING POLICIES Basis of Presentation: The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10 -Q and Rule 10 - 01 of Regulation S- X. They do not include all information and notes required by GAAP for complete financial statements. However, except as disclosed herein, there has been no material change in the information disclosed in the Notes to Consolidated Financial Statements included in the Annual Report on Form 10 -K of the Company for the year ended December 31, 2017. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. On April 20, 2018, the Company completed a 1 -for- 12 reverse stock split of the shares of the Company’s common stock (the “Reverse Stock Split”). As a result of the Reverse Stock Split, every 12 shares of issued and outstanding common stock were combined into one issued and outstanding share of common stock, and the par value per share was changed to $0.18 per share. The number of authorized shares of common stock was not reduced as a result of the Reverse Stock Split. The Company’s common stock began trading on a reverse stock split-adjusted basis on April 20, 2018. All share and per share data included in this report has been retroactively restated to reflect the Reverse Stock Split. Use of Estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Recently Issued Accounting Pronouncements: In February 2016, Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016 - 02, Lease Accounting Topic 842. This ASU requires a lessee to recognize lease assets and liabilities on the balance sheet for all arrangements with terms longer than 12 months. The new standard applies a right-of-use (ROU) model that requires a lessee to record, for all leases with a lease term of more than 12 months, an asset representing its right to use the underlying asset for the lease term and a liability to make lease payments. The lease term is the non-cancellable period of the lease, and includes both periods covered by an option to extend the lease, if the lessee is reasonably certain to exercise that option, and periods covered by an option to terminate the lease, if the lessee is reasonably certain not to exercise that termination option. For leases with a lease term of 12 months or less, a practical expedient is available whereby a lessee may elect, by class of underlying asset, not to recognize an ROU asset or lease liability. A lessee making this accounting policy election would recognize lease expense over the term of the lease, generally in a straight-line pattern. The lessor accounting remains largely consistent with existing GAAP. The new standard takes effect in 2019 for public entities. The Company has not currently adopted the provisions of ASU No. 2016 - 02 and believes that the impact of adopting ASU 2016 - 02 will not be material to its consolidated financial statements, though will require the recognition of an operating lease liability and right-of-use asset upon adoption, based on the lease composition disclosed in Footnote 11. In November 2016, the FASB issued ASU No. 2016 - 18, Statement of Cash Flows , amending the presentation of restricted cash within the statement of cash flows. The new guidance requires that restricted cash be included within cash and cash equivalents on the statement of cash flows. The Company adopted the provisions of ASU No. 2016 - 18 as of January 1, 2018 and has included restricted cash with cash and cash equivalents on the accompanying statement of cash flows, including reclassifying 2017 balances. For the three and nine months ended September 30, 2018 and September 30, 2017, we included $55,000 of restricted cash in cash and cash equivalents on the statement of cash flows. The restricted cash represents a required deposit for the Company credit card and is restricted until the Company no longer has the credit card or the limit changes on the credit card. In July 2017, the FASB issued ASU 2017 - 11, Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception . Part I of this ASU addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of future equity offerings. Current accounting guidance requires financial instruments with down round features to be accounted for at fair value. Part II of the Update applies only to nonpublic companies and is therefore not applicable to the Company. The amendments in Part I of the Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. This Update is effective for public entities for fiscal years beginning after December 15, 2018. Early adoption is permitted. The Company early adopted the provisions of ASU No. 2017 - 11 as of January 1, 2018. As the Company does not have any financial instruments with down round features, this ASU did not have a material impact on the financial statements upon adoption. In June 2018, the FASB issued ASU 2018 - 07, Compensation-Stock Compensation Improvements to Nonemployee Share Based Payment Accounting. This ASU simplifies several aspects of the accounting for non-employee share-based payment transactions resulting from expanding the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide financing to the issuer or was granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers . This update is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted. The Company early adopted the provisions of ASU No. 2018 - 17 as of April 1, 2018 and it did not have a material impact on the financial statements upon adoption.

XML 22 R11.htm IDEA: XBRL DOCUMENT

Note 4 - Prepaid Expenses

9 Months Ended

Sep. 30, 2018

Notes to Financial Statements

Prepaid Expenses [Text Block]

NOTE

PREPAID EXPENSES

Prepaid expenses consisted of the following:

	September 30,		December 31,
	2018		2017
Prepaid insurance	$	46,618	$	125,056
Retainer and security deposits		16,718		14,218
Professional services		93,557		97,788
Prepaid research and development		104,299
Financial exchange fees		13,750
Other		15,389		13,882
	$	290,331	$	250,944

XML 23 R12.htm IDEA: XBRL DOCUMENT

Note 5 - Research and Development Tax Rebate Receivable	9 Months Ended
Note 5 - Research and Development Tax Rebate Receivable	Sep. 30, 2018
Notes to Financial Statements
Research and Development Tax Rebate Receivable [Text Block]	NOTE 5: RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE On May 23, 2017 Atossa formed a wholly-owned subsidiary in Australia called Atossa Genetics AUS Pty Ltd. The purpose of this subsidiary is to perform research and development activities (“R&D”) including our Phase 1 and Phase 2 Endoxifen clinical trials. Australia offers an R&D cash rebate of $0.435 per dollar spent on qualified R&D activities incurred in the country. For the nine months ended September 30, 2018, the Company incurred qualified R&D expenses of approximately $764,000 and recorded a rebate receivable of approximately $333,000 and a corresponding credit to R&D expenses for the nine months ended September 30, 2018. At September 30, 2018, we had a total R&D rebate receivable of approximately $481,000 that includes approximately $148,000 receivable remaining from the year ended December 31, 2017.

XML 24 R13.htm IDEA: XBRL DOCUMENT

Note 6 - Payroll Liabilities

9 Months Ended

Sep. 30, 2018

Notes to Financial Statements

Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]

NOTE

PAYROLL LIABILITIES

Payroll liabilities consisted of the following:

	September 30, 2018		December 31, 2017
Accrued bonus payable	$	480,917	$	566,000
Accrued vacation		156,775		147,861
Accrued payroll liabilities		68,458		71,006
Total payroll liabilities	$	706,150	$	784,867

XML 25 R14.htm IDEA: XBRL DOCUMENT

Note 7 - Stockholders' Equity

9 Months Ended

Sep. 30, 2018

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

NOTE

STOCKHOLDERS’ EQUITY

The Company is authorized to issue a total of

185,000,000

shares of stock consisting of

175,000,000

shares of common stock, par value

$0.18

per share, and

10,000,000

shares of preferred stock, par value

$0.001

per share. The Company has designated

750,000

shares of Series A junior participating preferred stock, par value

$0.001

per share,

4,000

shares of Series A convertible preferred stock, par value

$0.001

per share, and

25,000

shares of Series B convertible preferred stock, par value

$0.001

per share, through the filings of certificates of designation with the Delaware Secretary of State.

shares of Series A junior participating preferred stock and

shares of Series A convertible preferred stock are issued and outstanding as of

September 30, 2018.

May 19, 2014,

the Company adopted a stockholder rights agreement which provides that all stockholders of record on

May 26, 2014

received a non-taxable distribution of

one

preferred stock purchase right for each share of the Company’s common stock held by such stockholder. Each right is attached to and trades with the associated share of common stock. The rights will become exercisable only if

one

of the following occurs: (

) a person becomes an “Acquiring Person” by acquiring beneficial ownership of

15%

or more of the Company’s common stock (or, in the case of a person who beneficially owned

15%

or more of the Company’s common stock on the date the stockholder rights agreement was executed, by acquiring beneficial ownership of additional shares representing

2.0%

of the Company’s common stock then outstanding (excluding compensatory arrangements)), or (

) a person commences a tender offer that, if consummated, would result in such person becoming an Acquiring Person. If a person becomes an Acquiring Person, each right will entitle the holder, other than the Acquiring Person and certain related parties, to purchase a number of shares of the Company’s common stock with a market value that equals twice the exercise price of the right. The initial exercise price of each right is

$15.00,

so each holder (other than the Acquiring Person and certain related parties) exercising a right would be entitled to receive

$30.00

worth of the Company’s common stock. If the Company is acquired in a merger or similar business combination transaction at any time after a person has become an Acquiring Person, each holder of a right (other than the Acquiring Person and certain related parties) will be entitled to purchase a similar amount of stock of the acquiring entity.

2018

Subscription Rights Offering of Units Consisting of Series B Convertible Preferred Stock and Warrants

May 9, 2018,

the Company’s Registration Statement on Form S-

with the Securities and Exchange Commission was declared effective to offer subscription rights to purchase up to

25,000

units at

$1,000

per unit with each unit consisting of

one

share of Series B convertible preferred stock and warrants to purchase

284

shares of common stock.

May 29, 2018,

the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series B convertible preferred stock with the Delaware Secretary of State creating a new series of its authorized preferred stock, par value

$0.001

per share, designated as the Series B convertible preferred stock. The number of shares initially constituting the Series B preferred stock was set at

25,000

shares.

May 30, 2018,

the Company completed its previously announced rights offering pursuant to which the Company sold an aggregate of

13,624

units consisting of an aggregate of

13,624

shares of Series B convertible preferred stock and

3,869,216

warrants, with each warrant exercisable for

one

share of common stock at an exercise price of

$4.048

per share (the

“2018

Warrants”), resulting in net proceeds to the Company of approximately

$12.3

million, after deducting expenses relating to the rights offering, including dealer-manager fees and expenses, and excluding any proceeds received upon exercise of any warrants.

Series B Convertible Preferred Stock

The terms and provisions of our Series B convertible preferred stock are:

Conversion.

Each share of Series B convertible preferred stock is convertible at our option at any time on or after the

first

anniversary of the closing of the rights offering or at the option of the holder at any time, into the number of shares of our common stock determined by dividing the

$1,000

stated value per share of the Series B convertible preferred stock by a conversion price of

$3.52

per share. In addition, the conversion price per share is subject to adjustment for stock dividends, distributions, subdivisions, combinations or reclassifications. Subject to limited exceptions, a holder of the Series B convertible preferred stock will

not

have the right to convert any portion of the Series B convertible preferred stock to the extent that, after giving effect to the conversion, the holder, together with its affiliates, would beneficially own in excess of

9.99%

of the number of shares of our common stock outstanding immediately after giving effect to its conversion.

Fundamental Transactions.

In the event we effect certain mergers, consolidations, sales of substantially all of our assets, tender or exchange offers, reclassifications or share exchanges in which our common stock is effectively converted into or exchanged for other securities, cash or property, we consummate a business combination in which another person acquires

50%

of the outstanding shares of our common stock, or any person or group becomes the beneficial owner of

50%

of the aggregate ordinary voting power represented by our issued and outstanding common stock, then, upon any subsequent conversion of the Series B convertible preferred stock, the holders of the Series B convertible preferred stock will have the right to receive any shares of the acquiring corporation or other consideration it would have been entitled to receive if it had been a holder of the number of shares of common stock then issuable upon conversion in full of the Series B convertible preferred stock.

Dividends.

Holders of Series B convertible preferred stock shall be entitled to receive dividends (on an as-if-converted-to-common-stock basis) in the same form as dividends actually paid on shares of the common stock when, as and if such dividends are paid on shares of common stock.

Voting Rights.

Except as otherwise provided in the certificate of designation or as otherwise required by law, the Series B convertible preferred stock has

voting rights.

Liquidation Preference

Upon our liquidation, dissolution or winding-up, whether voluntary or involuntary, holders of Series B convertible preferred stock will be entitled to receive out of our assets, whether capital or surplus, the same amount that a holder of common stock would receive if the Series B convertible preferred stock were fully converted (disregarding for such purpose any conversion limitations under the certificate of designation) to common stock, which amounts shall be paid pari passu with all holders of common stock.

Redemption Rights.

We are

not

obligated to redeem or repurchase any shares of Series B convertible preferred stock. Shares of Series B convertible preferred stock are

not

otherwise entitled to any redemption rights, or mandatory sinking fund or analogous provisions.

2018

Warrants

The terms and conditions of the warrants included in the

2018

rights offering are as follows:

Exercisability

. Each warrant is exercisable at any time and will expire

four

years from the date of issuance. The warrants are exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and payment in full for the number of shares of our common stock purchased upon such exercise, except in the case of a cashless exercise as discussed below.

Cashless Exercise

. If at any time there is

effective registration statement registering, or the prospectus contained therein is

not

available for issuance of, the shares issuable upon exercise of the warrant, the holder

may

exercise the warrant on a cashless basis. When exercised on a cashless basis, a portion of the warrant is cancelled in payment of the purchase price payable in respect of the number of shares of our common stock purchasable upon such exercise.

Exercise Price

. Each warrant represents the right to purchase

one

share of common stock at an exercise price of

$4.048

per share. In addition, the exercise price per share is subject to adjustment for stock dividends, distributions, subdivisions, combinations, or reclassifications, and for certain dilutive issuances. Subject to limited exceptions, a holder of warrants will

not

have the right to exercise any portion of the warrant to the extent that, after giving effect to the exercise, the holder, together with its affiliates, and any other person acting as a group together with the holder or any of its affiliates, would beneficially own in excess of

4.99%

of the number of shares of our common stock outstanding immediately after giving effect to its exercise. The holder, upon notice to the Company,

may

increase or decrease the beneficial ownership limitation provisions of the warrant, provided that in

event shall the limitation exceed

9.99%

of the number of shares of our common stock outstanding immediately after giving effect to the exercise of the warrant.

Transferability

. Subject to applicable laws and restrictions, a holder

may

transfer a warrant upon surrender of the warrant to us with a completed and signed assignment in the form attached to the warrant. The transferring holder will be responsible for any tax that liability that

may

arise as a result of the transfer.

Exchange Listing

. We do

not

intend to apply to list the warrants on any securities exchange or recognized trading system.

Rights as Stockholder

. Except as set forth in the warrant, the holder of a warrant, solely in such holder’s capacity as a holder of a warrant, will

not

be entitled to vote, to receive dividends, or to any of the other rights of our stockholders.

Redemption Rights

. We

may

redeem the warrants for

$0.18

per warrant if the volume-weighted-average-price of our common stock equals or exceeds

$10.56

per share for

ten

consecutive trading days, provided that we

may

not

do so prior to the

first

anniversary of closing of the rights offering.

Accounting Treatment

$5,363,759,

which is net of issuance costs allocated to the warrants. Due to the allocation of a portion of the proceeds to the warrants, the convertible preferred stock contained a beneficial conversion feature upon issuance, which was recorded in the amount of

$4,782,100

based on the relative fair value of the beneficial conversion feature. The discount on the convertible preferred stock was

$11,479,308,

which consists of the beneficial conversion feature of

$4,782,100,

the allocation of a portion of the proceeds to the warrants in the amount of

$5,363,759,

and the total issuance costs related to the financing of

$1,333,449.

The discount on the convertible preferred stock of

$11,479,308

was recorded as a deemed dividend upon issuance of the convertible preferred stock. The deemed dividend is reflected as an addition to net loss in the condensed consolidated statements of operations to arrive at net loss applicable to common shareholders. The Company has made an accounting policy election to record the deemed dividend related to discounts on convertible instruments at the time of issuance of the convertible instruments.

Outstanding Warrants

As of

September 30, 2018,

warrants to purchase

4,318,475

shares of common stock were outstanding including:

	Outstanding Warrants to Purchase Shares		Exercise Price			Expiration Date

2014 public offering		6,483		$540.00		January 29, 2019
Placement agent fees for Company’s offerings		1,106	381.60	–	540.00	November 4, 2018
2017 Warrant B private placement		441,670		3.78		December 22, 2018
2018 Warrants		3,869,216		4.05		May 30, 2022
		4,318,475

Conversion of Series B Convertible Preferred Stock

During the

three

and

nine

months ended

September 30, 2018,

certain holders of the Series B convertible preferred stock exercised their conversion option and converted an aggregate of

2,285

and

10,107

shares, respectively, into

649,156

and

2,871,303

shares, respectively, of the Company's common stock based on the conversion ratio of approximately

284

shares of common stock for each share of Series B convertible preferred stock.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Note 8 - Net Loss Per Share

9 Months Ended

Sep. 30, 2018

Notes to Financial Statements

Earnings Per Share [Text Block]

NOTE

NET LOSS PER SHARE

The Company accounts for and discloses net income (loss) per common share in accordance with Accounting Standards Codification ("ASC") Topic

260,

Earnings Per Share

. Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. In addition, in computing the dilutive effect of convertible securities, the numerator is adjusted to add back any convertible preferred dividends. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of potential future exercises of outstanding stock options and common stock warrants. Because the inclusion of potential common shares would be anti-dilutive for all periods presented they have been excluded from the calculation.

The following table summarizes the Company’s calculation of net loss per common share:

	Three Months Ended September 30,						Nine months Ended September 30,
	2018			2017			2018			2017
Net Loss Per Share
Numerator
Net loss	$	(3,309,866	)	$	(2,184,510	)	$	(9,326,825	)	$	(6,129,553	)
Deemed dividend attributable to preferred stock								(11,479,308	)		(2,568,132	)
Net loss attributable to common shareholders	$	(3,309,866	)	$	(2,184,510	)	$	(20,806,133	)	$	(8,697,685	)
Denominator
Weighted average common shares outstanding		5,183,492			1,034,262			3,645,682			657,184
Basic and diluted net loss per share	$	(0.64	)	$	(2.11	)	$	(5.71	)	$	(13.23	)

The following table sets forth the number of potential common shares excluded from the calculation of net loss per diluted share for the

three

and

nine

months ended

September 30, 2018

and

2017

because including them would be anti-dilutive:

	Three Months Ended September 30,				Nine months Ended September 30,
	2018		2017		2018		2017
Options to purchase common stock		783,794		176,502		388,377		100,505
Series A convertible preferred stock				42,480				74,651
Series B convertible preferred stock		1,338,916				751,332
Warrants to purchase common stock		4,716,935		138,365		2,644,946		227,229
Total		6,839,645		357,347		3,784,655		402,385

For the

three

and

nine

months ended

September 30, 2018

and

2017,

the average price of our common stock was less than the exercise price of the vested stock options and exercisable warrants.

XML 27 R16.htm IDEA: XBRL DOCUMENT

Note 9 - Income Taxes	9 Months Ended
Note 9 - Income Taxes	Sep. 30, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 9: INCOME TAXES Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. As a result of the Company’s cumulative losses, management has concluded that a full valuation allowance against the Company’s net deferred tax assets is appropriate. No income tax liabilities existed as of September 30, 2018 and December 31, 2017 due to the Company’s continuing operating losses.

XML 28 R17.htm IDEA: XBRL DOCUMENT

Note 10 - Concentration of Credit Risk	9 Months Ended
Note 10 - Concentration of Credit Risk	Sep. 30, 2018
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	NOTE 10: CONCENTRATION OF CREDIT RISK Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At September 30, 2018 and December 31, 2017, the Company had $12,685,587 and $6,967,469 in excess of the FDIC insured limit, respectively.

XML 29 R18.htm IDEA: XBRL DOCUMENT

Note 11 - Commitments and Contingencies	9 Months Ended
Note 11 - Commitments and Contingencies	Sep. 30, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 11: COMMITMENTS AND CONTINGENCIES Lease Commitments On November 1, 2018, the Company entered into an operating lease to pay $3,660 monthly rent for a term of 22 months. The total future minimum lease payments due under this lease are $80,500. Litigation and Contingencies On October 10, 2013, a putative securities class action complaint, captioned Cook v. Atossa Genetics, Inc., et al. , No. 2:13 -cv- 01836 -RSM, was filed in the United States District Court for the Western District of Washington against us, certain of our directors and officers and the underwriters of our November 2012 initial public offering. The complaint alleged that all defendants violated Sections 11 and 12 (a)( 2 ), and that we and certain of our directors and officers violated Section 15, of the Securities Act by making material false and misleading statements and omissions in the offering’s registration statement, and that we and certain of our directors and officers violated Sections 10 (b) and 20A of the Exchange Act and SEC Rule 10b - 5 promulgated thereunder by making false and misleading statements and omissions in the registration statement and in certain of our subsequent press releases and SEC filings with respect to our NAF specimen collection process, our ForeCYTE Breast Health Test and our MASCT device. The complaint sought, on behalf of persons who purchased our common stock between November 8, 2012 and October 4, 2013, inclusive, damages of an unspecific amount. On March 23, 2018, the parties filed a stipulation of settlement with the court to settle the matter for $3.5 million, completely funded by defendants’ insurers, and on July 20, 2018 the Court approved the settlement. This case is considered closed as of September 30, 2018. We are subject to other legal proceedings and claims that arise in the normal course of business. We believe these matters are either without merit or of a kind that should not have a material effect, individually or in the aggregate, on our financial position, results of operations or cash flows.

XML 30 R19.htm IDEA: XBRL DOCUMENT

Note 12 - Stock Based Compensation

9 Months Ended

Sep. 30, 2018

Notes to Financial Statements

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

NOTE

12:

STOCK BASED COMPENSATION

Stock Option and Incentive Plan

September 28, 2010,

the Board of Directors approved the adoption of the

2010

Stock Option and Incentive Plan the (

“2010

Plan”) to provide for the grant of equity-based awards to employees, officers, non-employee directors and other key persons providing services to the Company. Awards of incentive options

may

be granted under the

2010

Plan until

September 2020.

other awards

may

be granted under the

2010

Plan after the date that is

years from the date of stock-holder approval. An aggregate of

5,556

shares were initially reserved for issuance in connection with awards granted under the

2010

Plan and on

May 18, 2016,

an additional

11,111

shares were reserved for issuance under the

2010

Plan. On

May 9, 2017,

the stockholders approved an additional

125,000

shares for issuance under the

2010

Plan. On

April 12, 2018,

the stockholders approved an additional

500,000

shares for issuance under the

2010

Plan.

The following table presents the automatic additions to the

2010

Plan since inception pursuant to the “evergreen” terms of the

2010

Plan:

January 1,	Number of shares
2012		2,502
2013		2,871
2014		4,128
2015		5,463
2016		18,368
2017		12,623
2018		106,076
Total additional shares		152,031

The Company did

not

grant options to purchase shares of common stock during the

three

months ended

September 30, 2018

2017.

options were exercised during the

three

nine

months ended

September 30, 2018.

There are

3,197

shares available for grant under the

2010

Plan as of

September 30, 2018.

$332,063

and

$224,254

for the

three

months ended

September 30, 2018

and

2017,

respectively and

$726,252

and

$560,369

for the

nine

months ended

September 30, 2018

and

2017,

respectively (excluding the liability options discussed below).

Options issued and outstanding as of

September 30, 2018

under the

2010

Plan and their activities during the

nine

months then ended are as follows:

	Number of Underlying Shares			Weighted- Average Exercise Price Per Share		Weighted- Average Contractual Life Remaining in Years		Aggregate Intrinsic Value
Outstanding as of January 1, 2018		172,510		$	49.27			$
Granted		611,668			2.39
Forfeited		(417	)		5.64
Expired
Outstanding as of September 30, 2018		783,761			12.70		9.42	$
Exercisable as of September 30, 2018		199,949			40.62		8.95	$
Vested and expected to vest		783,761			12.70		9.42	$

September 30, 2018,

there were

583,812

unvested options outstanding and the related unrecognized total compensation cost associated with these options was approximately

$1,479,610.

This expense is expected to be recognized over a weighted-average period of

1.56

years.

Option Grants Classified as Liabilities (“Liability Grants”)

June 27, 2018,

the Company granted

2,300,000

options to the Chief Executive Officer and

700,000

to the Chief Financial Officer. Each option is exercisable for an equivalent number of shares of Company common stock. The options were granted pursuant to an option award agreement and were granted outside the Company’s

2010

Plan; however, they are subject to the terms and conditions of the

2010

Plan.

The Liability Grants are exercisable for shares of common stock at an exercise price of

$2.38

per share, which was the fair market value on the date of grant. The options have an exercise period of

ten

years from their date of issuance. If at the time the options are exercised the Company cannot deliver shares of common stock to the optionee including, for example, if there are insufficient shares available under the Plan at the time of exercise, then in lieu of the optionee paying the exercise price and the Company issuing shares of stock, the option

may

only be exercised on a cash “net basis” so that the Company will pay cash in an amount equal to the excess of the fair market value of the common stock over the option exercise price. There currently are

not

sufficient shares available under the Plan and the Company would be obligated to settle these options in cash if they were exercised. Because these options contain provisions that could require the Company to settle the options in cash in an event outside the Company’s control, they are accounted for as liabilities.

The Liability Grants are subject to vesting requirements. Twenty-

five

percent of the options have vested as of the grant date,

50%

of the options will vest quarterly over

two

years, and the remaining

25%

vest upon achievement of certain milestones related to clinical trial progress. As of

September 30 2018,

80%

of the options that vest upon achievement of clinical trial milestones are vested.

For the

three

and

nine

months ended

September 30, 2018,

the Company recognized compensation expense related to these options of

$623,496

and

$2,180,659,

respectively.

The fair value of liability options granted for the

nine

months ended

September 30, 2018

was calculated using the Black-Scholes option-pricing model applying the following assumptions:

	Nine months ended September 30,
	2018

Risk free interest rate	2.94	%
Expected term (in years)	4.75
Stock price	$1.75
Dividend yield		%
Expected volatility	122.0	%

XML 31 R20.htm IDEA: XBRL DOCUMENT

Note 13 - Restatement to Previously Issued Condensed Consolidated Financial Statements

9 Months Ended

Sep. 30, 2018

Notes to Financial Statements

Reclassifications [Text Block]

NOTE

13:

RESTATEMENT TO PREVIOUSLY ISSUED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The Company has corrected an inadvertent error in the calculation of the deemed dividend on Series B convertible preferred stock in the financial statements for the

three

and

six

months ended

June 30, 2018

that were included in the Company’s Form

-Q filed on

August 13, 2018 (

the “Original Form

-Q”). Accounting principles generally accepted in the United States of America require that we allocate the proceeds from the

May 2018

financing to the warrants and preferred stock issued in the financing and that we estimate and record any discount on the securities as a deemed dividend. In the financial statements included in the Original Form

-Q, we did

not

properly allocate the proceeds to the warrants, and we did

not

properly record the deemed dividend related to the warrant discount as additional paid in capital to common stock. The Company incorrectly stated the deemed dividend for the

three

and

six

months ended

June 30, 2018

$4,782,100

rather than

$11,479,308

The corrections result from application of technical accounting rules and do

not

impact cash or operations.

three

months and

six

months ended

June 30, 2018:

	For the Three Months Ended June 30, 2018						For the Six Months Ended June 30, 2018
	Previously Reported			Restated			Previously Reported			Restated
Deemed dividend attributable to preferred stock	$	(4,782,100	)	$	(11,479,308	)	$	(4,782,100	)	$	(11,479,308	)
Net loss applicable to common stockholders	$	(8,924,677	)	$	(15,621,885	)	$	(10,799,059	)	$	(17,496,267	)
Loss per common share -basic and diluted	$	(2.90	)	$	(5.08	)	$	(3.77	)	$	(6.11	)

The following table shows the effect of the restatement on certain line items within the Company’s Condensed Consolidated Statement of Stockholders’ Equity for the

six

months ended

June 30, 2018:

	Preferred Stock Additional Paid-in Capital						Common Stock Additional Paid-in Capital
	Previously Reported			Restated			Previously Reported			Restated
Issuance of Series B convertible preferred stock, net of issuance costs	$	12,290,537		$	6,926,778		$	0		$	5,363,759
Deemed Dividend on Series B convertible preferred stock	$	4,782,100		$	11,479,308		$	(4,782,100	)	$	(11,479,308	)
Conversion of Series B convertible preferred stock to common stock	$	(7,056,421	)	$	(7,821,992	)	$	6,656,442		$	7,422,013

XML 32 R21.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)	9 Months Ended
Significant Accounting Policies (Policies)	Sep. 30, 2018
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation: The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10 -Q and Rule 10 - 01 of Regulation S- X. They do not include all information and notes required by GAAP for complete financial statements. However, except as disclosed herein, there has been no material change in the information disclosed in the Notes to Consolidated Financial Statements included in the Annual Report on Form 10 -K of the Company for the year ended December 31, 2017. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. On April 20, 2018, the Company completed a 1 -for- 12 reverse stock split of the shares of the Company’s common stock (the “Reverse Stock Split”). As a result of the Reverse Stock Split, every 12 shares of issued and outstanding common stock were combined into one issued and outstanding share of common stock, and the par value per share was changed to $0.18 per share. The number of authorized shares of common stock was not reduced as a result of the Reverse Stock Split. The Company’s common stock began trading on a reverse stock split-adjusted basis on April 20, 2018. All share and per share data included in this report has been retroactively restated to reflect the Reverse Stock Split.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements: In February 2016, Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016 - 02, Lease Accounting Topic 842. This ASU requires a lessee to recognize lease assets and liabilities on the balance sheet for all arrangements with terms longer than 12 months. The new standard applies a right-of-use (ROU) model that requires a lessee to record, for all leases with a lease term of more than 12 months, an asset representing its right to use the underlying asset for the lease term and a liability to make lease payments. The lease term is the non-cancellable period of the lease, and includes both periods covered by an option to extend the lease, if the lessee is reasonably certain to exercise that option, and periods covered by an option to terminate the lease, if the lessee is reasonably certain not to exercise that termination option. For leases with a lease term of 12 months or less, a practical expedient is available whereby a lessee may elect, by class of underlying asset, not to recognize an ROU asset or lease liability. A lessee making this accounting policy election would recognize lease expense over the term of the lease, generally in a straight-line pattern. The lessor accounting remains largely consistent with existing GAAP. The new standard takes effect in 2019 for public entities. The Company has not currently adopted the provisions of ASU No. 2016 - 02 and believes that the impact of adopting ASU 2016 - 02 will not be material to its consolidated financial statements, though will require the recognition of an operating lease liability and right-of-use asset upon adoption, based on the lease composition disclosed in Footnote 11. In November 2016, the FASB issued ASU No. 2016 - 18, Statement of Cash Flows , amending the presentation of restricted cash within the statement of cash flows. The new guidance requires that restricted cash be included within cash and cash equivalents on the statement of cash flows. The Company adopted the provisions of ASU No. 2016 - 18 as of January 1, 2018 and has included restricted cash with cash and cash equivalents on the accompanying statement of cash flows, including reclassifying 2017 balances. For the three and nine months ended September 30, 2018 and September 30, 2017, we included $55,000 of restricted cash in cash and cash equivalents on the statement of cash flows. The restricted cash represents a required deposit for the Company credit card and is restricted until the Company no longer has the credit card or the limit changes on the credit card. In July 2017, the FASB issued ASU 2017 - 11, Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception . Part I of this ASU addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of future equity offerings. Current accounting guidance requires financial instruments with down round features to be accounted for at fair value. Part II of the Update applies only to nonpublic companies and is therefore not applicable to the Company. The amendments in Part I of the Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. This Update is effective for public entities for fiscal years beginning after December 15, 2018. Early adoption is permitted. The Company early adopted the provisions of ASU No. 2017 - 11 as of January 1, 2018. As the Company does not have any financial instruments with down round features, this ASU did not have a material impact on the financial statements upon adoption. In June 2018, the FASB issued ASU 2018 - 07, Compensation-Stock Compensation Improvements to Nonemployee Share Based Payment Accounting. This ASU simplifies several aspects of the accounting for non-employee share-based payment transactions resulting from expanding the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide financing to the issuer or was granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers . This update is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted. The Company early adopted the provisions of ASU No. 2018 - 17 as of April 1, 2018 and it did not have a material impact on the financial statements upon adoption.

XML 33 R22.htm IDEA: XBRL DOCUMENT

Note 4 - Prepaid Expenses (Tables)

9 Months Ended

Sep. 30, 2018

Notes Tables

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]

	September 30,		December 31,
	2018		2017
Prepaid insurance	$	46,618	$	125,056
Retainer and security deposits		16,718		14,218
Professional services		93,557		97,788
Prepaid research and development		104,299
Financial exchange fees		13,750
Other		15,389		13,882
	$	290,331	$	250,944

XML 34 R23.htm IDEA: XBRL DOCUMENT

Note 6 - Payroll Liabilities (Tables)

9 Months Ended

Sep. 30, 2018

Notes Tables

Schedule of Accrued Liabilities [Table Text Block]

	September 30, 2018		December 31, 2017
Accrued bonus payable	$	480,917	$	566,000
Accrued vacation		156,775		147,861
Accrued payroll liabilities		68,458		71,006
Total payroll liabilities	$	706,150	$	784,867

XML 35 R24.htm IDEA: XBRL DOCUMENT

Note 7 - Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2018

Notes Tables

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

	Outstanding Warrants to Purchase Shares		Exercise Price			Expiration Date

2014 public offering		6,483		$540.00		January 29, 2019
Placement agent fees for Company’s offerings		1,106	381.60	–	540.00	November 4, 2018
2017 Warrant B private placement		441,670		3.78		December 22, 2018
2018 Warrants		3,869,216		4.05		May 30, 2022
		4,318,475

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 36 R25.htm IDEA: XBRL DOCUMENT

Note 8 - Net Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2018

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended September 30,						Nine months Ended September 30,
	2018			2017			2018			2017
Net Loss Per Share
Numerator
Net loss	$	(3,309,866	)	$	(2,184,510	)	$	(9,326,825	)	$	(6,129,553	)
Deemed dividend attributable to preferred stock								(11,479,308	)		(2,568,132	)
Net loss attributable to common shareholders	$	(3,309,866	)	$	(2,184,510	)	$	(20,806,133	)	$	(8,697,685	)
Denominator
Weighted average common shares outstanding		5,183,492			1,034,262			3,645,682			657,184
Basic and diluted net loss per share	$	(0.64	)	$	(2.11	)	$	(5.71	)	$	(13.23	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	Three Months Ended September 30,				Nine months Ended September 30,
	2018		2017		2018		2017
Options to purchase common stock		783,794		176,502		388,377		100,505
Series A convertible preferred stock				42,480				74,651
Series B convertible preferred stock		1,338,916				751,332
Warrants to purchase common stock		4,716,935		138,365		2,644,946		227,229
Total		6,839,645		357,347		3,784,655		402,385

XML 37 R26.htm IDEA: XBRL DOCUMENT

Note 12 - Stock Based Compensation (Tables)

9 Months Ended

Sep. 30, 2018

Notes Tables

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]

January 1,	Number of shares
2012		2,502
2013		2,871
2014		4,128
2015		5,463
2016		18,368
2017		12,623
2018		106,076
Total additional shares		152,031

Share-based Compensation, Stock Options, Activity [Table Text Block]

	Number of Underlying Shares			Weighted- Average Exercise Price Per Share		Weighted- Average Contractual Life Remaining in Years		Aggregate Intrinsic Value
Outstanding as of January 1, 2018		172,510		$	49.27			$
Granted		611,668			2.39
Forfeited		(417	)		5.64
Expired
Outstanding as of September 30, 2018		783,761			12.70		9.42	$
Exercisable as of September 30, 2018		199,949			40.62		8.95	$
Vested and expected to vest		783,761			12.70		9.42	$

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	Nine months ended September 30,
	2018

Risk free interest rate	2.94	%
Expected term (in years)	4.75
Stock price	$1.75
Dividend yield		%
Expected volatility	122.0	%

XML 38 R27.htm IDEA: XBRL DOCUMENT

Note 13 - Restatement to Previously Issued Condensed Consolidated Financial Statements (Tables)

9 Months Ended

Sep. 30, 2018

Notes Tables

Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]

	For the Three Months Ended June 30, 2018						For the Six Months Ended June 30, 2018
	Previously Reported			Restated			Previously Reported			Restated
Deemed dividend attributable to preferred stock	$	(4,782,100	)	$	(11,479,308	)	$	(4,782,100	)	$	(11,479,308	)
Net loss applicable to common stockholders	$	(8,924,677	)	$	(15,621,885	)	$	(10,799,059	)	$	(17,496,267	)
Loss per common share -basic and diluted	$	(2.90	)	$	(5.08	)	$	(3.77	)	$	(6.11	)

	Preferred Stock Additional Paid-in Capital						Common Stock Additional Paid-in Capital
	Previously Reported			Restated			Previously Reported			Restated
Issuance of Series B convertible preferred stock, net of issuance costs	$	12,290,537		$	6,926,778		$	0		$	5,363,759
Deemed Dividend on Series B convertible preferred stock	$	4,782,100		$	11,479,308		$	(4,782,100	)	$	(11,479,308	)
Conversion of Series B convertible preferred stock to common stock	$	(7,056,421	)	$	(7,821,992	)	$	6,656,442		$	7,422,013

XML 39 R28.htm IDEA: XBRL DOCUMENT

Note 2 - Going Concern (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
Note 2 - Going Concern (Details Textual) - USD ($)	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Net Income (Loss) Attributable to Parent, Total	$ (3,309,866)	$ (2,184,510)	$ (9,326,825)	$ (6,129,553)
Net Cash Provided by (Used in) Operating Activities, Total			(6,517,985)	$ (4,911,268)
Cash and Cash Equivalents, at Carrying Value, Ending Balance	12,935,587		12,935,587		$ 7,217,469
Working Capital	$ 10,400,000		$ 10,400,000

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 40 R29.htm IDEA: XBRL DOCUMENT

Note 3 - Summary of Accounting Policies (Details Textual)	Apr. 20, 2018	Sep. 30, 2018 USD ($) $ / shares	Dec. 31, 2017 $ / shares	Sep. 30, 2017 USD ($)
Common Stock, Par or Stated Value Per Share \| $ / shares		$ 0.18	$ 0.18
Restricted Cash and Cash Equivalents, Total \| $		$ 55,000		$ 55,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	12

XML 41 R30.htm IDEA: XBRL DOCUMENT

Note 4 - Prepaid Expenses - Schedule of Prepaid Expenses (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Prepaid insurance	$ 46,618	$ 125,056
Retainer and security deposits	16,718	14,218
Professional services	93,557	97,788
Prepaid research and development	104,299
Financial exchange fees	13,750
Other	15,389	13,882
	$ 290,331	$ 250,944

XML 42 R31.htm IDEA: XBRL DOCUMENT

Note 5 - Research and Development Tax Rebate Receivable (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	May 23, 2017
Research and Development Expense, Total	$ 1,421,851	$ 742,450	$ 3,360,563	$ 2,110,846
Increase (Decrease) in Research and Development Tax Rebate Receivable			122,218
Research and Development Tax Rebate Receivable	480,495		480,495		$ 358,277
Atossa Genetics AUS Pty Ltd [Member]
Research and Development Cash Rebate per Dollar						$ 0.435
Research and Development Expense, Total			764,000
Increase (Decrease) in Research and Development Tax Rebate Receivable			333,000
Research and Development Tax Rebate Receivable	$ 481,000		$ 481,000		$ 148,000

XML 43 R32.htm IDEA: XBRL DOCUMENT

Note 6 - Payroll Liabilities - Schedule of Payroll Liabilities (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Accrued bonus payable	$ 480,917	$ 566,000
Accrued vacation	156,775	147,861
Accrued payroll liabilities	68,458	71,006
Total payroll liabilities	$ 706,150	$ 784,867

XML 44 R33.htm IDEA: XBRL DOCUMENT

Note 7 - Stockholders' Equity (Details Textual)		3 Months Ended			6 Months Ended	9 Months Ended
Note 7 - Stockholders' Equity (Details Textual)	May 30, 2018 USD ($) $ / shares shares	Sep. 30, 2018 USD ($) $ / shares shares	Jun. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Jun. 30, 2018 USD ($)	Sep. 30, 2018 USD ($) $ / shares shares	Sep. 30, 2017 USD ($)	May 29, 2018 $ / shares	May 09, 2018 $ / item shares	Dec. 31, 2017 $ / shares shares	May 19, 2014 $ / shares shares
Number of Shares Authorized to Issue		185,000,000				185,000,000
Common Stock, Shares Authorized		175,000,000				175,000,000				175,000,000
Common Stock, Par or Stated Value Per Share \| $ / shares		$ 0.18				$ 0.18				$ 0.18
Preferred Stock, Shares Authorized		10,000,000				10,000,000				10,000,000
Preferred Stock, Par or Stated Value Per Share \| $ / shares		$ 0.001				$ 0.001				$ 0.001
Stockholder Rights Agreement, Number of Preferred Stock Right Distributed for Each Share of Common Stock											1
Stockholder Rights Agreement, Acquiring Person, Percentage of Ownership											15.00%
Stockholder Rights Agreement, Acquiring Person, Additional Percentage of Ownership											2.00%
Stockholder Rights Agreement, Initial Exercise Price of Each Right \| $ / shares											$ 15
Stockholder Rights Agreement, Share Price \| $ / shares											$ 30
Class of Warrant or Right, Outstanding		4,318,475				4,318,475
Consummate a Business Combination, Percentage of Acquired Outstanding Shares		50.00%				50.00%
Consummate a Business Combination, Percentage of Aggregate Ordinary Voting Power		50.00%				50.00%
Preferred Stock, Deemed Dividend \| $			$ 11,479,308		$ 11,479,308	$ 11,479,308	$ 2,568,132
Payments of Stock Issuance Costs \| $						$ 1,333,449
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		4,318,475				4,318,475
Conversion of Stock, Shares Converted		2,285				10,107
The 2018 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 4.048	$ 4.048				$ 4.048
Warrants and Rights Outstanding, Term		4 years				4 years
Warrants Exercisable, Ownership Percentage of Company’s Shares Allowed		4.99%				4.99%
Warrants and Rights Outstanding, Redemption Price \| $ / shares		$ 0.18				$ 0.18
Warrants and Rights Outstanding, Redeemable, Volume-weighted-average-price of Our Common Stock \| $ / shares		$ 10.56				$ 10.56
The 2018 Subscription Rights Offering [Member]
Number of Units Authorized to Purchase, Maximum									25,000
Purchase Price of Unit \| $ / item									1,000
Number of Series B Convertible Preferred Stock and Warrant in Each Unit									1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right									284
Number of Units Sold	13,624
Proceeds from Issuance of Stock units \| $	$ 12,300,000
Adjustments to Additional Paid in Capital, Beneficial Conversion Feature on Preferred Stock \| $						$ 4,782,100
Preferred Stock, Deemed Dividend \| $						11,479,308
Payments of Stock Issuance Costs \| $						1,333,449
The 2018 Subscription Rights Offering [Member] \| The 2018 Warrants [Member]
Class of Warrant or Right, Outstanding	3,869,216
Warrants Allocated to Common Stock , Net of Issuance Cost \| $		$ 5,363,759				$ 5,363,759
Series A Junior Participating Preferred Stock [Member]
Preferred Stock, Shares Authorized		750,000				750,000
Preferred Stock, Par or Stated Value Per Share \| $ / shares		$ 0.001				$ 0.001
Preferred Stock, Shares Issued, Total		0				0
Preferred Stock, Shares Outstanding, Ending Balance		0				0
Series A Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized		4,000				4,000				4,000
Preferred Stock, Par or Stated Value Per Share \| $ / shares		$ 0.001				$ 0.001				$ 0.001
Preferred Stock, Shares Issued, Total		0				0
Preferred Stock, Shares Outstanding, Ending Balance		0				0				0
Series B Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized		25,000				25,000				0
Preferred Stock, Par or Stated Value Per Share \| $ / shares		$ 0.001				$ 0.001		$ 0.001		$ 0.001
Preferred Stock, Shares Issued, Total		3,517				3,517				0
Stated Value per Share \| $ / shares		1,000				1,000
Preferred Stock, Convertible, Conversion Price \| $ / shares		$ 3.52				$ 3.52
Preferred Stock, Convertible, Ownership Percentage of Company’s Shares Allowed		9.99%				9.99%
Convertible Preferred Stock, Shares Issued upon Conversion		284				284
Preferred Stock, Shares Outstanding, Ending Balance		3,517				3,517				0
Series B Convertible Preferred Stock [Member] \| The 2018 Subscription Rights Offering [Member]
Stock Issued During Period, Shares, New Issues	13,624
Common Stock [Member]
Conversion of Stock, Shares Issued		649,156				2,871,303

XML 45 R34.htm IDEA: XBRL DOCUMENT

Note 7 - Stockholders' Equity - Schedule of Warrants (Details)	9 Months Ended
	Sep. 30, 2018 $ / shares shares
Class of Warrant or Right, Outstanding (in shares) \| shares	4,318,475
The 2014 Public Offering [Member]
Class of Warrant or Right, Outstanding (in shares) \| shares	6,483
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares	$ 540
Expiration Dates of Class of Warrant or Right	January 29, 2019
Placement Agent Fee [Member]
Class of Warrant or Right, Outstanding (in shares) \| shares	1,106
Expiration Dates of Class of Warrant or Right	November 4, 2018
Placement Agent Fee [Member] \| Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares	$ 381.60
Placement Agent Fee [Member] \| Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares	$ 540
The 2017 Warrant B Private Placement [Member]
Class of Warrant or Right, Outstanding (in shares) \| shares	441,670
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares	$ 3.78
Expiration Dates of Class of Warrant or Right	December 22, 2018
The 2018 Warrants [Member]
Class of Warrant or Right, Outstanding (in shares) \| shares	3,869,216
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares	$ 4.05
Expiration Dates of Class of Warrant or Right	May 30, 2022

XML 46 R35.htm IDEA: XBRL DOCUMENT

Note 8 - Net Loss Per Share - Schedule of Earnings Per Share (Details) - USD ($)	3 Months Ended			6 Months Ended	9 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Sep. 30, 2017	Jun. 30, 2018	Sep. 30, 2018	Sep. 30, 2017
Net loss	$ (3,309,866)		$ (2,184,510)		$ (9,326,825)	$ (6,129,553)
Deemed dividend attributable to preferred stock		$ (11,479,308)		$ (11,479,308)	(11,479,308)	(2,568,132)
Net loss applicable to common stockholders	$ (3,309,866)	$ (15,621,885)	$ (2,184,510)	$ (17,496,267)	$ (20,806,133)	$ (8,697,685)
Weighted average shares outstanding - basic and diluted (in shares)	5,183,492		1,034,262		3,645,682	657,184
Loss per common share -basic and diluted (in dollars per share)	$ (0.64)	$ (5.08)	$ (2.11)	$ (6.11)	$ (5.71)	$ (13.23)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 47 R36.htm IDEA: XBRL DOCUMENT

Note 8 - Net Loss Per Share - Schedule of Antidilutive Securities (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Number of potential common shares excluded (in shares)	6,839,645	357,347	3,784,655	402,385
Employee Stock Option [Member]
Number of potential common shares excluded (in shares)	783,794	176,502	388,377	100,505
Series A Convertible Preferred Stock [Member]
Number of potential common shares excluded (in shares)		42,480		74,651
Series B Convertible Preferred Stock [Member]
Number of potential common shares excluded (in shares)	1,338,916		751,332
Warrant [Member]
Number of potential common shares excluded (in shares)	4,716,935	138,365	2,644,946	227,229

XML 48 R37.htm IDEA: XBRL DOCUMENT

Note 9 - Income Taxes (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Accrued Income Taxes, Total	$ 0	$ 0

XML 49 R38.htm IDEA: XBRL DOCUMENT

Note 10 - Concentration of Credit Risk (Details Textual) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Cash, Uninsured Amount	$ 12,685,587	$ 6,967,469

XML 50 R39.htm IDEA: XBRL DOCUMENT

Note 11 - Commitments and Contingencies (Details Textual) - USD ($)	Nov. 01, 2018	Mar. 23, 2018
Loss Contingency, Damages Paid, Value		$ 3,500,000
Subsequent Event [Member]
Operating Lease, Lessee, Monthly Rent Expense	$ 3,660
Lessee, Operating Lease, Term of Contract	1 year 300 days
Operating Leases, Future Minimum Payments Due, Total	$ 80,500

XML 51 R40.htm IDEA: XBRL DOCUMENT

Note 12 - Stock Based Compensation (Details Textual) - USD ($)						3 Months Ended		9 Months Ended
	Jun. 27, 2018	Apr. 12, 2018	May 09, 2017	May 18, 2016	Sep. 28, 2010	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Liability Options [Member]
Allocated Share-based Compensation Expense, Total						$ 623,496		$ 2,180,659
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 2.38
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Awards Vested						80.00%		80.00%
Liability Options [Member] \| Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	25.00%
Liability Options [Member] \| Share-based Compensation Award, Tranche Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	50.00%
Liability Options [Member] \| Share-based Compensation Award, Tranche Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	25.00%
Liability Options [Member] \| Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	50.00%
Liability Options [Member] \| Chairman of the Board, President and Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	2,300,000
Liability Options [Member] \| Chief Financial Officer, General Counsel and Secretary [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	700,000
The 2010 Stock Option and Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Period for Granting Shares					10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross								611,668
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price								$ 2.39
The 2010 Stock Option and Incentive Plan [Member] \| Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					5,556
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized		500,000	125,000	11,111
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period						0		0
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant						3,197		3,197
Allocated Share-based Compensation Expense, Total						$ 332,063	$ 224,254	$ 726,252	$ 560,369
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance						583,812		583,812
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options						$ 1,479,610		$ 1,479,610
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition								1 year 204 days

XML 52 R41.htm IDEA: XBRL DOCUMENT

Note 12 - Stock Based Compensation - Additional Shares Authorized (Details) - shares	12 Months Ended							84 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2017
The 2010 Stock Option and Incentive Plan [Member]
Total additional shares (in shares)	106,076	12,623	18,368	5,463	4,128	2,871	2,502	152,031

XML 53 R42.htm IDEA: XBRL DOCUMENT

Note 12 - Stock Based Compensation - Stock Option Activity (Details) - The 2010 Stock Option and Incentive Plan [Member] - USD ($)	9 Months Ended
	Sep. 30, 2018
Outstanding, shares (in shares)	172,510
Outstanding, Weighted average exercise price per share (in dollars per share)	$ 49.27
Granted, shares (in shares)	611,668
Granted, Weighted average exercise price per share (in dollars per share)	$ 2.39
Forfeited, shares (in shares)	(417)
Forfeited, Weighted average exercise price per share (in dollars per share)	$ 5.64
Expired, shares (in shares)
Expired, Weighted average exercise price per share (in dollars per share)
Outstanding, shares (in shares)	783,761
Outstanding, Weighted average exercise price per share (in dollars per share)	$ 12.70
Outstanding, weighted average contractual life remaining in years (Year)	9 years 153 days
Outstanding, Aggregate intrinsic value
Exercisable, shares (in shares)	199,949
Exercisable, Weighted average exercise price per share (in dollars per share)	$ 40.62
Exercisable, weighted average contractual life remaining in years (Year)	8 years 346 days
Exercisable, Aggregate intrinsic value
Vested and expected to vest, shares (in shares)	783,761
Vested and expected to vest, Weighted average exercise price per share (in dollars per share)	$ 12.70
Vested and expected to vest, weighted average contractual life remaining in years (Year)	9 years 153 days
Vested and expected to vest, Aggregate intrinsic value

XML 54 R43.htm IDEA: XBRL DOCUMENT

Note 12 - Stock Based Compensation - Valuation Assumptions (Details) - Liability Options [Member]	9 Months Ended
	Sep. 30, 2018 $ / shares
Risk free interest rate	2.94%
Expected term (in years) (Year)	4 years 273 days
Stock price (in dollars per share)	$ 1.75
Dividend yield
Expected volatility	122.00%

XML 55 R44.htm IDEA: XBRL DOCUMENT

Note 13 - Restatement to Previously Issued Condensed Consolidated Financial Statements (Details Textual) - USD ($)	3 Months Ended			6 Months Ended	9 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Sep. 30, 2017	Jun. 30, 2018	Sep. 30, 2018	Sep. 30, 2017
Preferred Stock, Deemed Dividend		$ 11,479,308		$ 11,479,308	$ 11,479,308	$ 2,568,132
Series B Convertible Preferred Stock [Member]
Deemed Dividend on Series B Convertible Preferred Stock		11,479,308		11,479,308
Previously Reported [Member]
Preferred Stock, Deemed Dividend		4,782,100		4,782,100
Previously Reported [Member] \| Series B Convertible Preferred Stock [Member]
Preferred Stock, Deemed Dividend		$ 4,782,100		$ 4,782,100

XML 56 R45.htm IDEA: XBRL DOCUMENT

Note 13 - Restatement to Previously Issued Condensed Consolidated Financial Statements - Restatements (Details) - USD ($)	3 Months Ended			6 Months Ended	9 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Sep. 30, 2017	Jun. 30, 2018	Sep. 30, 2018	Sep. 30, 2017
Deemed dividend attributable to preferred stock		$ (11,479,308)		$ (11,479,308)	$ (11,479,308)	$ (2,568,132)
Net loss applicable to common stockholders	$ (3,309,866)	$ (15,621,885)	$ (2,184,510)	$ (17,496,267)	$ (20,806,133)	$ (8,697,685)
Loss per common share -basic and diluted (in dollars per share)	$ (0.64)	$ (5.08)	$ (2.11)	$ (6.11)	$ (5.71)	$ (13.23)
Issuance of Series B convertible preferred stock, net of issuance costs					$ 12,290,551
Deemed Dividend on Series B convertible preferred stock
Conversion of Series B convertible preferred stock to common stock
Additional Paid in Capital, Convertible Preferred Stock [Member]
Issuance of Series B convertible preferred stock, net of issuance costs		$ 6,926,778			6,926,778
Deemed Dividend on Series B convertible preferred stock		11,479,308			11,479,308
Conversion of Series B convertible preferred stock to common stock		(7,821,992)			(10,106,990)
Additional Paid in Capital, Common Stock [Member]
Issuance of Series B convertible preferred stock, net of issuance costs				$ 5,363,759	5,363,759
Deemed Dividend on Series B convertible preferred stock				(11,479,308)	(11,479,308)
Conversion of Series B convertible preferred stock to common stock				7,422,013	$ 9,590,167
Previously Reported [Member]
Deemed dividend attributable to preferred stock		(4,782,100)		(4,782,100)
Net loss applicable to common stockholders		$ (8,924,677)		$ (10,799,059)
Loss per common share -basic and diluted (in dollars per share)		$ (2.90)		$ (3.77)
Previously Reported [Member] \| Additional Paid in Capital, Convertible Preferred Stock [Member]
Issuance of Series B convertible preferred stock, net of issuance costs		$ 12,290,537
Deemed Dividend on Series B convertible preferred stock		4,782,100
Conversion of Series B convertible preferred stock to common stock		$ (7,056,421)
Previously Reported [Member] \| Additional Paid in Capital, Common Stock [Member]
Issuance of Series B convertible preferred stock, net of issuance costs				$ 0
Deemed Dividend on Series B convertible preferred stock				(4,782,100)
Conversion of Series B convertible preferred stock to common stock				$ 6,656,442

EXCEL 57 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ">2;4T?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ )Y)M32?HAPZ" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " GDFU-HG<& NX K @ $0 &1O8U!R;W!S+V-O M&ULS9+!:L,P#(9?9?B>*$Z@%)/ZTM%3!X,5-G8SMMJ:Q8ZQ-9*^_9RL M31G; ^QHZ?>G3Z!6!Z'[B,^Q#QC)8GH87>>3T&'#SD1! "1]1J=2F1,^-X]] M=(KR,YX@*/VA3@AU5:W (2FC2,$$+,)"9+(U6NB(BOIXQ1N]X,-G[&:8T8 = M.O24@)<'O:O\SK%M8G4EYC_I6LH$O #;M-?FVVCX<=DW7%UP7G!6\.?"WX2M3U^^3Z MP^\N['ICC_8?&]\$90N_[D)^ 5!+ P04 " GDFU-F5R<(Q & "<)P M$P 'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03 M621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS M[BYBZ(:(E/)X8-DOV]:[MR_>X%#BVR]*+41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C( MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU M+,76>)7 \:V@S&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=* MY \FIS_I,C0'HYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_ MT=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R MSTS0LS0[=R M2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZ MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)2 M56 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE ML<%5'<]56_*POFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7G MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5 M' 86%S+D4.Z2D 83 >LX=SFWJXPD6L_UC6'ODR MWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\ MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHS MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\! M4$L#!!0 ( ">2;4UR/V&JB@( $8) 8 >&PO=V]R:W-H965T&UL?5;MCILP$'P5Q ,(DZ !3VPG7 MMZ]M.,K92_^ ;69VO/8.=M$S_BINE$KOK:E;L?%O4G;K(!#EC39$/+&.MNK+ MA?&&2-7EUT!TG)*S(35U@,,P#1I2M?ZV,&-'OBW87=952X_<$_>F(?S/GM:L MW_C(?Q]XKJXWJ0>";=&1*_U!Y<_NR%4OF**^J6R%&GULPR)XZ# C8C\@\ R!)D2@ M8D\"&!+88X>./PH<7$0$"T1@!I&A1S-Z#--CD!X;>CRC)]8"N(@4%DA @<2A M9Y; @$@,HAU6.,[S,%K!,BDHDSHRN27C(A8$,E @<^C(+A4 LE K.2B1NWRK M6/8 9*%:5J#$RN7'E@0 26 )%,*>"MT(J>TJ ),MJ"PX%[D1["V', N;CD#[ M[A!V(F!KVP\C9E[ 21JG28(7I& CH\B50G9" &9)!?8[N2Z'MO_%>3Z'H>S+?RH [L>N:;&3JD-F'2.62HUV/K(-39V2@TPOZT2S$ZE MAO*K.<"%5[)[:VX/L]'IDK SQV#P#S[<,+X3?JU:X9V85&>C.<$NC$FJIA(^ MJ26]J4O-U*GI1>IFIMI\.-F'CF3=>&L)IJO3]B]02P,$% @ )Y)M3: Q M2L'H P 5A$ !@ !X;"]W;W)K7IOW6[6/L9]^/]:E[G._[_OQ0%-UF'X]5]ZDYQU/Z9]>TQZI/Q?:E MZ,YMK+9CT+$N4"E7'*O#:;YVN6B>>WKPRD^M;/N]7BLVG]7L6XNCW.8 MOS_X>GC9]\.#8KDX5R_QC]C_>7YJ4ZFX9=D>CO'4'9K3K(V[Q_EG>%AC& )& MQ5^'>.GN[F=#4YZ;YMM0^'7[.%>#HUC'33^DJ-+E+:YC70^9DH]_IJ3S6YU# MX/W]>_:?Q\:GQCQ775PW]=^';;]_G(?Y;!MWU6O=?VTNO\2I078^FUK_6WR+ M=9(/3E(=FZ;NQM_9YK7KF^.4)5DY5M^OU\-IO%ZF_.]A<@!. 7@+ //# #T% M:!)07)V-3?U2]=5RT3:767L=K7,U3 IXT*DS-\/#L>_&_U)KN_3T;8GEHG@; M\DR2U56"]Y*/BC57:'63%*G^FPD43> 8K^_C08[78KP>X\U]/+&XNDK\*#F- M$L!26QL\:0L7>@1O7"D;,J(APPUI8N@JL7?U6*N4(F[^3_7!BQ6]6.[%$"^6 MU8*ETG=C<#4CR*PJC9'=.-&-XVXL<>-8-28H4Q+9FLNT#>B][,:+;CQWXX@; MSZH!!U;3@9)D.M!UZ)+Q-*0V;7F0A_*H'3&4"D:*KFA0 R5 M?'[Z-%C$#5:M"R[C)P-.8'Z,HGZ 512" MA4#]49.@0"6YO#*LAD^3C0X,K2 M43L\6=:.C%+D*+447,@1698&/-U]"3KCO<[!'664(D>II>A"SLB@ H *]#TJ M*#V$X)W/K$^4@8H2U%F3EC)F#A4H8Q4Y"2W=(:*P M$576E: H5P6E*W5P(3>I9+@BAZNE<)TT'TY?\K9#4,K;CN+N@#M\:'=-T\>45'U*;=S':GLKU''7#[<^W;?7D_ZUT#?GZ2M&2;4TQ&8NRJ@( !T+ 8 >&PO=V]R:W-H965T M&ULC99AKYHP%(;_"N$'7&BQ(#=J,EV6+=D24\J;+JYF0_F?K5;(4>17V6?5&Q6A:\#@0[+,-/ MZ'F#,A-@%;\+=I6#^\"T\LKYFQE\VR_#V!"QDNV424'UY<(VK"Q-)LWQMTL: M]C5-X/#^(_L7V[QNYI5*MN'EGV*O3LMP'@9[=J#G4KWPZU?6-43"H.O^.[NP M4LL-B:ZQXZ6T_\'N+!6ONBP:I:+O[;6H[?7:Y?\(@P-P%X#[ #2[&Y!T 8D3 M$+5DMM7/5-'50O!K(-JWU5"S*=!SHA=S9R;MVMEGNENI9R\KDB^BB\G32=:M M! \D>*S8^(HD[B61KM]#8! "V_C9(#Z-'8A6,K>2VDKBISA&#LB4:L22@"R) MS^)46;<2,JB"XO;GX#P@'!'-0**93^2\@'4KR4=]H[E#,R$:D1"0A/@DB4-" M_)8S B[.(\H14PHRI3[3S&%*O4J$X 03XA#Y.IP2E!,,\V0@3^;S.'76V8,\ MONXNSQSDF?L\*1R?@_'Y]+>9/_1M3JE&+"B&W2J>_CH[S7#99O[NFU*-:6YX M)_)I,I<&>74\E'N2,0=LGPCPS[G+@1\N OLB HPQOY$!]C$$&)F[E3K-U%Z: ME(UY8#=#@)UYF\EW*4R W>3+;JTN[&((L#%O*_G^E!"4N2B^ZA8*;& (<#!O M-_G6!*'X*A=Z*3/JOV@9 =E M;C-]+]H#6SM0O.D.HU%_(E[]!U!+ P04 " GDFU-OZ/KU$4;4YV"RI)L7)YNZ?75%F2>T>RWU4G4J;;%NC+(T8(2K* MDF,>SJ=MVULYGQ;G.CWF]JT,JG.6)>5_"YL6EUE(P\^&;\?]H6X:HOGTE.SM M=UO_=7HKW5-T];(]9C:OCD4>E'8W"U_IRYKJQJ E_C[:2S6X#QHI[T7QHWGX M?3L+2=,CF]I-W;A(W.7#+FV:-IY"?F/:GLLDC_ M.6[KPRPT8;"UN^2LS;ZZ7[1W^:X0:L-V!7 Q?[G@'O#?B7@;AK('H#\6P$V1M(+T+4 M:6\'@[-;#*6F6'7V1;KHV36,[.^U_;CPKU_HQUV0:?31^>F31 M(6R(T%MD!9$O(G+QKYU@6"<6#)BSVP!+2&@/63UTLK[KY*:;'!TKWMKSH3W' M[05J+UI[,;07WEAWB&Z1O!M(P:B1WH O(:<%$]*;NA7$.%=$*NZ-#.08I<0( MAL*XAQZ40,9>X/H7J M4U"?\O0I&(>3./:WU!)RC$@9,U\?Y&+.-%$>MX:<5%)J,[(+-:I/0WU>G(4& M<7[!!2(@KA !<8D(>%>C034:J-%X&B$BO+XL#>P+9883?_L]=K5&7#%#]("[ M416CJF*HRMM1"X@ 58^1U6-D'2-C$S-#1P11@A]+!$0RX%PB\"WA[_PE KD! M]MY_*X1BPC\^4%?$C.@:.6XIU$5]713?948I7QQ"NM-"2.JO1(QT^TP9)GV5 M"*DHBZ4<.>LH>J:_4@:5,E\I9,"J?()9/<&L[S.WBO#CGW*HB/N*^--SAY C M0(W.'D/?G#D]4*,Q4C)^I( R,Y"8=)B_*2E9^)A M+#)1X$V*8&Q"02F 8'+B5PQK#*-\PL86*IZR4)BS&#]GH3!SD-1P$?LU!@)2 MP@53?J6!@%P)MQ#!B0%!)34=[*5.9#2HUC);[MO2N0HVQ3FOFX)CT'HMSU]9 M4^UY[0OZLJ1(^ZHIY]OJ\,M]]RW@SZ3<'_,J>"]J5V.VE>"N*&KKND\FKN,' MFVRO#ZG=U/'//_ 5!+ P04 " GDFU-V;:/ M',4# #:$ & 'AL+W=OIH=J]IXC1H^,@ ;6;__1I":?!Q0VX:(,]Y>?T> MUYC,SV7ULSYJW7B_\ZRH%_ZQ:4Z/05#OCCI/ZH?RI OSS:&L\J0QI]5K4)\J MG>R[HCP+"$(BR).T\)?S[MI3M9R7;TV6%OJI\NJW/$^J_U8Z*\\+'_L?%Y[3 MUV/37@B6\U/RJK_KYL?IJ3)GP:"R3W-=U&E9>)4^+/QO^'&+65O0$?^D^EQ? M'7OM4%[*\F=[\N=^X:/6D<[TKFDE$O/QKMJQ@K>?+[\ID6W>>YU_\H0OH ,!83?+*!] 1T*Q.T"UA>P MSSN0FP6\+^!# ;\]!M$7B,\[R)L%LB^00P&F70,OZ7;MVB1-LIQ7Y=FK+C/N ME+03&S]*,R%V[<6N_]UWIF.UN?J^#,-Y\-[J],CJ@I!K1(V1-404&B,;!X+' M2.1 R!B)'0@=(UL'P@8D,&$,B1!G(J2K9]?UW$H$(DQ:P[T@O$.*#B&"8\6) MVPIU6J'0BK"L0,2VLIY&-A=$7KEE4E)FI1]!3.(PE$(RJTT0G G.B*#$FCE; M2 I%0Q%*=T[,F1.#.5DC7#'0#TP%L7QOH!#[P@AW&N'0B/W?Q,& L>5BS8%7 MH8B0TI+:P+O9C8V@%*>"2FZU(9Z6VD(I3(A"G&-W0L*9D( )65Y6$ %36@ O M,R9#@I&]ZDQK15#+*15/2VUO(J-PI#,<">J!C15D0#H2=@HSJ2BR)]"T5@2U M9FZQ>%IL>Q,9Y1,Z\PD=^5@/D57H,(PPLE<\B)%08HJHVX]R^E$./]::N5)P M*<163]?*[5DH\!2%:AR+D%K/P @**JX0%E8*,1P Z-E-9)011NX=!G*D9!E> M.2 PK>]@-GFM;;36N.(W+LR#/=<(9A$T_NR]1W,Y@XFNH.),=P$SA0E(B3< MSN@.\.(X5X/(WOWVD/7-Z,<@Q @Q3FAA'_ER+TUPW!+918VVQ&#^T^[ M;Q QILT**6S?$%2*8;,[B-$3?Y"8:2LU(*K M%[3VK?_OI'I-B]I[*1OSKM>]D1W*LM%&%3V8)AQULA].,GUHVD-ICJO+V_;E MI"E/_2\)P?!SQO)_4$L#!!0 ( ">2;4U4FP&;L@$ )<# 8 >&PO M=V]R:W-H965T&UL;5/;;MLP#/T501]0.7*VM(%MH.DP;$ + M!!VV/2LV;0O5Q9/DN/W[ZN)X7I<7BZ0.#P]IJIBT>;$]@$.O4BA;XMZY84^( MK7N0S-[H 92_:;61S'G7=,0.!E@3DZ0@-,L^$\FXPE418T=3%7IT@BLX&F1' M*9EY.X#04XDW^!)XYEWO0H!4Q< Z^ 'NYW TWB,+2\,E*,NU0@;:$M]O]H<\ MX"/@%X?)KFP4.CEI_1*<[TV)LR (!-0N,#!_G.$!A A$7L:?F1,O)4/BVKZP M?XV]^UY.S,*#%K]YX_H2WV+40,M&X9[U] WF?CYA-#?_"&<0'AZ4^!JU%C9^ M43U:I^7,XJ5(]II.KN(YS?R7M.L)=$Z@2P)-O:1"4?D7YEA5&#TADV8_L/"+ M-WOJ9U.'8!Q%O//BK8^>JTVV*\@Y$,V80\+0-69!$,^^E*#72ASH_^G9[76" M_*K&/!)L_R&X^Z Q8781HQ(FS_/M]NY#(;(:C 33Q96PJ-:CBNNXBBY;=T_C M8/_"T\H^,=-Q9=%)._][XA!;K1UX.=F-WX/>OY+%$="Z8.Z\;=*N),?I87X& M9'F+U3M02P,$% @ )Y)M3Q, Q$'NQ:($6"+;8]EJQ MF=A8R7(E)=Z^?2E9\=J<89'>Q)+R<_@/#Y]&7)SJYGN[\[Z;_*C*0WL_W77= M\6X^;S<[7Q7MI_KH#^$_SW53%5VX;5[F[;'QQ79H5)5SS#(SKXK]8;I<#,\> MF^6B?NW*_<$_-I/VM:J*YI^5+^O3_12F[P^^[E]V7?]@OEP_1-GN*W]H]_5ATOCG^^D#W*T5]@T&Q9][?VJOKB=]*D]U_;V_^75[/\UZ M1[[TFZX/482?-[_V9=E'"C[^'H-.+WWV#:^OWZ-_&9(/R3P5K5_7Y5_[;;>[ MG^;3R=8_%Z]E][4^_>+'A/1T,F;_FW_S99#W3D(?F[ILA[^3S6O;U=48)5BI MBA_GW_UA^#V-\=^;R0UP;("7!J'O_VI 8P/ZV4 -R9^=#:E^+KIBN6CJTZ0Y MS]:QZ!<%W%$8S$W_Z!Q"1H:$\W220L*C& &@*HJP Y18-PEMA!<.Y1 MO!5&S8TA0 R3'COBP9(3+C,/-(\0(VO4W*X_G6<4N^$Z0)/9!+1 ABAPBBHV M0!R/,YM;8#,FZ$ AI; .,DA!H"1;1!R3,\H5Q6 7=$3Z"D"WAF2> @>JBA$& M')4ZT_'DK@69Q>3XR$ %CDN(U^H*.#!G1H-U>?PVEY3*A7>Q28P2RG#%3,!' M8C&BS$/DK .,:S7DL)MII>(960O!4KL592 B"G8@MH,?M,.#)>W(<$6A",3$ MTD$9A\@)!A@#2!"Q-PYR9EJEB1(5(,HX1(Y#P'BKH\0Y=)G6$)OB2F7 N%0= MAS(242@LXQIXA4+):"%G&W$M"&?H%+J4*1F**)27&)DB""G+ MT9G4^H$2;Y\:D5I7,1W3"/DFPC&26D5 H8ER9 M"2*V3X@7DY [ I,E_,A@) &,%(-1$'$_')[DLI09&8LD8)%B+ HB;H:C$\*' MI(+$?%/BVY@7G1 7 BOBU:0.7ZPFMB3+4JM'IBP)E$V1D60RDO!UG&(]R1@C M 6.L&"=.IP15 ]6$X3XV>K^!N?3X6_1GF?$K[>]&\[ _M MY*GNNKH:3@&?Z[KSP67V*K[IZN-X\CN_'#\O M_P502P,$% @ )Y)M3?6DBWRW 0 T@, !@ !X;"]W;W)K;0?@T*L4RA:X0%(0FR1XS*/O9,I<#TYP!2>#[" E,V]'$'HL\ Z_ M.YYXV[G@(&7>LQ9^@OO5GXRWR,)2 WA]&NSBA4 M9$R\I W!]?F?_%FOWM9R9A3LM M_O#:=07>8U1#PP;AGO3X ',]UQC-Q?^ "P@?'I3X')46-JZH&JS3Q:>>'>@OC=5<,96 MQ#LOWGKOI=RE-SFY!*(YYCC%T'7,$D$\^Y*";J4XTO_@=!N>;BI,(SS]H'"_ M39!M$F21(/M \/53B1LQ6?(I"5GU5()IXS195.E!Q4E>>9>!O:7Q3?Z%3]/^ MR$S+E45G[?S+QOXW6COP4I(K/T*=_V"+(:!QX7CCSV8:L\EPNI]_$%F^2;4W03H-8M@$ -(# 8 >&PO=V]R:W-H965T&UL;5/;;M0P$/T5RQ]0;YP45JLD4K<(@032J@AX]B:3B^I+L)U- M^7O&3AI"R8OM&9]SYN)Q/AG[[#H 3UZ4U*Z@G??#B3%7=:"$NS,#:+QIC%7" MHVE;Y@8+HHXD)1D_'-XQ)7I-RSSZ+K;,S>AEK^%BB1N5$O;W&:29"IK05\=3 MWW8^.%B9#Z*%;^"_#Q>+%EM5ZEZ!=KW1Q$)3T(?D=,X"/@)^]#"YS9F$2J[& M/ ?C#1R)]] M[;N"'BFIH1&C]$]F^@1+/?>4+,5_@1M(A(=,,$9EI(LKJ4;GC5I4,!4E7N:] MUW&?YIO[9*'M$_A"X"OA&..P.5#,_(/PHLRMF8B=>S^(\,3)B6-OJN",K8AW MF+Q#[ZU,LB1GMR"T8,XSAF\Q*X*A^AJ"[X4X\__H?)^>[F:81GJZC9X>]P6R M78$L"F3_E,C?E+B'2=\$89N>*K!MG"9'*C/J.,D;[SJP#SR^R5_X/.U?A6U[ M['S9V/_&& ^8RN$.1ZC##[8:$AH?CN_Q;.2;4U6:'^!MP$ -(# 9 >&PO=V]R:W-H965T]#^ID&CN/.F M:9GM#? ZDI1DZ6YWQQ07FI9Y])U-F>/@I-!P-L0.2G'S^P02QX(F]-WQ(MK. M!0$1I Q"/HU?LR9=0@;B^ORN_AQK][5&#="\X?H*YGEM*YN*_P!6DAX=,?(P*I8TKJ0;K4,TJ/A7%WZ9=Z+B/ MT\U],M.V">E,2!?"(<9A4Z"8^1-WO,P-CL1,O>]Y>.+DF/K>5,$96Q'O?/+6 M>Z]EDF4YNP:A&7.:,.D:LR"85U]"I%LA3NE_]'2;OM_,QY1N7?P!02P,$ M% @ )Y)M3013&UL;5/MCIP@%'T5P@,L,VJ[TXF:[&S3M$F;3+;I]C>C5R4+7 LX;M^^ M@(ZU6_\ ]W+.N1]<\A'-B^T ''E54MN"=L[U1\9LU8'B]@Y[T/ZF0:.X\Z9I MF>T-\#J2E&3);O>>*2XT+?/H.YLRQ\%)H>%LB!V4XN;W"22.!=W3F^-)M)T+ M#E;F/6_A.[@?_=EXBRTJM5"@K4!-##0%?=@?3UG 1\"S@-&NSB14'C+Q,2J4-JZD&JQ#-:OX5!1_G7:AXSY. M-^F-MDU(9D*R$ Z1P*9 ,?./W/$R-S@2,_6^Y^&)]\?$]Z8*SMB*>.>3M]Y[ M+??9?';8%L4R"+ M MD_)1[>E+B%^? F"%OU5(%IXS194N&@XR2OO,O /B3Q3?["IVG_QDTKM"47 M=/YE8_\;1 <^E=V='Z'.?[#%D-"X<+SW9S.-V60X[.2;4TG ;LOM0$ -(# 9 >&PO=V]R:W-H965T/@I-!P-L0.2G'SYP02QX*F].9X%FWG@H.5 M><];^ [N1W\VWF(+2RT4:"M0$P--01_3XVD?XF/ 3P&C79U)J.2"^!*,+W5! MDR ()%0N,'"_7>$)I Q$7L;OF9,N*0-P?;ZQ?XJU^UHNW,(3RE^B=EU!#Y34 MT/!!NF<%TL:55(-UJ&86+T7QUVD7.N[C=/-P M@VT#LAF0+8!#!+ I453^D3M>Y@9'8J;>]SP\<7K,?&^JX(RMB'=>O/7>:YG> M)SF[!J(YYC3%9.N8)8)Y]B5%MI7BE/T'S[;ANTV%NPC?K;/O#ML$^TV"?238 M_U-B^J[$K9CW*MFJIPI,&Z?)D@H''2=YY5T&]C&+;_(6/DW[-VY:H2VYH/,O M&_O?(#KP4I([/T*=_V"+(:%QX?C!G\TT9I/AL)]_$%N^2;4U*MN8FL@$ -(# 9 >&PO=V]R:W-H965T M\,QPSIF+Q]F(YM6V (Z\:=79G+;.]4?&;-F"%O8!>^C\GQJ-%LZ[IF&V-R"J M2-**\=WN'=-"=K3(8NQLB@P'IV0'9T/LH+4POT^@<,SIGMX"+[)I70BP(NM% M ]_ ?>_/QGML4:FDALY*[(B!.J=/^^,I#?@(^"%AM"N;A$XNB*_!^5SE=!<* M @6E"PK"'U=X!J6"D"_CUZQ)EY2!N+9OZA]C[[Z7B[#PC.JGK%R;TT=**JC% MH-P+CI]@[N= R=S\%[B"\O!0B<]1HK+Q2\K!.M2SBB]%B[?IE%T\QUG_1MLF M\)G [PAL2A0K_R"<*#*#(S'3['L1KGA_Y'XV90C&4<1_OGCKH]=B?T@R=@U" M,^8T8?@:LR"85U]2\*T4)_X?G6_3D\T*DTA/UMF3QVV!=%,@C0+I/RVF=RUN M80YW2=AJIAI,$[?)DA*'+F[R*KHL[!./=_(7/FW[5V$:V5ER0>=O-LZ_1G3@ M2]D]^!5J_0-;' 6U"^9[;YMIS2;'83^_(+8\X^(/4$L#!!0 ( ">2;4W, MK2D\M0$ -(# 9 >&PO=V]R:W-H965TL!CMNW+V#'\SK_ >[EG',_ MN*0]FC?; #CRKJ2V&6V<:P^,V:(!Q>T-MJ#]385&<>=-4S/;&N!E)"G)DM7J MEBDN-,W3Z#N9/,7.2:'A9(CME.+FXP@2^XRNZ=7Q(NK&!0?+TY;7\ KN9WLR MWF*32BD4:"M0$P-51N_7A^,VX"/@EX#>SLXD5')&? O&]S*CJY 02"A<4.!^ MN\ #2!F$?!I_1DTZA0S$^?FJ_A1K][6*=="_8?X.Q MGATE8_$_X +2PT,F/D:!TL:5%)UUJ$85GXKB[\,N=-S[X69WI2T3DI&03(1] M)+ A4,S\D3N>IP9[8H;>MSP\\?J0^-X4P1E;$>]\\M9[+_EZ=YNR2Q :,<;# F5"\<[?S;#F V&PW;\06SZQODG4$L#!!0 ( ">2;4TNEZH MM@$ -(# 9 >&PO=V]R:W-H965T]#^ID&CN/.F:9GM#? ZDI1D:9+<,<6% MIF4>?6=3YC@X*32<#;MS\.8'$L: [^NYX$FWG@H.5><];^ GN5W\VWF*+ M2BT4:"M0$P--0>]WQ],^X"/@6-*JL$Z5+.*3T7QMVD7.N[C=).E,VV;D,Z$="$<8APV M!8J9?^&.E[G!D9BI]ST/3[P[IKXW57#&5L0[G[SUWFNYN_V?4E1+H5XI3^1T^WZ=EFAEFD9^OHV6%;8+\IL(\"^[7 7?*AQ"W,QR+9 MJJ<*3!NGR9(*!QTG>>5=!O8^/B+[!Y^F_0'XR9_--&:3X;"??Q!;OG'Y%U!+ P04 " GDFU-W ;V=[8! M #2 P &0 'AL+W=OM\?&7-E"UJX&]-#AS>UL5IX-&W#7&]!5)&D%>.[W1W30G:T MR*+O;(O,#%[)#LZ6N$%K8?^<0)DQIWOZYGB63>N#@Q59+QKX#OY'?[9HL46E MDAHZ)TU'+-0YO=\?3VG 1\!/":-;G4FHY&+,2S"^5#G=A81 0>F#@L#M"@^@ M5!#"-'[/FG0)&8CK\YOZ8ZP=:[D(!P]&_9*5;W-ZH*2"6@S*/YOQ">9Z;BF9 MB_\*5U (#YE@C-(H%U=2#LX;/:M@*EJ\3KOLXCY.-\GM3-LF\)G %$AQF%3 MH)CY9^%%D5DS$COUOA?AB?='CKTI@S.V(MYA\@Z]UV)_QS-V#4(SYC1A^!JS M(!BJ+R'X5H@3_X_.M^G)9H9)I"?KZ,EA6R#=%$BC0/I/BW#\1.>[31FD^%-/_\@MGSCXB]02P,$% @ )Y)M37S)+G.W 0 MT@, !D !X;"]W;W)K&UL;5/;;IPP$/T5RQ\0 M[P+9K%: E$U5M5(KK5*U??;" %9\H;99TK_OV!!*4UYLS_B<,Q>/\]'8%]/*JI'8%[;SO3XRYJ@/%W9WI0>--8ZSB'DW;,M=;X'4D*[ %!>:EGGT M76R9F\%+H>%BB1N4XO;W&:09"[JG;XYGT78^.%B9][R%;^"_]Q>+%EM4:J% M.V$TL= 4]'%_.FH?5?0(R4U-'R0_MF,GV"NYYZ2N?@O M< .)$ )QJB,='$EU>"\4;,*IJ+XZ[0+'?=QNLG2F;9-2&9"LA".,0Z; L7, M/W#/R]R:D=BI]ST/3[P_)=B;*CAC*^(=)N_0>ROWA_NKJ.GQVV!;%,@BP+9/R4>WI6XA7EX%X2M>JK MMG&:'*G,H.,DK[S+P#XF\4W^PJ=I_\IM*[0C5^/Q96/_&V,\8"J[.QRA#C_8 M8DAH?#@^X-E.8S89WO3S#V++-R[_ %!+ P04 " GDFU-S\P0-[@! #2 M P &0 'AL+W=O552VX)VSO5'QFS5@>+V!GO0_J9!H[CSIFF9[0WP.I*49&F2W#'%A:9E'GUG M4^8X."DTG VQ@U+<_#Z!Q+&@._KF>!)MYX*#E7G/6_@.[D=_-MYBBTHM%&@K M4!,#34$?=L=3%O 1\"Q@M*LS"95<$%^"\:4N:!(2 @F5"PK<;U=X!"F#D$_C MUZQ)EY"!N#Z_J7^*M?M:+MS"(\J?HG9=00^4U-#P0;HG'#_#7,\M)7/Q7^$* MTL-#)CY&A=+&E52#=:AF%9^*XJ_3+G37CBW3'UO:F",[8BWOGDK?=>R]W=(6?7(#1C3A,F76,6!//J M2XAT*\0I_8^>;M/WFQGN(WV_CKX_; MDFP)9%,C^*?'#NQ(W,/?)NR!LU5,% MIHW39$F%@XZ3O/(N _N0QC?Y"Y^F_1LWK="67-#YEXW];Q =^%22&S]"G?]@ MBR&A<>%X[\]F&K/)<-C//X@MW[C\ U!+ P04 " GDFU-K_@R+[8! #2 M P &0 'AL+W=O;*%K1P=Z:'#F]J8[7P:-J&N=Z"J"))*\9WNWNFA>QHD47? MQ1:9&;R2'5PL<8/6POXY@S)C3A/ZZGB23>N#@Q59+QKX#OY'?[%HL46EDAHZ M)TU'+-0Y?4A.YWW 1\!/":-;G4FHY&K,F#@L#M!H^@5!#" M-'[/FG0)&8CK\ZOZIU@[UG(5#AZ-^B4KW^;T2$D%M1B4?S+C9YCK^4#)7/Q7 MN(%">,@$8Y1&N;B2Z%D%4]'B9=IE%_=QNCG%)DU([%3[WL1GC@Y<>Q-&9RQ%?$.DW?HO17)(&UL;5/;;IPP$/T5RQ\0[[+D MHA4@95-5J=1*JT1MG[TP@!7;0VRSI'\?V["4;GG!,\,Y9RX>9P.:-]L"./*A MI+8Y;9WK]HS9L@7%[0UVH/V?&HWBSKNF8;8SP*M(4I(EF\T=4UQH6F0Q=C1% MAKV30L/1$-LKQ;4!!(*%U0X/XXPQ-(&81\&>^3 M)IU3!N+2OJA_C;W[7D[^M032J^%,4_QE/H> Z3_H6V3D@F0G)%8&.B6/D7[GB1&1R( M&6??\7#%VWWB9U.&8!Q%_.>+MSYZ+K;W:<;.06C"'$9,LL3,".;5YQ3)6HI# M\A\]6:?O5BO<1?INF7WWL"Z0K@JD42#]I\7;JQ;7,'=72=ABI@I,$[?)DA)[ M'3=Y$9T7]C&)=_(7/F[[#VX:H2TYH?,W&^=?(SKPI6QN_ JU_H'-CH3:!?/> MVV92;4U'6VF8TP$ )P$ 9 M>&PO=V]R:W-H965T\9GSID9/,Y&J5YU"V#0F^"=SG%K M3'\D1) [F!_]65F++"P5$]!I)CNDH,[Q M?7P\[1W> UX8C'JU1ZZ2BY2OSOA2Y3AR"0&'TC@&:IX K=PEXG5 M*"77_HO*01LI9A:;BJ!OT\HZOX[3R2Z=P\(!R1R0+ &IUR&3D,_\D1I:9$J. M2$V][ZG[Q?$QL;TIG=.WPI_9Y+7U7HOX<,C(U1'-F-.$2=:8!4$L^R*1A"1. MR3_A23A\$\QPX\,W'S),PP3;(,'6$VP_$'RZ*3& 2:.PR"XHL@L0Q#R-"5K=#@&K\7&A4RJ'S,[GR+J-WG_C;]1<^S>TWJAK6 M:721QMY1?Y-J*0W85*([6W!KGXK%X% ;MSW8O9H&9C*,[.>W@"P/4O$'4$L# M!!0 ( ">2;4T%73D\LP$ -(# 9 >&PO=V]R:W-H965T,9O7H(2]P1:T_U.B4<)Y MUU3,M@9$$4%*,KY:W3$E&DVS),:.)DNP<[+1<#3$=DH)\^\ $ON4KNDE\-Q4 MM0L!EB6MJ. %W._V:+S')I:B4:!M@YH8*%/ZL-X?MB$_)OQIH+!LYZ50R .?VA?U[[-WW68=J9/%2E'@?SD;' MLQ_Y+[!E !\!_ K AD)1^3?A1)88[(D99M^*<,7K/?>SR4,PCB+^\^*MCYZS M]>XV8>= -.8?2O"E$@?^'YPOPS>+"C<1OOFB\&Z98+M(L(T$ MVR\$]UP#CW?RF3YL^R]AJD9;!)MYX*#E7G/ M6_@.[D=_-MYB"TLM%&@K4!,#34$?TN-I'^)CP+. T:[.)%1R07P)QI>ZH$D0 M!!(J%QBXWZ[P"%(&(B_CU\Q)EY0!N#Z_L7^*M?M:+MS"(\J?HG9=00^4U-#P M0;HG'#_#7,\M)7/Q7^$*TH<')3Y'A=+&E52#=:AF%B]%\==I%SKNXW1SF\ZP M;4 V [(%<(AYV)0H*O_('2]S@R,Q4^]['IXX/6:^-U5PQE;$.R_>>N^U3 _W M.;L&HCGF-,5DZY@E@GGV)46VE>*4_0?/MN&[386["-_]H_!NFV"_2;"/!/LU MP7WRKL2MF/=%LE5/%9@V3I,E%0XZ3O+*NPSL0Q;?Y&_X-.W?N&F%MN2"SK]L M['^#Z,!+26[\"'7^@RV&A,:%XP=_-M.838;#?OY!;/G&Y1]02P,$% @ M)Y)M34&%U<.W 0 T@, !D !X;"]W;W)K&UL M;5/M;ML@%'T5Q .4A'A-&MF6FD[3)JU2U&G;;V)?VZC@ZP&.V[7Y7_Q)K][5]^)\,3;(_>]*8(SMB+>^>2M]U[S[1U/ MV34(39C3B.%+S(Q@7GT.P=="G/A_=+Y.WZUFN(OTW3+ZX79=(%D52*) \D^) MNP\EKF&2#T'8HJ<:3!VGR9("^S9.\L([#^P]CV_R%SY.^Z,PM6PMN:#S+QO[ M7R$Z\*EL;OP(-?Z#S8:"RH7CWI_-.&:CX;";?A";OW'^!E!+ P04 " G MDFU-4KO] $! W! &0 'AL+W=OPZ@]FF]"]_6Q#*,O$_:] MG'O.N;9OLD'I=],"6/0AN#0Y;JWM#H28L@5!S9WJ0+HOM=*"6A?JAIA. ZU" MD> D6:UV1% F<9&%W$D7F>HM9Q).&IE>"*K_'(&K(<=K?$V\LJ:U/D&*K*,- M_ #[LSMI%Y&9I6("I&%*(@UUCA_7AV/J\0'PQF PBSWRG9R5>O?!]RK'*V$ M.)36,U"W7. )./=$SL;OB1//DKYPN;^R?PV]NU[.U,"3XK]89=L<[S&JH*8] MMZ]J^ 93/RE&4_//< 'NX-Z)TR@5-^$7E;VQ2DPLSHJ@'^/*9%B'B?]:%B]( MIH+DIH",0L'Y%VIID6DU(#V>?4?]%:\/B3N;TB?#481OSKQQV4NQ?D@S1(OWT0=;D+Y9JF^W\4)ME&";2#8_M/B[J;% M&.8^+I)&1=((P?Y&)(9YN!$ABXL3H)OP9 TJ52_#N"RR\U0$N'B/^'C2+U0 MW3!IT%E9]WS")==*67!65G?.2^NF> XXU-9O[]U>CV]Y#*SJIC$E\W]%\1=0 M2P,$% @ )Y)M3:L31D?/ 0 G 0 !D !X;"]W;W)K&UL=53;CILP$/T5RQ^P#B2AJPB0-EM5K=1*T59MGQT8+EH;4]N$ M[=]W; BEU'W!GO&9>M]%YZD:K&@[N&AB!BFY_G4&H<:,1O3N M>&GKQCH'R].>U_ 5[+?^HM%B"TO92NA,JSJBHG?&IS.C.)00""NL8."XW> 8A'!&F\7/FI(ND"USO[^P??.U8RY4;>%;B M1UO:)J./E)10\4'8%S5^A+F>(R5S\9_A!@+A+A/4*)0P_DN*P5@E9Q9,1?*W M:6T[OXXS_STL'!#/ ?$F@$U"/O/WW/(\U6HD>NI]S]TOCDXQ]J9P3M\*?X;) M&_3>_2HPV)88P_\GR&!0Y!@CV&Y$0YA 628(B28#@N!$)8;;M8JO;(4'7 M?BX,*=30^9E<>9?1>XK][?H#G^;V"]=UVQER51;OJ+])E5(6,)7= Q;)[G7GQ.!S1OM@%P MY%VKUF:T<:X[,&:+!K2P=]A!Z_]4:+1PWC4ULYT!44:25HPGR3W30K8T3V/L M9/(4>Z=D"R=#;*^U,+^/H'#(Z(9> Z^R;EP(L#SM1 W?P'WO3L9[;%8II8;6 M2FR)@2JCCYO#<1?P$?!#PF 7-@F=G!'?@O.YS&@2"@(%A0L*PA\7> *E@I O MX]>D2>>4@;BTK^HOL7??RUE8>$+U4Y:NR>B>DA(JT2OWBL,GF/KY0,G4_!>X M@/+P4(G/4:"R\4N*WCK4DXHO18OW\91M/(=)_TI;)_")P&\(;$P4*W\63N2I MP8&8\.7 _FR($XRCB/U^\]=%+SI.'E%V"T(0YCAB^P&QF!//J;)&PQ4PVFCMMD M28%]&S=Y$9T7]I''._D+'[?]JS"U;"TYH_,W&^=?(3KPI21W?H4:_\!F1T'E M@OG@;3.NV>@X[*87Q.9GG/\!4$L#!!0 ( ">2;4W5VQ3$;@( )0' 9 M >&PO=V]R:W-H965T$VD6O)C(%I.R=Z0ZBJ 88B#FI2-GZ7& M]LRSE)UD53;TF7OB5->$_UO1BG5+'_COAI?R6$AM"+*T)4?ZD\I?[3-7JV#T MLB]KVHB2-1ZGAZ7_"!9;K/$&\+NDG;B:>SJ3'6.O>O%MO_1#+8A6-)?: U'# MF:YI56E'2L;?P:<_AM3$Z_F[]ZW)7>6R(X*N6?6GW,MBZ<]\;T\/Y%3)%]9] MI4,^R/>&Y+_3,ZT47"M1,7)6"?/W\I.0K!Z\*"DU>>O'LC%CU^]@,-#^H A+*>,PC"-#AK1P-FU6/@%28!MY#-%')!!$K J *Z M5*S@A YO ZRGB,2";#YU\O2YD^T4$H7N3")G/2/#CV_J:15KU6,2@VD,YDL4 MA?,9QE;2#B $LQC9)[1Q .<1Q#.(K HX@!C .4*1.\G8F63L2-(^C1Z#;B(A MD,QGMJ1X*BF> Z#4NR4AIR3DD!19=4<322KU"*%98FF_%[A%$^T)!$F,YV[I MV"D=.Z3'EG0\"03".-2?)?T.8"\IN'HA:LJ/YGT77LY.C=27^\HZMI!'J%\8 MR[X"BS5PV#=@\=1WB(O[OE_](/Q8-L+;,:G>-?/Z'!B35.D/'U1)"]4BQT5% M#U)/$S7G?:/H%Y*U0P\,QD:<_0=02P,$% @ )Y)M3??^GD;U 0 < 4 M !D !X;"]W;W)K&ULA53;CILP$/T5Q ?$W+S) M1H"TFV352JT4;=7VV4DF :W!U';"]N_KVU) 5O8%>^QSSIPQH\E[QM]$!2"# M]X:VH@@K*;LU0N)804/$@G70JILSXPV1*N07)#H.Y&1(#45)%#V@AM1M6.;F M;,_+G%TEK5O8\T!H]/!UU,11MH04#A*K4#4/^A_F)J5[4X)6C^0F)(R0#(<[N M$E)'2 ="&M\E9(Z0#83D?@;L"/@_P3ZOK=T\YI9(4N:<]0&W[= 1W77Q&JO? M==2'YN^8._6>0IW>RB3&.;II(8=YMIAD@GF88C8^S'**V?HPJREFY\,\#ABD M:AD*2KP%)48@&PLDTP326:=8#![YC.2;4T&PO=V]R:W-H965T"M;3JY"RNE^BT \E2QELHGWK-.GURX:*G2IK@" MV0M&SS:H;0",HA2TM.["(K>^@RAR?E--W;&#".2M;:GX6[*&#[LP#M\=S_6U M4L8!BKRG5_:3J5_]06@+S%G.=3( M^:LQOIUW862 6,-.RF2@>KFS/6L:DTAC_)ERAG-)$[C M_*[/JMJ%61B&O7,AZ]LZ@>'P=3\=W9GC98;$EWCQ!MI?X/332K>3EDT M2DO?QK7N[#J,)X1,8?X . 7 .2!._AN I@#D!("1S+;ZF2I:Y((/@1C_K)Z: M;R+>(GV9)^.T=V?/=+=2>^\%A$D.[B;1I"E'#5QJ'A7[M0)%LP1H@)D">BF@ MC4\>*+!#,6J(U716DZ1IG#DD:U4,<813/PWRTB /3>K0C!J\K).2%8U'E<"% MZ@$F\<(D'ACBP"2K,AN$L:/:>U2$9!_ 8"\,]L X/9=XW7.4P,W&H5FG2H@? M)?6BI!X4IT:9KE$0P9%#LL[T$0GQDI U"7)JE&1-@E'FWHE'A;(,^F$R'TR9 MK;Y_N(D0BIU*'AF.-DGBE *+,6+&^@\JKG4G@R-7>B+9N7'A7#&=,GK2W)5^ M26:C81=EMD3OQ3A/1T/Q?GHJP/Q>%?\ 4$L#!!0 ( ">2;4TXWM]#M0( M '@) 9 >&PO=V]R:W-H965T>>>[D"9FC6DJHR@@"D M446+.ES,[-J36,SX495%S9Y$((]51<6_)2OY>1[&X=O"CV)_4&8A6LP:NF<_ MF?K5/ D]BSJ5;5&Q6A:\#@3;S/H8 T.PB-\%.\O>.#"I/'/^8B9?M_,0 M&$>L9!ME)*C^G-B*E:51TC[^.M&PBVF(_?&;^MHFKY-YII*M>/FGV*K#/,S" M8,MV]%BJ'_S\A;F$DC!PV7]C)U9JN'&B8VQX*>UOL#E*Q2NGHJU4]+7]%K7] MGIW^&\U/@(X .X*._1$!.0*Z$/"'!.P(^-8(B2,DMT9('2&]E4 <@5P(R&Y@ M6UV[73E5=#$3_!R(MN,::AH[GA+=$!NS:/??_J=W3.K5TP*B>!:=C)##+%L, M[&'( )*/(1=$I UT+J#/Q1*.Z/ ZP&J,( -(_JG(P^%78QS!$"<#S_D8AE *DG00]F&,@W$, M,ISZ\\/>_+ G/SPPU&*2?GX0Z@0'?L92F/BM)%XKB<=*,BAU,K*",X G UA^ M&VR=C"N=9)"\XSKUNDX]KM_9 >(5(!X!,FCC%I/UC(([W"O.59C,&R;[O)'S M;%0VDF( @#_.Q!MG,;&W5[@,-OQ8*W/4]%:[9\(]-'?"8'T93U>Q9SV/IP_M(^ B MW[Y)OE.Q+VH9/'.E;R)[7^PX5TS;!W>ZY@?]#.HF)=LI,R1Z+-JW0#M1O''O MG*A[;"W^ U!+ P04 " GDFU-HN8@COL! ! !0 &0 'AL+W=OL( M_W,$RL;<]=U'X*6]-E('4)$-Y K?0?X83ER-T)*E;COH1[3*F-Z_XC M^R=3NZKE3 24C/YJ:]GD;NHZ-5S(CM..<_V&S&X+9$"P&/_JO(9P-X<: )C)3ZD:]HMPK0F^1 M( 6P4 16BL#XHW<4SQN*29,836\T4>H]^\D&92_#<>QY_\ )K3CA'B?R-CB3 M!J_F\7&<)'B#8Y%%21K[=IS(BA-9;)2PMLC1*XV2#@U9G6;\MWPB_MKUPSDRJ:V$.[X4Q"2JE M]Z1R-NHY6P84+E)W$]7GTZ6>!I(-\WN%ED>S^ M02P,$% @ )Y)M31NR M6\\9!@ \R0 !D !X;"]W;W)K&ULC9K;(!P#K;*4+5ADQ(AFQ5:J9V]]H)2J#&8-9VPNS;KVT<@EK=MN9B..1O M]2]+_M22F1WSXE>YL;8:_=YE^_)ZO*FJP]5T6KYL["XM)_G![NN_O.;%+JWJ MC\7;M#P4-EVW0;MLRJ-(3W?I=C^>S]KOGHKY+'^OLNW>/A6C\GVW2XO_;FR6 M'Z_';/SYQ8_MVZ9JOIC.9X?TS?ZTU5^'IZ+^-#VWLM[N[+[M'/W-+':F7J;5NE\5N3' M47&ZV0YIY.6FXHY&N9H%I ME*NYQ33:U7Q#-"QQ-7 MR/-H=N"=%I@8*1.&M5J]JV&Q2IJ_X%K&*)T7 G!*^+D,[BI8 MN0I1.OXE[E_Z_CG(M3AIDHM!*9RTNFB#S4\L:0 M/ SF85X>035D'',!ZH4+)8&3)5E@-!U18"7(>35$ 2H2$)'_2+7 M#8%1AG!4*^@&$WEN^D6N&X*1#(&DUM"-+X*K_VVG<68IDR81$;AOO@6T=A?< MVC)8>8\H:W3$3'#BDA%D9@B:M8&VM&]+""$E10@"J0QAJH[A^/A0)>ZH8:'K MBH P0PBK$^@J]I)Q'GN6?!6+6$3@FA&\9@B,#54T$C#F"(P-@.1-)[I<)^4D M@G7N(DRV')2YQ@FZN'H#]'F&T,].,7ORR:P#)G.2AS'1$K $=6 $/UBD B1Y!H M ^^=R*'!XHLBSD!1(X ,8Y@*J3*I#,1D.,(Y&(&,R'X(M(0Z.((NF(.TR3^ MM8N)I5X0?!,(WV)XR-&)G/X(S:E4!)$$PI%8PE1^O\=:83 M76:3)N:,3$;MXK$2$-Z9 MESPZ+$S4;@0F E'JPU.I$[9CVUAB!((! 2Q 1- M!$$"@15''(Z\3P(1ZX0S*AG! H&Q ,*T$UT.O!):&)7 RS@L=%T1W! 8-ZAQ M)Z @L,TEW+(('PJG@QW8L4&=>_Q#\$,B_/".)*1?T6!G$H,RUQ&!&8EA!I:A MG>BR]_ "]4I<)P2")(*@Q#L<\_>SGI,^B>N$X)/T^:2)VTI2!WT(=+S))WWH M2'_J!:E60RK7-4$OB1WW>=-3A4W/(-EJ4.8:)Y I$63ZL]A'IG>M^R2N$X*G M$N&I/XO]VLIS,BA9]4I)%LA,J+?BL"P M"L&P"L-PF.PA3+8:E+G](Z"N0J"N?&(+Q6!A%*1:(2IJ2 CZ*XS^$&30IXC M(8\9!E2N'V(-4$B-FL # >5O9\4$/I!:#JEQ& B>.0Y('+= M4(^%D(4B@0>PRG^,X^U@E@,BUPU!?X70WV.N0@IF9+J'J%:(BII>Q#*AL&6" MJ#$406^%%,D)L'JCD,TUO1E5!.653_F$8)(FF*L1YB;PS$_[6VM?"1 0/VJ87/U]H?@[T9UJ\;??EZ#FOJGS7_ESA-<\K6S<:3>KF-C9=GS]D M]K5JWIKZ?7'Z&<[I0Y4?NI\83<^_BJMK]]B9.@ TQM)[F^?8TAE(.UE#\!F_',>N*!7=Z$ M?%-GSK7W7I6U6OEGK9LG0M3^S"NF%J+AM7ER%+)BV@SEB:A&BM-9MQ-DO6S8B?_@ M^F>SDV9$!I9#4?%:%:+V)#^N_ T\;2EM%UC$KX+?U.C>:[?R*L1;._AZ6/E! M6Q$O^5ZW%,QU$J^^OM+TJ+JF>O[[,GP![1?084%H%Y!.R%;^B6FV7DIQ\V1G?L/:_QB>J/%FWTY:*^PS M4[PRL]@( P."&/9!@F(26SI;'@8!3A"B-8:6(/I ),: M.TQL,;7%1"%D41KC0A$J%"%"%">(48+X@4KC6:5)E(6X2H*J)(A*.%'I,.E( M)8XH2(J(1!,1#.,P/$-%,H0@P0ERE"!_P/!\9CB 2P4"/"7! VZ@H-2A MXT@C(!29@P)-VP;H Z>C!^4C3\(,%BY3\%@"ELO<08$'#K#$S8J-'C_+@.<2 MD&""BP(/'6"IFQZU'O3A-11!DKJD\.@!EJN9*^G\+URDKK."QP^P_,V.-0(" MQP< $3"/*;4Y0G%$TBQ<$WM[T'QAV.=Y!0%8IEM6I_Q@(IE\E,OK>5UR>;*>CO+VXU+;-<.W=3&-E/D/[QKQ;XS>2IJ MY;T*;;H.VQL&ULC9;;CILP$(9?!7'?@,\0)9$V!])*K;3:JNTUFS@)6L 4G*1] M^]K 9L%V=W,3L//]XQG/&,_L*NJ7YL2Y]/X4>=G,_9.4U30(FMV)%VDS$14O MU3\'41>I5,/ZS=-]*RKR (8A#8HT*_W%K)U[K!Y#_S7B:?L>))Z(EC,JO3(OW/YHWJLU2BX6=EG!2^;3)1>S0]S_P%, MMTSS+? SX]=F\.[I2)Z%>-&#+_NY'VJ'>,YW4EM(U>/"5SS/M2'EQN_>IG]; M4@N'[Z_6DS9V%WF:^Y'O[?DA/>?R25P_\SX>XGM]\%_YA><* MUYZH-78B;]I?;W=NI"AZ*\J5(OW3/;.R?5Y[^Z\RMP#V G@3J+7?$Z!>@-X$ M^%T![@7X7@'I!>1>EV@OH/<*6"]@ADM!M[MMNM:I3!>S6ER]NBNX*M5U#:9, M%<1.3[;Y;_]3&6O4[&6! )H%%VVH9Y8= P<, V-D8R,(X#&3V,R;E4 Y>?,4 MNCQ=0DL.QPNL; (!,F;6-L,,,YL[S"0?.K-]=Z%1N,B9&-3J\4 ?F7GI$-8B M98M\0BB,(TJ-H!T@!!$F(#3"&9==$A\7 ?PPDUSMK*09&)=8@<%)P \T)P4-2B$N>*YN6R=5 3:#YJ0D& M=U[!ZV/;XC3>3IQ+J;^R@]E;%_4 ]9UIS"_!= T<\XGJNKHFZLY#JIF[OTX,0DBOOPXG*[DEUB;=!S@]2OS+U7G>]4C>0HNK;P.#6BR[^ M 5!+ P04 " GDFU-4SSV-\(" #)"0 &0 'AL+W=OJKEKV)"*Y;QHJ M_LU8S8^3.(O? \_5=J=,()F..[IE/YGZU3T)/4I.*NNJ8:VL>!L)MIG$C]EH MF5F"1?RNV%&>O4>FE!?.7\W@VWH2IR8C5K.5,A)4/PYLSNK:*.D\_@ZB\6E. M0SQ_?U?_8HO7Q;Q0R>:\_E.MU6X2%W&T9ANZK]4S/WYE0T$XCH;JO[,#JS7< M9*+G6/%:VM]HM9>*-X.*3J6A;_VS:NWS..B_T\($,!# B:#GOD6 P%^$-!- M AH(Z-X9\$# S@Q)7[LU@$3EF 4!8SX-'!Y01S'T$5- MD8LT8= L:/GHPJS",:O'8(MI+28O8)DC[!3DXR F$#G>+P(P4J <.W)+'X=2 M L<+@\%RT.!\LJP X*X#O\P5ZBI("D1(X]/BPC.4[=-?=AL-!RCHO+@%J: MXO2*.WFPN-PK+L_#?!+DDSO,\3'NAI@3?Z$!*E+'E\^%EKX0T?OJRF=;!$LJ M?$NN[).Y>P.:P;0Q5X@65Y"]ZP) #-8P!R[I[B/ SE")7+,7H: @ #@KGYR=@TU M3&QM3R"C%=^WRARR9]%3W_$(S#7FQ&?9:)X%X@O3I]AK[T.^;W)^4+&M6AF] M<*4O3WO%;3A73*>?/NC$=[JO.@UJME'FE>AWT3<7_4#Q;FB2;4UT\%"ZH@$ (L# 9 >&PO=V]R:W-H965T592NY9.WL\;QEP_@>+NQLR@<6*"TV[)M;VMFO,R4NA86^).RG%[=\M2+.TM*0OA4=Q MG'PHL*Z9^1%^@/\Y[RUF;%49A +MA-'$PMC2C^5F5P5\!/P2L+B+F(1.#L8\ MA>3KT-(B& ()O0\*')B-=_)+^Y+Q1606M*/Z<5J'C MNJ2=^[M,>YM094*U$LK;=PEU)M17!):3?OG)Q M=<8V81XB1D=,<>7B/40RP2[&$J[I=VZ/0CMR,!XG'.O 0 F , M !D !X;"]W;W)K&UL?5/M;J,P$'P5Y >HP220 M1H!TS>ET)[52U-/U?CNP!*O^X&PGM&]?V[@H3:O[@[WKF?'LLJXFI9_- &"3 M%\&EJ=%@[;C%V+0#"&INU C2G?1*"VI=J(_8C!IH%TB"8Y*F!1:42=14(;?7 M3:5.EC,)>YV8DQ!4O]X!5U.-,O2>>&3'P?H$;JJ1'N$WV#_C7KL(+RH=$R - M4S+1T-?H6[;=$8\/@"<&D[G8)[Z2@U+//OC5U2CUAH!#:[T"=?-5(_$]DV=\UL?3+T+IRY:HW+GINZ&(N9LQ MY )#/B)VGQ%YND"P,["X(%^Z((&_^N!B=>5BQI0!(P,F(\5FO=Z45V8^ XO; MHEP5MU>.\$6/_,P^4'UDTB0'95V[0U-ZI2PXS?3&#<+@GLD2<.BMWY9NK^=A MF0.KQO@.\/(8FS=02P,$% @ )Y)M3=2&@JG; 0 Y00 !D !X;"]W M;W)K&UL?53M;ML@%'T5BPMZV,E M'3FG\N\#,#$6*$+OB>?NT&J;P&4^T /\!/UKV$D3X86E[CCTJA-](*$IT'VT MV1*+=X#?'8SJ;![83O9"O-K@6UV@T!H"!I6V#-0,)]@"8Y;(V/@S MS]_9GUSOII<]5; 5[*6K=5N@-0IJ:.B1Z6B[S%\1S0;P41.33@F0N2/X7I*[YR9EK M]9%J6N92C(&NEX%>Z'-V74GK!%"@V$,[XSOUMPY2\"@T7:Z,G,Y_7E3H,4P7RIXN=G* M?U!+ P04 " GDFU-5($LX-$# "9$@ &0 'AL+W=OS'H+J*:!R+J"[*)MRLQFO/[6:EWOJJ M;.1S&W1O=5VT_]W)2IW7(0D_+GPO7X^]OA!M5J?B5?XI^[].S^UP%EVR[,M: M-EVIFJ"5AW7X&[G]QJ@.&(F_2WGN9L>!'LJ+4C_TR7:_#F.M2%9RU^L4Q?#U M+N]E5>E,@XY_3=+P4E,'SH\_LC^,@Q\&\U)T\EY5_Y3[_K@.LS#8RT/Q5O7? MU?E)F@'Q,#"C_UV^RVK M9*AQDY5W?@WV+UUO:I-ED%*7?RB+S:K5IV#=K+!J=!N([=$;].=OCKNRO&? MPS[JAJOO&\:25?2N,QGF;F*HQ7";N8<883-?(":UF:\0D]G, \3D-O/H,]0F MGGPB=9#MITF^+2:)AJF_S#^%YY^."9+Y6)(8SL#@# S(0)S9F)AT9)J1$90E MN;- 6Q^C)(L%SV%!"2PH 00Y\W8W,?F\TLULG:TR'"[#@3+,*0,Q"5Q%P%4$ MD,'9^X\0XT[M,F,I26$E*9 AA3-D<(8,R.!XZPYBD.7/X2JYGX$C.UIW+[ I MQ5V(A")E7@AB= $[G2+

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end

XML 58 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 59 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 61 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 124 205 1 false 37 0 false 5 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.atossagenetics.com/20180930/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.atossagenetics.com/20180930/role/statement-condensed-consolidated-balance-sheets-unaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) Sheet http://www.atossagenetics.com/20180930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.atossagenetics.com/20180930/role/statement-condensed-consolidated-statements-of-operations-unaudited- Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited) Sheet http://www.atossagenetics.com/20180930/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited Condensed Consolidated Statement of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (Parentheticals) Sheet http://www.atossagenetics.com/20180930/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited-parentheticals Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (Parentheticals) Statements 6 false false R7.htm 006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.atossagenetics.com/20180930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited- Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 007 - Disclosure - Note 1 - Nature of Operations Sheet http://www.atossagenetics.com/20180930/role/statement-note-1-nature-of-operations- Note 1 - Nature of Operations Notes 8 false false R9.htm 008 - Disclosure - Note 2 - Going Concern Sheet http://www.atossagenetics.com/20180930/role/statement-note-2-going-concern- Note 2 - Going Concern Notes 9 false false R10.htm 009 - Disclosure - Note 3 - Summary of Accounting Policies Sheet http://www.atossagenetics.com/20180930/role/statement-note-3-summary-of-accounting-policies- Note 3 - Summary of Accounting Policies Notes 10 false false R11.htm 010 - Disclosure - Note 4 - Prepaid Expenses Sheet http://www.atossagenetics.com/20180930/role/statement-note-4-prepaid-expenses- Note 4 - Prepaid Expenses Notes 11 false false R12.htm 011 - Disclosure - Note 5 - Research and Development Tax Rebate Receivable Sheet http://www.atossagenetics.com/20180930/role/statement-note-5-research-and-development-tax-rebate-receivable- Note 5 - Research and Development Tax Rebate Receivable Notes 12 false false R13.htm 012 - Disclosure - Note 6 - Payroll Liabilities Sheet http://www.atossagenetics.com/20180930/role/statement-note-6-payroll-liabilities- Note 6 - Payroll Liabilities Notes 13 false false R14.htm 013 - Disclosure - Note 7 - Stockholders' Equity Sheet http://www.atossagenetics.com/20180930/role/statement-note-7-stockholders-equity Note 7 - Stockholders' Equity Notes 14 false false R15.htm 014 - Disclosure - Note 8 - Net Loss Per Share Sheet http://www.atossagenetics.com/20180930/role/statement-note-8-net-loss-per-share- Note 8 - Net Loss Per Share Notes 15 false false R16.htm 015 - Disclosure - Note 9 - Income Taxes Sheet http://www.atossagenetics.com/20180930/role/statement-note-9-income-taxes Note 9 - Income Taxes Notes 16 false false R17.htm 016 - Disclosure - Note 10 - Concentration of Credit Risk Sheet http://www.atossagenetics.com/20180930/role/statement-note-10-concentration-of-credit-risk- Note 10 - Concentration of Credit Risk Notes 17 false false R18.htm 017 - Disclosure - Note 11 - Commitments and Contingencies Sheet http://www.atossagenetics.com/20180930/role/statement-note-11-commitments-and-contingencies- Note 11 - Commitments and Contingencies Notes 18 false false R19.htm 018 - Disclosure - Note 12 - Stock Based Compensation Sheet http://www.atossagenetics.com/20180930/role/statement-note-12-stock-based-compensation- Note 12 - Stock Based Compensation Notes 19 false false R20.htm 019 - Disclosure - Note 13 - Restatement to Previously Issued Condensed Consolidated Financial Statements Sheet http://www.atossagenetics.com/20180930/role/statement-note-13-restatement-to-previously-issued-condensed-consolidated-financial-statements Note 13 - Restatement to Previously Issued Condensed Consolidated Financial Statements Notes 20 false false R21.htm 020 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.atossagenetics.com/20180930/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.atossagenetics.com/20180930/role/statement-note-3-summary-of-accounting-policies- 21 false false R22.htm 021 - Disclosure - Note 4 - Prepaid Expenses (Tables) Sheet http://www.atossagenetics.com/20180930/role/statement-note-4-prepaid-expenses-tables Note 4 - Prepaid Expenses (Tables) Tables http://www.atossagenetics.com/20180930/role/statement-note-4-prepaid-expenses- 22 false false R23.htm 022 - Disclosure - Note 6 - Payroll Liabilities (Tables) Sheet http://www.atossagenetics.com/20180930/role/statement-note-6-payroll-liabilities-tables Note 6 - Payroll Liabilities (Tables) Tables http://www.atossagenetics.com/20180930/role/statement-note-6-payroll-liabilities- 23 false false R24.htm 023 - Disclosure - Note 7 - Stockholders' Equity (Tables) Sheet http://www.atossagenetics.com/20180930/role/statement-note-7-stockholders-equity-tables Note 7 - Stockholders' Equity (Tables) Tables http://www.atossagenetics.com/20180930/role/statement-note-7-stockholders-equity 24 false false R25.htm 024 - Disclosure - Note 8 - Net Loss Per Share (Tables) Sheet http://www.atossagenetics.com/20180930/role/statement-note-8-net-loss-per-share-tables Note 8 - Net Loss Per Share (Tables) Tables http://www.atossagenetics.com/20180930/role/statement-note-8-net-loss-per-share- 25 false false R26.htm 025 - Disclosure - Note 12 - Stock Based Compensation (Tables) Sheet http://www.atossagenetics.com/20180930/role/statement-note-12-stock-based-compensation-tables Note 12 - Stock Based Compensation (Tables) Tables http://www.atossagenetics.com/20180930/role/statement-note-12-stock-based-compensation- 26 false false R27.htm 026 - Disclosure - Note 13 - Restatement to Previously Issued Condensed Consolidated Financial Statements (Tables) Sheet http://www.atossagenetics.com/20180930/role/statement-note-13-restatement-to-previously-issued-condensed-consolidated-financial-statements-tables Note 13 - Restatement to Previously Issued Condensed Consolidated Financial Statements (Tables) Tables http://www.atossagenetics.com/20180930/role/statement-note-13-restatement-to-previously-issued-condensed-consolidated-financial-statements 27 false false R28.htm 027 - Disclosure - Note 2 - Going Concern (Details Textual) Sheet http://www.atossagenetics.com/20180930/role/statement-note-2-going-concern-details-textual Note 2 - Going Concern (Details Textual) Details http://www.atossagenetics.com/20180930/role/statement-note-2-going-concern- 28 false false R29.htm 028 - Disclosure - Note 3 - Summary of Accounting Policies (Details Textual) Sheet http://www.atossagenetics.com/20180930/role/statement-note-3-summary-of-accounting-policies-details-textual Note 3 - Summary of Accounting Policies (Details Textual) Details 29 false false R30.htm 029 - Disclosure - Note 4 - Prepaid Expenses - Schedule of Prepaid Expenses (Details) Sheet http://www.atossagenetics.com/20180930/role/statement-note-4-prepaid-expenses-schedule-of-prepaid-expenses-details Note 4 - Prepaid Expenses - Schedule of Prepaid Expenses (Details) Details 30 false false R31.htm 030 - Disclosure - Note 5 - Research and Development Tax Rebate Receivable (Details Textual) Sheet http://www.atossagenetics.com/20180930/role/statement-note-5-research-and-development-tax-rebate-receivable-details-textual Note 5 - Research and Development Tax Rebate Receivable (Details Textual) Details http://www.atossagenetics.com/20180930/role/statement-note-5-research-and-development-tax-rebate-receivable- 31 false false R32.htm 031 - Disclosure - Note 6 - Payroll Liabilities - Schedule of Payroll Liabilities (Details) Sheet http://www.atossagenetics.com/20180930/role/statement-note-6-payroll-liabilities-schedule-of-payroll-liabilities-details Note 6 - Payroll Liabilities - Schedule of Payroll Liabilities (Details) Details 32 false false R33.htm 032 - Disclosure - Note 7 - Stockholders' Equity (Details Textual) Sheet http://www.atossagenetics.com/20180930/role/statement-note-7-stockholders-equity-details-textual Note 7 - Stockholders' Equity (Details Textual) Details http://www.atossagenetics.com/20180930/role/statement-note-7-stockholders-equity-tables 33 false false R34.htm 033 - Disclosure - Note 7 - Stockholders' Equity - Schedule of Warrants (Details) Sheet http://www.atossagenetics.com/20180930/role/statement-note-7-stockholders-equity-schedule-of-warrants-details Note 7 - Stockholders' Equity - Schedule of Warrants (Details) Details 34 false false R35.htm 034 - Disclosure - Note 8 - Net Loss Per Share - Schedule of Earnings Per Share (Details) Sheet http://www.atossagenetics.com/20180930/role/statement-note-8-net-loss-per-share-schedule-of-earnings-per-share-details Note 8 - Net Loss Per Share - Schedule of Earnings Per Share (Details) Details 35 false false R36.htm 035 - Disclosure - Note 8 - Net Loss Per Share - Schedule of Antidilutive Securities (Details) Sheet http://www.atossagenetics.com/20180930/role/statement-note-8-net-loss-per-share-schedule-of-antidilutive-securities-details Note 8 - Net Loss Per Share - Schedule of Antidilutive Securities (Details) Details 36 false false R37.htm 036 - Disclosure - Note 9 - Income Taxes (Details Textual) Sheet http://www.atossagenetics.com/20180930/role/statement-note-9-income-taxes-details-textual Note 9 - Income Taxes (Details Textual) Details http://www.atossagenetics.com/20180930/role/statement-note-9-income-taxes 37 false false R38.htm 037 - Disclosure - Note 10 - Concentration of Credit Risk (Details Textual) Sheet http://www.atossagenetics.com/20180930/role/statement-note-10-concentration-of-credit-risk-details-textual Note 10 - Concentration of Credit Risk (Details Textual) Details http://www.atossagenetics.com/20180930/role/statement-note-10-concentration-of-credit-risk- 38 false false R39.htm 038 - Disclosure - Note 11 - Commitments and Contingencies (Details Textual) Sheet http://www.atossagenetics.com/20180930/role/statement-note-11-commitments-and-contingencies-details-textual Note 11 - Commitments and Contingencies (Details Textual) Details http://www.atossagenetics.com/20180930/role/statement-note-11-commitments-and-contingencies- 39 false false R40.htm 039 - Disclosure - Note 12 - Stock Based Compensation (Details Textual) Sheet http://www.atossagenetics.com/20180930/role/statement-note-12-stock-based-compensation-details-textual Note 12 - Stock Based Compensation (Details Textual) Details http://www.atossagenetics.com/20180930/role/statement-note-12-stock-based-compensation-tables 40 false false R41.htm 040 - Disclosure - Note 12 - Stock Based Compensation - Additional Shares Authorized (Details) Sheet http://www.atossagenetics.com/20180930/role/statement-note-12-stock-based-compensation-additional-shares-authorized-details Note 12 - Stock Based Compensation - Additional Shares Authorized (Details) Details 41 false false R42.htm 041 - Disclosure - Note 12 - Stock Based Compensation - Stock Option Activity (Details) Sheet http://www.atossagenetics.com/20180930/role/statement-note-12-stock-based-compensation-stock-option-activity-details Note 12 - Stock Based Compensation - Stock Option Activity (Details) Details 42 false false R43.htm 042 - Disclosure - Note 12 - Stock Based Compensation - Valuation Assumptions (Details) Sheet http://www.atossagenetics.com/20180930/role/statement-note-12-stock-based-compensation-valuation-assumptions-details Note 12 - Stock Based Compensation - Valuation Assumptions (Details) Details 43 false false R44.htm 043 - Disclosure - Note 13 - Restatement to Previously Issued Condensed Consolidated Financial Statements (Details Textual) Sheet http://www.atossagenetics.com/20180930/role/statement-note-13-restatement-to-previously-issued-condensed-consolidated-financial-statements-details-textual Note 13 - Restatement to Previously Issued Condensed Consolidated Financial Statements (Details Textual) Details http://www.atossagenetics.com/20180930/role/statement-note-13-restatement-to-previously-issued-condensed-consolidated-financial-statements-tables 44 false false R45.htm 044 - Disclosure - Note 13 - Restatement to Previously Issued Condensed Consolidated Financial Statements - Restatements (Details) Sheet http://www.atossagenetics.com/20180930/role/statement-note-13-restatement-to-previously-issued-condensed-consolidated-financial-statements-restatements-details Note 13 - Restatement to Previously Issued Condensed Consolidated Financial Statements - Restatements (Details) Details http://www.atossagenetics.com/20180930/role/statement-note-13-restatement-to-previously-issued-condensed-consolidated-financial-statements-tables 45 false false All Reports Book All Reports atos-20180930.xml atos-20180930.xsd atos-20180930_cal.xml atos-20180930_def.xml atos-20180930_lab.xml atos-20180930_pre.xml http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/us-gaap/2018-01-31 true true ZIP 63 0001437749-18-020638-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-18-020638-xbrl.zip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�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end